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Abstract
Abstract
CRISPR/Cas is the prokaryotic adaptive immune response to viral invasion. Its mecha-
nism is reminiscent of the eukaryotic RNA interference. The host actively incorpo-
rates short sequences from invading genetic elements (viruses or plasmids) into a re-
gion of its genome that is characterized by clustered regularly interspaced short palin-
dromic repeats (CRISPRs) and a number of CRISPR-associated (cas) genes. Themolecu-
lar memory of previous infections can be transcribed and processed into small RNAs
(crRNAs) that guide a multiprotein–nucleic acid interference complex to recognize and
cleave incoming foreign genetic material. Three pathways (I, II, III) are defined by their
protein machinery and target specificity (DNA vs. RNA). In types I and III, the main
protagonist of the interference complex is the Cas7 protein. Up to six copies of Cas7 con-
stitute the complex’smain building block that assembles around the crRNA and provides
a platform for protein interactions and target binding.
During my PhD work, I solved the crystal structures of two Cas7 orthologs from differ-
ent archaeal species, at 1.8 Å forThermofilum pendens (Tp) Csc2 and at 2.37 Å forMeth-
anopyrus kandleri (Mk) Csm3. The crystal structures of MkCsm3 and TpCsc2 were
solved by experimental phasing and revealed a core RRM-like domain with a β1-α1-β2-
β3-α2-β4 arrangement of secondary structure elements. The core is flanked by three
peripheral domains that are defined by insertions within the core. Structural superposi-
tion of the RRM-like core domains ofMkCsm3 and TpCsc2 with the representatives of
other Cas families (5/6/7) revealed the highest homology beyond the RRM with a Cas7
family homolog. Thus I showed that Cas7 family proteins share equivalent insertions,
forming homologous peripheral domains.
Using the information obtained from structural data, I investigated the RNA binding
propertiesMkCsm3, TpCsc2 and a Cas7 protein from subtype I-A,Thermoproteus tenax
(Tt) Csa2. All orthologs bound RNA in a sequence-independent manner, according to
their physiological function of spacer binding. Furthermore, a combined approach con-
sisting of mutation analysis, UV-based protein–RNA crosslinking, mass spectrometry
and fluorescence anisotropy mapped the RNA interacting regions to two structurally
highly conserved positively charged surfaces.
v
Taken together, this thesis describes a comprehensive structural study of the Cas7 family,
defining the family’s structural features. These structural data from single proteins and
the mapped RNA binding interfaces agree with protein–RNA interactions observed in
the Escherichia coli interference complex.
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Preface
Two decades after scientists first proposed that prokaryotes possess an adaptive immune
system, we stand before a young yet quickly evolving field of research. Bacteria and ar-
chaea actively incorporate phage DNA or RNA into their genomes within clustered reg-
ularly interspaced short palindromic repeats (CRISPRs). These loci form a molecular
memory of previous infection that is used to transcribe a guide RNA (crRNA) that can
target and silence foreign genetic elements. ThreeCRISPRpathways have been identified
in different organisms, varying by the nature of their targets and their proteinmachinery.
The heart of type I and III CRISPR responses is the crRNA-guided interference complex,
composed of up to 11 proteins. It distinguishes self from non-self DNA and specifically
targets foreign nucleic acid sequences for degradation via its associated nuclease activ-
ity.
In the work that has led to this doctoral thesis, I structurally and functionally charac-
terized Cas proteins belonging to the Cas7 family. These proteins constitute the core of
the interference complexes, interacting with all other subunits and the guide RNA. Cas7
proteins achieve this by undergoing versatile structural rearrangements of secondary
structural elements in peripheral domains. I focused on Cas7 homologs from three dif-
ferent subtypes and species, applying a combined approach of X-ray crystallography as
well as biochemical, biophysical and mass spectrometric methods to comprehensively
classify and functionally elucidate Cas7 family features. This led to three publications
that will be discussed in the cumulative thesis.
The first chapter is a general introduction to the biological background of the CRISPR
pathways. The second chapter includes my results in form of three original manuscripts,
all introduced with a short summary. The first twomanuscripts constitute mymain PhD
work. For this thesis, I added unpublished follow-up data to the third manuscript. The
last chapters feature a comprehensive discussion that integrates my findings with new
insights from recent studies published after my research papers.
xi

1 Introduction
1.1 Phages and prokaryotes: instigators of evolution
Prokaryotic viruses (phages) are themost abundant biological entities on earth [1]. They
outnumber their hosts, bacteria and archaea, by an order of magnitude. Phage abun-
dance as well as their genetic and morphological diversity has made these viruses a ma-
jor evolutionary driving force for bacterial and archaeal communities alike, influencing
nearly every ecological setting [2, 3]. Many viruses insert their own genetic information
into the host’s genome [4]. This horizontal gene transfer is a double-edged sword: on
the one hand, viruses can shuttle antibiotic resistance genes between bacteria; on the
other hand, viruses exploit their host’s resources and may eventually induce cell lysis
and death. Consequently, bacteria and archaea have evolved a plethora of innate, multi-
layered defense strategies against invading genetic elements (Fig. 1) [5]. These include
(1) the blockage of phage adsorption bymasking ormutation of surface receptors, which
prevents attachment and virus entry [6]; (2) the methylation of certain DNA sequence
motifs in the host genomes in combinationwith the expression of corresponding restric-
tion enzymes, which exposes non-self DNA to nucleolytic digestion while endogenous
DNA is protected[7]; (3) abortive infection, which induces apoptosis and sacrifices the
infected cell to protect other cells of the same species [8].
Each of these well-studied pathways acts at different stages of infection and has evolved
species-specific protein machineries [11]. All of these strategies recognize the invader
independent of previous encounters. Historically, our appreciation of the microbial im-
mune system has been largely restricted to such innate immune response mechanisms.
Conversely, the ability to establish amolecularmemory of previous pathogen encounters
and to elicit an adaptive immune response upon re-infection was considered a hallmark
of higher organisms. Recently, however, a nucleic acid-based prokaryotic adaptive im-
mune system was discovered [12, 13] .
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Figure 1: Prokaryotic defense strategies.
Several defense strategies, innate and adaptive, can act independently or in conjunction to prevent
phage invasion. Adsorption blockage is achieved by masking the cell surface via post-translational
modification, by high mutation rates of the cell surface receptors or blocking phage injection (top
left panels). In case of successful phage entry, the invading DNA is directly targeted by the host’s
restriction enzymes (R); methylation (M,methyltransferase) of host DNAmotives prevents self cleavage
(mid-bottom panel). A second option is the CRISPR pathway (right panel). The foreign genomic
elements are incorporated into the host genome, recalled after a new invasion and used to target
complementary sequences for degradation using an elaborate CRISPR machinery (C). The last resort
is abortive infection, which sacrifices the cell in benefit of the population, before virus replication can
occur (left-bottom panel). Adapted from refs. [9, 10].
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1.2 The CRISPR response in a nutshell
Almost all archaea and half of the bacteria were found to contain clustered regularly in-
terspaced short palindromic repeats (CRISPR), in which mobile genetic elements, such
as sequences derived fromphageDNA/RNAare incorporated (Fig. 1, right panel) [14, 15]
. This process requires an arsenal of CRISPR associated (Cas) proteins and establishes a
molecular memory in the form of a genomic structure where variable, invader-derived
stretches (‘spacers’) alternate with constant, host-specific repeat sequences. Upon re-
infection, the stored information can be accessed in order to destroy invading nucleic
acids. To that end, the locus is transcribed and the transcript is processed into a guide
RNAwith the help of another set of proteins. Finally, an interference complex assembles
around the guide RNA. This complex recognizes and targets sequences complementary
to the guide for nucleolytic degradation – an approach reminiscent of the eukaryotic
RNA inference pathway.
1.3 The CRISPR locus
The machinery required for the CRISPR-mediated immune response is encoded by one
contiguous sequence in the prokaryotic genome. The defining feature of a CRISPR locus,
the repeat-spacer-repeat pattern (Fig. 2), was first discovered by sequencing a chromo-
somal fragment of Escherichia coli [16]. Two decades later, a vast number of CRISPR
arrays in numerous species have been identified and the sheer complexity of the system
has become apparent.
CRISPR locus
Leader
cas genes
SpacerRepeat
Figure 2: The CRISPR locus.
An A/T-rich leader sequence is followed by a series of repeats (black rectangles), separated by variable
spacer sequences derived from invading genetic elements (green–purple). CRISPR-associated (cas)
genes encode the protein machinery. Adapted from ref. [10].
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A combination of computational and molecular biology approaches have shown that
all CRISPR loci share a common design and are composed of four universally present
elements [17, 18]. The first striking feature is a series of short sequences, termed re-
peats, ranging from 20–50 base pairs with a conserved sequence at the 3′ end: GAAAN,
implicated in protein-binding [19]. The repeats of one locus are almost always identical
with respect to size and sequence. However, repeats of different loci vary in sequence,
length and secondary structure of their transcripts. Comprehensive studies of proka-
ryoticCRISPR arrays have classified repeats based on their sequence and found thatmost
bacterial repeats were palindromic, whereas most archaeal repeats were not [19]. The
second feature is determined by non-identical spacer sequences of similar length that
separate the repeats. Analyses of bacterial, archaeal and viral genome sequences have
led to the understanding that the variable spacer elements are virus-derived and confer
resistance to the corresponding viruses [20, 21]. The third element is an adenine/thymine
(A/T)-rich sequence of approximately 100–500 base pairs that flanks the CRIPSR locus
and is termed the leader [14]. Initial observations indicated that new spacers are inser-
ted near the leader sequence. More detailed analyses showed that the leader contains
promoter elements and is a binding site for putative regulatory proteins, controlling ex-
pression and spacer acquisition [22, 23]. The number of the repeat-spacer-repeat clusters
and their individual length is variable within a CRISPR array. Most species containmul-
tiple unrelated loci in their genomes. The total length of each locus spans hundreds to
several thousand base pairs and depends solely on previous exposure of the archaea or
bacteria to the vast diversity of mobile genetic elements.
1.4 The CRISPR-associated protein machinery
A variable cassette of so called CRISPR-associated (cas) genes forms the final building
block of the CRISPR locus (Fig. 2). The cas genes lie adjacent to the CRIPSR array and
encode all proteins that are necessary for mediating the adaptive immune response (Fig.
3) [24]. Cas genes exhibit an exceptional degree of variation and add to the complexity
of the system [25]. Twenty-five cas gene products have been defined to date, of which six
are generally conserved (cas1–6) and only two (cas1 and cas2) are present in all CRISPR
loci [14, 26]. Cas genes encode a large group of proteins with functions ranging from
nucleolytic or helicase enzymatic activity to unique RNA binding properties (Table 1).
4
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Table 1: Overview of major Cas protein families
Cas protein Subtype Name RRM-like Function
family domain
Cas1 I, II, III Cas1 No Adaptation
Cas2 I, II, III Cas2 Yes Adaptation
Cas4 I, II No Adaptation
Csn2 II Csn2 No Adaptation
Cas6 I, III Cas6 Yes Processing:
metal-independent
ribonuclease
Cas7 I, III Subtype-specific Yes Interference:
nomenclature backbone of the
I-A: Csa2 crRNP complex.
I-D: Csc2
I-B/C/E: Cas7 Target Cleavage (RNA):
I-F:Csy3 catalytic Cas7-like
III-A: Csm3 protein Cmr4
III-B: Cmr4
Large I, III I: Cas8 (I-D: Cas10) Yes Interference:
subunit III: Cas10 (Csm1/ interaction with Cas7/5,
Cmr2) capping of 5′ crRNA end,
PAM recognition
Small I, III I-A: Csa5 No Interference:
subunit I-E: Cse2 interaction with Cas7
III-A:Csm2
III-B:Cmr5
Cas5 I, III I:Cas5(a-f) Yes Interference:
III-A:Csm4 (non-catalytic homologs)
III-B:Cmr3 interaction with Cas7/8/10.
Processing:
(catalytic homolog)
(I-C) Cas6 substitute
Cas3 I Cas3 (helicase) No Target cleavage (DNA):
Cas3HD superfamily 2 helicase
and HD-nuclease domain
Cas9 II Target recognition No Processing,
and nuclease lobes Interference,
with two active sites Target cleavage (DNA)
(NHN, RuvD)
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These RNA-binding proteins are commonly known as repeat-associatedmysterious pro-
teins (RAMPs) [24]. They harbor one or more domains that are reminiscent of the RNA
recognition motif (RRM, also known as the ferridoxin-like fold) a structural motif that
is ubiquitously found to be involved in nucleic acid interactions in many protein classes
[27, 28]. In the case of RAMPs, the RRM-like β1-α1-β2-β3-α2-β4 topology is interrupted
by various secondary structure elements. A common feature of all RAMP RRM-like do-
mains is a conserved glycine-rich loop between α1 and β2, which has been implicated in
RNA binding [29]. Conversely, they have lost the conserved consensus sequences on β1
and β3, which often mediate protein–RNA binding in most ribonucleoprotein particles
(RNPs) [27]. Other loops and peripheral domains vary between different RAMPs and
serve as a basis for classification [30].
1.4.1 CRISPR-associated protein classification
Comprehensive phylogenetic, computational and structural studies have defined three
distinct CRISPR systems, each characterized by the presence of a signature gene [30]:
• type I: Cas3, a target-degrading nuclease/helicase.
• type II: Cas9, an RNA-binding and target DNA-degrading nuclease.
• type III: Cas10, a large protein, whose function remains elusive.
The presence and organization of cas genes within the operon further define a total of 10
subtypes (I-A–F, II-A–C, III-A/B) [30]. Complementary ways of classifying the different
CRISPR machineries are based on features of the repeat sequences themselves or on
functional characteristics:
• type I: targets DNA using the ‘Cascade’ interference complex.
• type II: targets DNA using a single protein, Cas9.
• type III-A: targets DNA using the Csm interference complex.
• type III-B: targets RNA using the Cmr interference complex.
An overview of subtype classification and predicted as well as experimentally deter-
mined Cas protein functions is given in Table 1 and Fig. 3.
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Figure 3: Cas systems.
Basedon thepresence of a signature Cas gene (indicatedby an asterisk) theCas proteins canbedivided
into three general types, which coincide with their functional purpose (Type I/II/III-A DNA targeting,
III-B RNA targeting). These are further divided into distinct sub-types (a representative selection shown
in the five panels). While type I and type III systems contain multiple subunits, the type II system
contains a minimalistic set of proteins. Boxes highlight the variation of potential components of the
crRNP complexes for each system. Adapted from ref. [10].
1.5 Three steps towards survival
The CRISPR/Cas-mediated immune response pathway can be divided into three gene-
ral phases, all of which are mediated by single Cas proteins or multiple Cas protein-
containing complexes (Fig. 4):
• Acquisition of new spacers: Nucleases and recombinases acquire and incorporate
new spacers into the host genome between the repeat sequences.
• crRNA biogenesis and processing: CRISPR RNAs (crRNAs) are transcribed from
the repeat and spacer regions and processed into crRNA guides by ribonucleases.
• Target interference and degradation: multi-protein complexes involving RNA-
binding proteins assemble around the crRNA guides. They recognize, capture and
finally degrade DNA or RNA targets with the help of nucleases.
7
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Figure 4: The CRISPR pathway.
Cas genes located adjacent to the repeat-spacer sequences encode a proteinmachinery (Cas proteins),
which administrate the general phases of the immune response. Cas genes, Cas proteins as
well as other involved proteins (grey) are colored based on their functional contribution to spacer
acquisition (yellow), crRNAbiogenesis processing (pink), crRNPassembly and target binding (blue), and
degradation (purple). In the initial step, invading foreign DNA is recognized and processed fragments
(protospacers – green box) are integrated between a repeat of the CRISPR locus. Spacer acquisition
is mediated by the universally conserved proteins Cas1 and Cas2 (yellow circles) and has been linked
to DNA repair/recombination enzymes (grey circle). As a response to new invasion, the second phase
of the CRISPR pathway is initiated: the expression of long primary crRNA transcripts. These are then
endonucleolytically processed into mature crRNAs that serve as a template for the assembly of the
crRNP. In the final interference step, the fully assembled complex detects the complementary target
and initiates its nucleolytic degradation. Adapted from ref. [10]
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1.5.1 Step 1: Acquisition of new spacers
It is widely appreciated that the selection of new spacers from the target DNA (proto-
spacers) is driven by a type-specific short sequence of 2–3 nucleotides in length, collec-
tively known as protospacer adjacent motifs (PAMs) [31, 32]. (Fig. 5). Despite being the
subject of extensive studies, the detailedmolecular understanding of spacer recognition,
fragmentation and insertion remain incomplete. In type I systems, these are located at
the 3′ end of the protospacer, whereas in type II systems they are located at the 5′ end
of the protospacer. Type III systems lack this principle of selection [33]. Upon recogni-
tion, protospacers are processed to a defined length and inserted in a PAM-dependent
orientation [34]. The place of insertion is located within the first repeat, closest to the
leader region [13]. During the process, the leader end repeat is nicked on opposite ends
of the two strands, before the protospacer is inserted. After ligation and gap filling, this
results in the duplication of the first repeat [35]. This mechanism of leader-directed in-
sertion explains why the order of spacers reflects the chronology of infection. Moreover,
initial spacer insertion accelerates subsequent uptake: a positive feedback loop, known
as priming, that enhances resistance [36].
‘Self ’ versus ‘non-self ’ discrimination is central to this system, as it prevents cytotoxic
autoimmune responses. Occasional insertion of chromosomal (self) DNA fragments
have been reported in combination with modified PAMs or systems in which Cas pro-
teins responsible for target recognition are absent [37, 38]. This observation suggests
that the ability to distinguish between self and non-self DNAmay not only lie within the
acquisition but also at the final target interference step.
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Figure 5: Spacer acquisition, biogenesis and processing.
a. In types I and II, protospacers (green) from the invasive genetic material, in this case phage DNA,
are recognized via a short three-nucleotide protospacer adjacent motif (PAM – red). The protospacer
is further processed and the leader end repeat is opened in order to allow spacer integration. During
this process the initial repeat is duplicated. b. The transcription of the CRISPR array produces a long
pre-CRISPR RNA (pre-crRNA), which is primarily processedwithin the repeat sequences (pink triangles).
In type I and III systems, this step is catalyzed by the endoribonuclease Cas6 (pink circle). The product
is a crRNAs in which spacers are flanked by repeat-derived handles: a 5′ handle of 8 nucleotides, and a
longer 3′ handle. The 3′ handle is either a stable hair-pin structure or, if unstructured, it is subject to
additional processing (yellow triangles) by unknown ribonucleases. c. Crystal structure of a Cas6 family
protein in complex with its crRNA substrate. Thermus thermophilus ribonucleases Cas6e (from the type
I-E system; PDB code 4AL7) binds the stem-loop of the crRNA (blue). The active site, which contains a
conserved histidine residue shown as a stick, is encircled. Adapted from ref. [10].
Cas1/2: hallmark proteins of CRISPR
The highly conserved proteins Cas1 and Cas2 together are fundamental for the adapt-
ation phase [35]. Overexpression of both proteins promotes additional spacer inser-
tion, and overexpression of either one leads to a decrease in spacer acquisition. The
presence of Cas1 and Cas2 in all subtypes suggests that this mechanism is universally
conserved. The tight functional interplay between these two proteins is supported by
species-specific fusion of the cas1/cas2 genes and underlined by the recently published
crystal structure of the E. coli Cas1-Cas2 multi-protein complex [39, 40]. The structural
study demonstrates that an intact complex is essential for spacer acquisition in vivo.
However it is Cas1 that is required for initial processing and spacer integration, sug-
gesting a non-enzymatic role of Cas2 in type I-E. Structural characterization of these
two proteins (single and in complex) from different species has shown that they are ho-
modimeric metal-dependent nucleases [40–44]. Cas1 folds into an amino-terminal β-
strand domain via which it dimerizes, and a carboxy-terminal α-helical domain which
harbors the metal-binding site and residues crucial for DNA cleavage. Cas2 harbors an
10
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RRM-like fold with a typical β1-α1-β2-β3-α2-β4 arrangement. Variable loop regions po-
tentially point to the different substrate preferences and subsequent activity (endoribo-
nuclease, deoxyribonucleases) [29]. The β-sheets from two Cas2 proteins form a con-
served metal-binding dimerization interface. However these achievements have not yet
shed light on themolecular mechanism of spacer acquisition. Future investigation of ac-
cessory factors (RecBCD and RuvB), additional type-specific Cas proteins (Csn2, Cas4,
Csa1 and Cas3) and cases of gene fusions (Cas4–Cas1 and Cas1–Cas2, Cas2–Cas3) will
contribute to completing the picture [39, 45, 46].
1.5.2 Step 2: crRNA biogenesis and processing
Upon re-infection, the saved information is utilized and the transcription of the repeat-
spacer-repeat regions is initiated via the regulatory regionwithin the leader (see Box 1).
The resulting long transcripts, termed precursor CRISPR RNAs (pre-crRNAs), are then
endonucleolytically processed in one or more steps by subtype-specific Cas proteins,
yielding the mature crRNA [47, 48]. The latter contains the full spacer sequence and
elements from the repeat, which can then be recognized by the downstream protein
machinery.
Box 1 Expression Regulation.
One explanation for why this unique prokaryotic adaptive immune system re-
mained enigmatic to scientists for such a long time is found in E. coli. In this well-
studied model organism, the CRISPR machinery is transcriptionally tightly regu-
lated, leading to constitutive, but very low expression levels. Although the details
of expression regulation and subtype-specific transcription remain unclear, stress-
dependent factors have been observed such as the disturbance of the cell surface
as well as simultaneous up-regulation along with restriction and modification pro-
teins and the accumulation of CRISPR transcripts by phage exposure. Factors which
possibility control gene expression are small molecules such as cyclic AMP (cAMP)
together with putative transcriptional factors such as Csa3 and Cxs1 (contain dinuc-
leotide binding properties).
11
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Cas6 processing
In both types I and III, the endonuclease Cas6 is responsible for the primary processing
of the pre-crRNA [49, 50]. It is structurally organized around one or two opposing RRM-
like domains, and exhibits strong variation of the additional secondary structure ele-
ments [29]. These contribute to RNAbinding aswell as the positioning of the active site –
a consequence of secondary structure diversity of its substrate, the repeat [48]. Common
to all Cas6 family proteins is the composition of catalytic residues. A highly conserved
histidine joined by a tyrosine or serine and a lysine residue catalyze the nucleophilic at-
tack of a 2′-hydroxyl of a target ribose residue, resulting in cleavage of a single phospho-
diester bond within the repeat. The processed crRNAs typically possess a repeat-derived
5′ handle of 8 nucleotides with a free 5′ OH, followed by the spacer and a repeat-derived
3′ handle of variable size with either a 3′ phosphate or a cyclic 2′-3′ phosphate [48]. This
handle forms a hairpin structure in some systems [50]. In those systems, Cas6 family
proteins (type I-E/type I-F) often exhibit a high affinity towards the hairpin structure
of the repeat and stay associated with the product, laying the foundation of the crRNP
complex [51].
Maturation
In types I-E and I-F, the processed crRNA is the template for crRNP complex forma-
tion [51–53]. In most systems, however, further trimming of the RNA from the 3′-end
is required, resulting in a mature crRNA. Interestingly, in type III systems, this 3′-end
trimming process removes all repeat-derived nucleotides [22, 33]. In addition, trimming
may optionally continue to remove 6 spacer-derived nucleotides, resulting in two dis-
tinct crRNA species (ruler mechanism) [54, 55].
The type II CRISPR system combines the basic molecular mechanisms of crRNA pro-
cessing and later target cleavage. However it predominantly functions with completely
different protein machinery and pathway (Box 2).
12
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Box 2 Subtype II.
Selective pressure has driven the evolutionary diversification of the protein ma-
chinery [37]. In contrast to the closely related pathways and players of the types
I and III, type II possesses the most unique CRISPR locus. Two major differences
in the locus architecture distinguish this subtype from the rest: first, a gene that en-
codes a so-called transactivating crRNA (tracrRNA), consisting of a 25 nucleotide
anti-repeat sequence and region which folds into distinct secondary structure ele-
ments required for Cas9 recognition [56]. Second, only 3–4 cas genes are present,
of which 2–3 encode proteins of the adaptation machinery (Cas1, Cas2, Csn2/Cas4)
[30]. The largest gene, cas9, encodes amultifunctional protein possessing two endo-
nucleolytic activities [57]. This protein alone combines functionalities that are dis-
tributed over many individual proteins in other subtypes.
In type II CRISPR-Cas systems, pre-crRNA transcripts hybridize with complement-
ary sequences of Cas9-bound tracrRNA and are initially processed by RNase III
[56]. PAM-dependent recognition of the foreign nucleic acid sequence guides the
mature Cas9:tracrRNA:crRNA complex to the target [58, 59]. Cas9 then excites its
double endonuclease activity and cleaves the complementary strand with its HNH
domain and non-complementary strand with its RuvC-like domain [57]. Recently
the crystal structures of apo-Cas9 and target-bound Cas9 complex have revealed
the extensive nucleic acid interaction interfaces and a unique bi-lobed architecture
– one lobe responsible for RNAand target binding the other harboring the nucleases
and the PAM interacting domain. [60, 61].
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1.5.3 Step 3: Target interference and degradation
The protein machinery of the crRNP interference complexes:
commonalities and differences
Upon initial Cas6 processing, one or more copies of four Cas proteins assemble around
the guide crRNA [62]. Recent structural and native mass spectrometric studies of types
I-A/C/E/F and III-A/B of the multi-subunit crRNP complexes have shown that the ba-
sic building blocks are universally present (Fig. 6) [51, 63–67]. Despite subtype-specific
variations of crRNP protein composition, a common set of proteins defines the overall
architecture of the interference complexes. Central and common to all complexes is the
helical arrangement of multiple monomers of Cas7 family proteins around the crRNA
[51, 63]. Structural studies of type I-E show how a string of Cas7 monomers cradle the
RNA within a central cleft [51, 68]. Atomic-resolution data of single proteins along-side
bioinformatics studies have defined the common structural denominators of this pro-
tein family: a central RRM-like fold flanked by three distinct peripheral domains, which
together define the central ribonucleotide binding cleft and flexible domain, synergistic-
ally mediating non-canonical RNA binding [29]. EM studies prove that the length of the
guide RNA and further subunits determine the extent of oligomerization and stabilize
the Cas7 backbone (ranging from four to six copies in III-B to seven copies in I-E). At
the 5′ end, Cas7 interacts with the large subunit protein (in type I a Cas8 homolog; in
type III a Cas10 homolog) and a non-catalytic Cas5 family protein [68, 69]. Together
these proteins structurally cap the 5′-end of the crRNP complex. Next, small subunits
coat the helical backbone [68, 69]. These structurally homologous proteins are helical
domains and are subtype-specifically single proteins (Csa5, Cse2 in type I and Csm2,
Cmr5 in type III systems) or extensions of the larger subunits (small helical domain of
Cmr2, predicted helical C-terminal domain of Cas8 homologs) [29, 30]. Electronmicro-
scopy and protein-crosslinking studies of type III-A and -B complexes picture how these
small subunit proteins entwine the Cas7-like oligomer (Cmr4) from foot (larger subunit
Cmr2/Csm1 and Cas5-like proteins Cmr3/Csm4) to head [65, 69]. Beyond this general
organization, prokaryotes have developed a vast phylogenetic divergence amongst the
subtypes, which is reflected in the low sequence conservation and structural homology
within a protein family [30, 70]. This feature is a consequence of the different func-
tional requirements of the respective system: the nature of the target (DNA/RNA) and
its cleavage.
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Figure 6: Overview of the crRNP interference complexes.
a. schematic representation of the subunit composition of different type I and III interference
complexes. The crRNA spacer is colored green, the flanking repeats black. Conserved Cas protein
families as well as the large and small subunits are colored according to their homology. The specific
name of the sub-type is written in brackets and numbers refer to protein names typically used for
individual subunits of each subtype (e. g. subunit 3 of III-A (Csm) refers to Csm3). In type I-A, Cas3
nuclease and helicase domains have been suggested to be part of the complex, in type I-E the Cas3
HD domain is fusedwith the large subunits (highlighted by a dashedmargin). Protein subunits with an
RNA-recognition motif (RRM)-like fold are outlined boldly. The overview illustrates the essential role
of Cas7 proteins in the complex. For type III-A Csm complex an additional small Cas7 homologue has
been proposed (gray).
b. Comparison of selected crystal structures of of types I and III. Left: crystal structure of the type I-E
complex from E. coli: two views of the crRNA-bound complex (120○ rotation; PDB 1VY8), bound to the
dsDNA target (EMDB accession 5314) and with additional Cas3 (EMDB 5929, 5930). Right: Cryo-EM
structure of Sulfolobus solfataricus III-A Csm (EMDB 2420) and pseudo-atomic model of Pyrococcus
furiosus III-B Cmr complex (Benda et al., 2014, [69]). Adapted from ref. [10] and updated with the most
recent available structures.
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Interference and degradation mechanisms
The complementarity of the crRNA spacer to the invading nucleic acids provides the
molecular basis for successful target capture and subsequent degradation. In addition,
the immune response requires subtype-specific Cas proteins that facilitate sequence re-
cognition, stabilize the hybridization and expose the target to nucleolytic cleavage.
Interference
In type I systems, two factors are responsible for target binding: First, PAM sequence re-
cognition not only plays a role for the integrationmachinery, but the samemotif ensures
specificity of target recognition [71]. As the sequence is not complementary to crRNA,
protein interactions mediate PAM recognition [72]. Chemical probing and EM studies
have connected proteins of the crRNP complex such as E. coli Cse1 to PAM scanning
[72]. In type III systems, which work PAM-independently, the role is attributed to the
left-over 5′ repeat derived handle. Base-pairing of this with chromosomal host DNA in-
hibits the interference step and prevents self-destruction [33]. How type III complexes
facilitate target binding beyond the general non-specific binding events and thermal dif-
fusion remains elusive and will be better understood as soon as high resolution struc-
tural data with the target become available. The second factor that favors hybridization
in type I and III-A complexes is the so-called seed sequence [51, 73]. This stands for the
first 8 nucleotides (1–5, 7–8) of the spacer. Single mutations in the seed sequence escape
the machinery, while mutations in other regions of the spacer will still bind with high
affinity [51, 71].
Degradation
In Type I pathways, correct base pairing induces the recruitment of Cas3 and crRNA
guided ATP-independent strand unwinding of the dsDNA, which results in R-loop for-
mation [74]. Interestingly, biochemical data show that base pairing of crRNA and target
DNA occur every 5–6 helical segments, with short non-helical segments up to three
bases in between [51, 68]. This binding pattern is reminiscent of the DNA-DNA interac-
tion mediated by the RecA protein during homologous recombination [75]. In addition,
hybridization coincides with conformational changes within the complex, visualized by
electronmicroscopic studies of apo and target-bound complexes [51, 76]. This conform-
ational change is believed to induce the recruitment of a Cas3 supposedly in close prox-
imity to the large subunit and Cas5 of the complex. In type I-E Cas3 a superfamily 2
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Figure 7: Target recognition and interference in type I and III crRNP interference complexes.
The mechanism of target binding and degradation differs with regard to the substrate’s (RNA in blue,
DNA in gray) and system’s protein machineries.
a. type I, Cascade. b. type III-A, Csm. c. type III-B, Cmr. Interference complexes are represented in
blue; protospacer-adjacent motif (PAM) highlighted in red; arrows indicate directionality of cleavage.
Adapted from ref. [10].
helicase domain is fused to a HD-nuclease [30]. The HD domain can be subtype spe-
cifically expressed as a single protein (I-A) or is fused with either the large subunit (I-D,
III-B) or with Cas5 (I-B) protein [30]. For type III pathways, the understanding of target
recognition and cleavage remains fragmentary. It is appreciated that type III-A Sulfolobus
solfataricus Csm complexes target DNA in vivo, with potential involvement of Csm6, a
Csx1 family protein [55]. Recent studies fromV. Siksnys show that aCsm complex cleaves
ssRNA in vitro via the catalytically active Cas7 family protein Csm3 (V. Siksnys, personal
communication). Similarly in type III-B the Cas7 family protein Cmr4 has been shown
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to possess ribonucleolytic activity [69]. Cas7 target cleavage explains the presence of a
distinct cleavage pattern due to multiple active sites [22, 69].
The complex interplay of these proteins assures an effective immune response. The grow-
ing availability of structural data of single proteins and sub-complexes confirms bioin-
formatic classification. Combined efforts have contributed to the global appreciation of
the CRISPR immune response. Despite the current general understanding of the path-
ways and detailed insights in functionalities of single proteins, molecular details and
evolutionary connections remain elusive. The future of CRISPR research relies both on
high-resolution atomic models of protein-nucleotide complexes and advanced know-
ledge of selective pressure within different ecological contexts.
1.6 Beyond adaptive immunity
1.6.1 Alternative CRISPR functions in prokaryotes
The CRISPR/Cas system developed functions outside the realm of innate immunity,
some of which have evolved alongside its primary function. For instance, constitutive
nuclease activity is prone to cause off-target cleavage effects. It is probably for this reason
that Cas1 from the E. coli system I-E was found to associate and interact with known
DNA repair factors and to be co-regulated with them after irradiation [46]. Off-target
effects also generate an selective advantage for strains with increased selectivity for non-
self (protospacer) vs. self (spacer) sequences and increase evolutionary fitness by accel-
erated local mutation rates [33]. Finally, the versatility of the system has led to it being
repurposed, both by nature as a means of endogenous gene regulation, as well as by
scientists as an extremely versatile tool for genome editing and manipulation (Box 3)
[57, 77].
1.6.2 CRISPR versus RNAi
The programmable, sequence-directed, RNA-guided character of the CRISPR system
has intriguing analogies to the eukaryotic RNA interference (RNAi) and related path-
ways [12]. In both cases, a protein machinery acts on nucleic acids, resulting in blockage
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of gene function. Specificity is conferred not by the proteins, but solely by the sequence
of an RNA guide that is processed from a longer precursor [78]. Inmany cases, the guide
RNAaswell as the target is originally derived from an invading genetic element, such as a
virus or transposon, pointing at the evolutionary origin of both systems [79]. However,
apart from these general principles, the prokaryotic and eukaryotic systems have dis-
tinct features: First and foremost, the protein machinery is entirely different and shows
no similarity on sequence or structural levels [78, 80]. crRNA transcripts arise from ge-
netic information that was incorporated into the host genome, whereas RNAi guides
can be derived directly from the invasive nucleic acid [79]. Moreover, crRNA tran-
scripts are single-stranded, with some systems requiring specific secondary structure
elements. In contrast, RNAi requires long double-stranded RNA precursors, includ-
ing stem-loop structures [80]. CRISPR/Cas systems act predominantly on invasive ele-
ments, whereas the RNAi machinery has been extensively repurposed for the regulation
of endogenous transcripts, for instance by way of microRNAs; endogenous gene regula-
tion by CRISPR/Cas is only beginning to emerge in some species [22, 77]. Finally, RNAi
targets are exclusively RNAs, whereasCRISPR/Cas can act on bothDNAandRNA. From
a biotechnological point of view, this enabled scientists to exploit CRISPR/Cas for gen-
ome editing, whereas RNAi can be used only for post-transcriptional gene regulation.
Box 3 CRISPR-based technologies.
Given its simplicity, scientists have recognized the powerful potential of the type
II pathway and rapidly exploited it for genetic engineering [57]. For this, the
tracrRNA-crRNA duplex is substituted by a single guide RNA (sgRNA) – a fusion
of the two RNA molecules. This eliminates the maturation steps required for Cas9
activation and allows the synthetic production of a vast variety of guide RNAs. The
RNA-programmable Cas9 is directed towards site-specific DNA cleavage. Further
genetic manipulation of Cas9 itself and its nucleic acid partners expand the reper-
toire of Cas9 genome editing from insertion, deletions, silencing, directed target of
proteins to a DNA sequence in prokaryotes up to higher eukaryotes [81, 82].
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1.7 Aim of the thesis
The heart of the CRISPR/Cas-mediated immune response pathway is the interference
complex. In type I and III systems, multiple Cas7 proteins assemble around the guide
crRNA, pre-ordering the RNA in a helical fashion. Depending on Cas7 position in the
backbone, it contacts either Cas6, the large and small subunit. Thus Cas7 possesses mul-
tiple interaction surfaces for nucleic acid as well as protein interactions. I sought to in-
vestigate the structural basis that enables this versatile function and distinguishes Cas7
from the othermajor protein families. Due to poor sequence conservation, the structural
biological approach was indispensable for subsequent biochemical analysis.
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2.1 Publication 1: Structure and RNA-binding properties of the type III-A CRISPR-
associated protein Csm3
Hrle, A., Su, A. A., Ebert, J., Benda, C., Randau, L., Conti, E. Structure and RNA-binding
properties of the type III-A CRISPR-associated protein Csm3. RNA Biol. (2013)
Themanuscript ‘Structure andRNA-binding properties of the type III-ACRISPR-associ-
ated protein Csm3’ presents the first high-resolution protein structures of a Cas7 protein
of the type III interference complex. The 2.37 Å crystal structure of MkCsm3 shows
that three domains are arranged around a central RRM-like fold. Structural superpos-
ition with representatives of the major Cas superfamililies 5, 6 and 7 confirm bioin-
formatic predictions that Csm3 is a Cas7 protein. MkCsm3 binds RNA in a sequence-
independent manner, but relies on a minimal length of 15 nucleotides. Based on surface
potential and conservation we investigated the RNA-binding interface. Mutation ana-
lysis pinpointed a conserved surface area involved in RNA binding.
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Introduction
For a long time, prokaryotic immune systems were believed to 
be restricted to “innate” immunity mechanisms (e.g., restriction 
modification systems)1 and to defense mechanisms that result 
in cell death upon infection (e.g., toxin-antitoxin systems).2 In 
the past decade, however, it has become clear that prokaryotes 
have evolved sophisticated and diverse adaptive immune systems 
that memorize previous attacks of foreign genetic elements. 
These systems consist of clustered regularly interspaced short 
palindromic repeats (CRISPR) and CRISPR-associated (Cas) 
proteins.3-5 CRISPR-Cas is a nucleic acid-based defense system 
against mobile genetic elements such as viruses.5 The CRISPR-
Cas machinery distinguishes foreign (non-self) target DNA from 
(self) targets that are, for example, provided by a host CRISPR 
locus.6,7
The central element of CRISPR arrays is the arrangement 
of DNA sequences of variable length (spacers) derived from 
foreign genetic elements and separated by short 24–48 nt repeat 
sequences.5 Upon infection, these clusters are transcribed into 
precursor crRNAs (pre-crRNA), which then are processed into 
mature CRISPR RNAs (crRNA).8-10 The common features of 
mature crRNAs are the spacer, which identifies the matching 
target (protospacer) via base pairing, and the 5’-terminal 8 nt 
repeat tag (psi-tag), which is complementary to the self DNA 
but not to 2–4 nt short protospacer adjacent motif (PAM) 
sequences.11 Adjacent to this array are the cas genes.12,13 These 
encode proteins that are responsible for mediating the CRISPR 
response and that have a variety of functions, including nucleic 
acid binding and cleavage.14
CRISPR-Cas systems have been classified into three main 
types (I, II, and III) and 10 subtypes by bioinformatic analyses 
based on their cas gene organization, on the sequence and the 
structure (known or predicted) of the corresponding proteins.15 
The three CRISPR types also differ in the composition and 
mechanisms of their effector complexes.16 Type I effector 
complexes are termed Cascade (CRISPR-associated complex for 
antiviral defense), type II effector complexes consist of a single 
Cas protein and two RNA molecules, and type III interference 
complexes are further divided into type III-A (Csm complex 
targeting DNA) and type III-B (Cmr complex targeting 
RNA).11,17 In recent years, structural information on Cas proteins 
has started to provide insights into the molecular mechanisms of 
crRNA binding and target recognition. The combination of X-ray 
crystallography8,18-22 and electron microscopic studies of the type 
I Cascade23-25 and of the Type III-B Cmr-complex26-28 has shown 
how some of the Cas proteins interact and bind crRNA.
Type I effector complexes are built around a central 
backbone composed of proteins of the Cas7 family.23,29 The 
crystal structure of a Cas7 type I protein has revealed the 
presence of a central RRM/ferredoxin-like domain with several 
insertions and a C-terminal extension.29 In type I systems, Cas7 
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The prokaryotic adaptive immune system is based on the incorporation of genome fragments of invading viral genetic 
elements into clustered regularly interspaced short palindromic repeats (cRIsPRs). The cRIsPR loci are transcribed 
and processed into crRNAs, which are then used to target the invading nucleic acid for degradation. The large family 
of cRIsPR-associated (cas) proteins mediates this interference response. We have characterized Methanopyrus kandleri 
csm3, a protein of the type III-A cRIsPR-cas complex. The 2.4 Å resolution crystal structure shows an elaborate four-
domain fold organized around a core RRM-like domain. The overall architecture highlights the structural homology to 
cas7, the cas protein that forms the backbone of type I interference complexes. csm3 binds unstructured RNAs in a 
sequence non-specific manner, suggesting that it interacts with the variable spacer sequence of the crRNA. The structural 
and biochemical data provide insights into the similarities and differences in this group of cas proteins.
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oligomerizes upon crRNA binding. In the best-characterized 
effector complex so far, the Escherichia coli Cascade complex, the 
crRNA binds within a super-helical grove formed by six copies of 
Cas7.23,30 This helical arrangement has also been observed within 
other type I systems.29,31,32 Despite the absence of significant 
sequence similarity, bioinformatic analysis has predicted that 
Cas7-like proteins also exist in type III systems.33 Recently, it was 
shown that a Csm3 (CRISPR-Cas Subtype Mtube, protein 3) 
from Staphylococcus epidermidis binds RNA molecules at multiple 
sites.34 Here, we present the crystal structure and RNA-binding 
properties of Methanopyrus kandleri Csm3. The structural and 
biochemical analysis of this type III-A Cas protein indicates 
that Csm3 is a Cas7-like protein capable of binding crRNA, 
suggesting it forms the backbone of the CRISPR-Cas Type III-A 
system effector complex.
Results and Discussion
Structure determination of Csm3
We expressed full-length Methanopyrus kandleri (Mk) Csm3 
(351 residues) in E. coli and purified it to homogeneity (Fig. S1A). 
Mk Csm3 yielded crystals in an orthorhombic space group 
(C222) containing two molecules per asymmetric unit and 
diffracting beyond 2.4 Å resolution. An X-ray fluorescence scan 
on the crystals showed an unexpected peak at the Zinc excitation 
energy, suggesting the presence of intrinsically bound Zinc ions 
in the crystallized protein. We exploited the presence of this 
anomalous scatterer to solve the structure by single-wavelength 
anomalous dispersion method (SAD). The phases (obtained from 
a single bound Zinc ion) were of sufficient quality to build the 
polypeptide chain. The structure was refined at 2.37 Å resolution 
to an R
free
 of 21.0%/R
work
 of 18.0% and good stereochemistry 
(Table 1). The final model includes most of the protein, with the 
exception of a disordered region between residues 200 and 214. 
The two independent molecules in the asymmetric unit are very 
similar, superposing with a root mean square deviation (rmsd) of 
0.22 Å for more than 95% of the Cα atoms. Static light scattering 
experiments of Csm3 in solution showed a mass of 33.3 kDa 
(Fig. S1B), consistent with the presence of a monomeric species. 
Thus, the interaction of the two molecules in the asymmetric unit 
reflects crystal packing contacts and not a physiological oligomer.
Csm3 is built of four domains organized around a central 
RRM-like fold
The crystal structure of Mk Csm3 reveals a compact 
architecture that can be described as composed of four domains: 
the core, the lid, the helical, and the C-terminal domains (Fig. 1A, 
in green, blue, red, and yellow, respectively). The core domain 
has a β1-α1-β2-β3-α2-β4 arrangement of secondary structure 
elements (Fig. 1B) with a topology typical of RRM-like and 
ferredoxin-like folds. Accordingly, the Mk Csm3 core domain 
folds into an antiparallel β-sheet, with two α-helices packed 
against the concave (back) surface. However, several features set 
the Mk Csm3 core domain apart from canonical RRM-like folds. 
In the β-sheet, strand β1 is long and highly bent, with a glycine 
Data collection
Native Native, Zn-SAD
Resolution range (Å) 69.49 - 2.37 (2.49 - 2.37) 49.86 - 3.20 (3.00–3.08)
Unit cell(Å)a
a = 95.75
b = 101.02
c = 174.17
a = 70.51
b = 70.51
c = 193.36
Total reflections 308429 672581
Unique reflections 34685 38958
Multiplicitya 8.9 (7.1) 56.3 (52.4)
completeness (%)a 99.5 (95.2) 99.9 (99.7)
Mean I/sigma(I) a 17.10 (2.72) 32.72(1.76)
Refinement
B-factor 42.57
R-factor(%) 18.09
R-free(%) 21.34
RMsD(bonds) (Å) 0.005
RMsD(angles) (Å) 0.85
Ramachandran favored (%) 95
Ramachandran outliers(%) 0.15
Table 1. Data collection and structure refinement statstics of csm3
aValues in parentheses correspond to the highest resolution shell.
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residue (Gly12) at the bending point effectively dividing it into 
two separate structural elements (strands β1
A
 and β1
B
, Fig. 1B). 
Strands β3 and β4, which sandwich β1, are also elongated (~12 
residues), while strand β2 is very short (three residues).
The secondary structure elements of the core are connected 
by loop regions ranging from 2–10 amino-acid residues (between 
β3-α2 and between α2-β4, respectively) or by larger insertions 
(between β1-α1, β2-β3, and α1-β2) (Fig. 1A and B). The 
35-residue long β1-α1 insertion contains a short β-hairpin 
and a one-turn α-helix (α
A
). On one side, it packs against 
the 45-residue long β2-β3 insertion, which also contains an 
α-helix (α
G
). On the other side, it packs against the α2-β4 
loop. Overall, these interactions form the lid domain, which is 
positioned at the top of the β-sheet and is partially disordered (at 
a glycine-containing loop in the β2-β3 insertion).
The 100-residue long α1-β2 insertion contains five short 
α-helices (α
B
 to α
F
) connected by extended segments (Fig. 1A 
and B). This insertion forms the α-helical domain and wedges 
between the two helices (α1 and α2) of the core domain, near 
the short edge of the β-sheet (i.e., near β2). The helical domain 
Figure 1. structure of Methanopyrus kandleri csm3. (A) The structure of Mk csm3 can be divided into four distinct elements: the core (green) and lid 
domain (blue), a helical N-terminal (red), and a c-terminal domain (yellow). The structural elements of the core adopt a ferredoxin-like fold with β-α-β-β-
α-β arrangement. The core is topologically interrupted by multiple insertions forming the lid and the helical N-terminal domain. The c-terminal domain 
packs against the core and is of mixed structural composition. The dashed blue line represents the missing disordered region between residues 200 
and 214. The two views are related by a 180° rotation as indicated. (B) Topology diagram of Mk csm3. helices are represented as circles and β-strands 
as arrows. The secondary structure elements have been labeled numerically maintaining the nomenclature of RRM domains. The β-strands of the 
c-terminal domain extending the RRM β-sheet have also been labeled numerically. The additional α-helices have been labeled with letters (αA to αL). (C) 
A structural zinc ion present in the helical N-terminal domain is shown as a gray sphere, together with the coordinating residues (a cysteine and three 
histidine residues).
24
Publication 1: Structure and RNA-binding properties of Csm3
www.landesbioscience.com RNA Biology 1673
binds a Zinc ion that is buried and is likely to have a structural 
role in stabilizing the fold of this domain (Fig. 1C). It connects 
helices (α
D
 to α
E
) and is coordinated by His86, Cys88, Cys115, 
and Cys118. Only the latter two residues are well conserved 
among Csm3 orthologs (Fig. S4A). However, other cysteine and 
histidine residues are present in the α1-β2 insertion of Csm3 
from other species (Fig. S4A). It is thus possible that other Csm3 
proteins might have a Zinc-binding domain in the corresponding 
region of the structure, albeit with a different topology.
Finally, the RRM-like domain is followed by a C-terminal 
domain (αH-β6-αI-αJ-β5-αK-αL) (Fig. 1A and B). The 
C-terminal domain extends the core β-sheet by two antiparallel β- 
strands (β5 and β6), which flank the long edge of the core domain 
β-sheet (at β4). It also contains three short α-helices and a long 
C-terminal α-helix. The C-terminal α-helix packs against α2, 
at the convex surface of the β-sheet. The short helices (αI and 
αJ) contact the lid and partly occlude the front surface of the 
β-sheet. In canonical RRM domains, this front surface features 
hydrophobic residues that are part of the so-called RNP1 and 
RNP2 motifs and that bind RNA.35 However, Mk Csm3 lacks 
the typical solvent-exposed hydrophobic residues that bind RNA 
in canonical RRM domains. Thus, the Mk Csm3 RRM seems 
to fulfill a structural purpose similar to other previously reported 
examples.36,37
Structural comparison of Csm3 with the Cas proteins of the 
RAMP superfamily
We compared the structure of Mk Csm3 with those of Cas5, 
Cas6, and Cas7, which represent the three major groups of 
Figure 2. structural similarity between csm3 and cas7. (A) Sso cas7 (PDB ID: 3Ps0, rmsd: 4.2Å, blue) shares the highest structural homology with Mk 
csm3 (gold) beyond the core domain (gray). Both proteins have a similar arrangement of auxiliary domains surrounding the RRM-like fold, as well as a 
conserved architecture of the c-terminal domain. (B) Topology diagram of Mk csm3 and Sso cas7 showing the connectivity of the RRM fold relative to 
the other domains. The topological arrangement of the insertions is similar in both proteins. similarities in secondary structure elements are highest 
within the core and low in the auxiliary domains.
25
2 Results
1674 RNA Biology Volume 10 Issue 11
evolutionary distinct RRM-containing proteins in the RAMP 
(repeat-associated mysterious protein) superfamily15 (Fig. 
S2A). Bacillus halodurans (Bh) Cas5d (PDB ID: 4F3M) has 
two RRM-like domains adjacent to each other and functions 
as an endoribonuclease in the pre-processing of crRNA 
transcripts. The N-terminal RRM-like domain contains the 
putative endoribonuclease site, which is centered at a histidine 
residue.18,31 Pyrococcus furiosus (Pf ) Cas6 (PDB ID: 3UFC) 
has an N-terminal RRM-like domain that packs against a 
twisted β-sheet domain.21 This RRM-like domain contains an 
endoribonuclease site that is also centered at a histidine residue, 
although the exact position differs from that of Bh Cas5d. The 
similarity of Mk Csm3 with Bh Cas5d and Pf Cas6 is limited 
to the RRM-like domain (Fig. S2A). Using the structural 
alignment program SSM as implemented in Coot,38 Mk Csm3 
superposed with Bh Cas5d with an rmsd of 3.9 Å over 80 Cα 
atoms and with Pf Cas6 with an rmsd of 4.1 Å over 125 Cα 
atoms. No prominent histidine residue or possible catalytic 
triad is however apparent from these structural alignments of 
Csm3. Consistently, Mk Csm3 did not exhibit any prominent 
endonucleolytic activity with repeat RNA or precursor RNA 
substrates (data not shown).
Bioinformatic analyses have predicted that Csm3 belongs to the 
Cas7 family of RAMP proteins.39 Superposition of Mk Csm3 with 
the Sulfolobus solfataricus (Sso) Cas7 (PDB ID: 3PS0) structure 
results in an rmsd of 4.2 Å over 110 Cα atoms. As with Cas5 
and Cas6, the structural similarity with Cas7 is primarily at the 
RRM-like domain. However, Mk Csm3 shares significant overall 
architectural analogy with Cas7 (Fig. 2A). In particular, the two 
proteins have a similar arrangement of domains around the RRM-
like fold. Cas7 contains a lid domain, a (mostly) helical domain, 
and a C-terminal domain at equivalent structural positions as 
described above for Csm3 (Fig. 2B). Although Cas7 is not a Zinc-
binding protein and although the exact topological arrangement 
of secondary structure elements differs from Mk Csm3, the overall 
dimensions and shape of the two proteins is remarkably similar 
(Fig. 2A). As Cas7 is a scaffold RNA-binding protein, we assessed 
whether Mk Csm3 might have similar RNA-binding properties.
Csm3 binds single-stranded RNAs in a sequence non-
specific manner
Figure 3. RNA-binding properties of csm3. (A) Mk csm3 binds to a physiological crRNA substrate (left panel). 32P-labeled crRNA transcripts were incu-
bated in the absence or presence of 5 µM, 10 µM, and 20 µM Mk csm3. (B) electrophoretic mobility shift assays were performed with the respective 
[32P]-5’-end labeled RNAs and increasing concentrations of Mk csm3 (0 µM, 1 µM, 30 µM, 100 µM). Mk csm3 binds to single-stranded RNA substrates (lane 
16–20) but not significantly to the repeat sequences (lanes 1–5 and 6–10). Binding to single-stranded RNA is dependent on length but not sequence 
(compare lanes 16–20 and 11–15). Weak binding of Mk csm3 to processed and unprocessed repeat sequences (lanes 1–5 and 6–10, respectively) is likely 
attributed to the ssRNA overhangs. (C) Methanopyrus kandleri repeat sequence conservation and predicted RNA folding.
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We performed electrophoretic mobility shift assays (EMSA) 
with crRNA substrates that were generated by in vitro 
transcription (Fig. 3A). These assays indicated that Mk Csm3 
binds crRNAs (Fig. 3A). The Mk crRNAs contain a highly 
conserved repeat sequence of 36 nucleotides that includes a 
predicted stable stem-loop of 16–18 nucleotides (Fig. 3B) and 
a highly conserved eight nucleotide AATGAAA(C/G) motif at 
the 5’ end (psi-tag). They also contain variable spacer sequences 
ranging from 40–50 nucleotides.40 We dissected which parts 
of the crRNA are recognized by Mk Csm3. In gel-shift assays, 
Csm3 showed weak binding to processed and unprocessed repeat 
sequences (Fig. 3C), but not to its stem-loop structure alone (Fig. 
S3A). We tested whether Mk Csm3 binds single-stranded RNA, 
which is present in part of the repeat sequence as well as in the 
variable spacer. In gel-shift assays, Csm3 bound a 15-mer polyU 
RNA or 15-mer polyA about 10 times stronger than the repeat 
sequence (Fig. 3A). Thus, the length of the single-stranded RNA 
might affect the strength of the interaction with Mk Csm3. Mk 
Figure 4. Identification of csm3 RNA-binding residues. (A) The structure of csm3 is shown in surface representations, in the same orientations as in 
Figure 1A, colored according to electrostatic potential. charged patches (blue) are present at the back of the lid domain as well as at the interface 
between the core and N-terminal helical domain. Negatively charged surfaces (red) are located along the front of the N-terminal insertion and cover 
the c-terminal domain. Two surface patches discussed in the text (patch 1 and 2) are indicated. (B) corresponding surface representations of csm3 
colored according to conservation with the csm3 family. The conservation is based on a comprehensive alignment (Fig. S4B). Increase in conservation 
is shown in increasingly darker shades (from to red). No or low conservation (white and yellow) is found in the N-terminal insertion and the c-terminal 
domain. highly conserved residues (orange and red) are located within the lid (patch 1) and core domains (patch 2) and coincide with positively charged 
surfaces (A). (C) sequence alignments of csm3 orthologs in regions corresponding to surface patches 1 and 2 (A and B). Residues selected for mutation 
analysis are highlighted with red dots. The unstructured loop (h199-s214) replaced by a (Gs)3 linker is represented as a dashed red line. (D) RNA binding 
of csm3 mutants to a single-stranded RNA substrate U15. Wild-type (WT) protein and the double mutation within the core domain (patch2) bind with 
comparable affinity. Replacement of the unstructured loop (h199-s214) by a -(Gs)3- linker does not impair binding, while the single mutation R21A has 
completely lost RNA binding ability at this condition. (E) coomassie-stained 12% sDs-PAGe gel of the purified protein samples used in the assays.
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Csm3 did not exhibit detectable RNA binding toward the 8 nt 
psi-tag in the gel-shift assays (Fig. 3C; Fig. S3A). We conclude 
that Mk Csm3 binds single-stranded RNAs from 15 nucleotides 
onwards in an apparently sequence non-specific manner and that 
RNA structures impair binding. This suggests that the variable 
sequence of the crRNA is bound by Mk Csm3, rather than the 
structured and conserved repeat.
To identify the RNA-binding interface, we examined the 
surface features of Mk Csm3 in terms of charge distribution 
(Fig. 4A) and evolutionary conservation (Fig. 4B and C). The 
lid domain contains a striking patch (1) of conserved and surface-
exposed positively charged residues including Arg217, Arg263, 
and Arg267 (Fig. S4A). Another positively charged residue, 
Arg21, is located at the center of this patch and approaches the 
position of Sso Cas7 His160, a residue that has been shown to be 
important for RNA binding.29 A single mutation of Mk Csm3 
Arg21 to Ala abolished RNA binding in EMSA assays (Fig. 4D). 
In the lid domain, the positively charged surface patch is near 
the disordered glycine-containing loop (Fig. 4C). This loop is 
conserved (Fig. 4C) but does not appear to be involved in RNA 
binding, as its deletion did not show a significant change in 
the EMSA assay as compared with the wild-type (WT) protein 
(Fig. 4D). Another striking surface patch (2) of Mk Csm3 is 
located at the interface between the lid domain and the helical 
domain. In particular, helix α1 exposes several conserved 
residues, including Pro50, Ser52, Ser53, and Arg57 (Fig. S4B). 
Mutation of this conserved surface patch (2), however, did not 
significantly impair RNA binding (Fig. S4C). We concluded 
that Csm3 uses the lid domain to bind single-stranded RNA. It 
is possible to envisage that the other conserved surface patches 
on Csm3 mediate other types of macromolecular interactions, 
including protein–protein interactions that form in Csm3-
containing effector complexes.
Conclusions
CASCADE/Cmr/Csm complexes share common 
functionalities, as reflected in their similar composition of 
proteins. Proteins of the Cas7 family are the backbone of the Type 
I effector complexes and are involved in interactions with both 
crRNA and other Cas proteins.19,29,32 Computational analyses 
predicted that Csm3 might fulfill the role of the backbone protein 
Cas7 in type III interference assemblies.39 Here, we show that Mk 
Csm3 has indeed a remarkably similar architecture as compared 
with Sso Cas7. We found that the structural similarity involves 
not only the central RRM-like domain, but also insertions at 
equivalent structural positions in the RRM fold. At the sequence 
level, however, the two proteins have almost completely diverged.
In line with the structural similarity to Cas7, Mk Csm3 
recognizes crRNA. We found that Csm3 binds to a variable 
sequence of ssRNA via the flexible insertion that forms a lid on 
top of the RRM domain. The overall affinity toward RNA is 
significant yet not strong. It is abolished through mutation of an 
arginine residue (Arg21Ala) yet hardly reduced when mutating 
other conserved residues within the positively charged surfaces. It 
is possible however that this region contributes to RNA binding 
when in the context of a fully assembled Csm complex. Type III 
systems further process premature crRNA to mature crRNA; 
Csm3, together with Csm2 and Csm5, were reported to be required 
for crRNA 3’ termini maturation.41 However, in our studies, we 
could not identify potential catalytic residues nor could we observe 
nucleolytic activity in biochemical assays. This is in agreement with 
S. epidermidis Csm3 studies indicating that crRNA maturation 
cleavage events are not performed by the Cas10/Csm complex.34
Cas7 proteins oligomerize with a helical arrangement around 
the crRNA and interact with other Cas proteins of the effector 
complex, such as the Cas5 in Type I-A.42 The S. solfataricus 
Cas7 protein was shown to be monomeric and is thought to 
require Cas5 and crRNA for nucleation and stabilization of its 
assembly.29 In agreement, Mk Csm3 also behaves as a monomer 
in solution and might only oligomerize in the context of the Csm 
complex. It is possible that the insertion domains that surround 
the RRM and/or the RRM itself might provide interfaces for 
protein–protein interactions.35 We note, however, in contrast 
to observations with bacterial S. epidermidis Csm3, we did not 
observe binding of RNA molecules in six nucleotide increments 
for Mk Csm3.34 Our structural observations provide a first 
step toward the structural elucidation of the Csm proteins and 
their respective role in the surveillance complex. Additionally, 
the structure will contribute to characterizing the evolutionary 
relationship within the Cas7 protein family. Further tentative 
type III members of this family (Cmr1, Cmr4, Cmr6, Csm5)39 
remain to be analyzed and classified.
Experimental Procedures
Protein expression and purification
Mk Csm3 wild-type and mutant proteins were expressed as 
recombinant His- and His-SUMO-tagged fusion protein using 
BL21-Gold (DE3) Star pRARE (Stratagene) in TB medium 
and induced overnight at 18 °C. The cells were lysed in buffer A 
(50 mM Tris pH 7.5, 200 mM NaCl, 10% Glycerol) supplemented 
with 10 mM Imidazole, DNase, protease inhibitors (Roche) by 
sonication. Proteins (wild-type and mutants) were purified using 
Nickel-based affinity chromatography. The His-SUMO tag was 
cleaved by adding SUMO protease overnight. Proteins were 
further purified by size-exclusion chromatography (Superdex 75, 
GE Healthcare) in gel-filtration buffer (buffer A supplemented 
with 2 mM DTT). Point mutations were introduced by Quick 
Change site directed mutagenesis according to the manufacturer’s 
instruction (Stratagene).
Crystallization, data collection, structure determination, 
and analysis
Crystallization was performed at room temperature using 
hanging drop vapor diffusion method and equal volumes of the 
protein at 20 mg/ml (gel-filtration buffer) and of crystallization 
buffer (25% MPD and 50 mM MES 6.0). Crystals were both 
flash-frozen directly from the crystallization drop as well as 
subjected to further dehydration (increasing amounts of MPD 
up to 60%) and diffracted beyond 2.4 Å.
All diffraction data was collected at 100 K at the beamline 
PXII of the Swiss Light Source (SLS) synchrotron and processed 
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using XDS.43 The structures were determined using the native 
data and Zn-SAD phases to build an initial model. This was 
then used as a search model for molecular replacement of higher 
resolution data using Phaser.44 Model building was performed 
manually with the program Coot38 and refined with PHENIX.45 
The data collection and refinement statistics are summarized 
in Table 1. Figures were prepared using PyMOL (http://www.
pymol.org).
Biochemical assays
The RNA molecules U15, A10, A15, A20, A40 were synthesized 
(Purimex). The crRNA (locus 5, spacer 5) was produced by in 
vitro run-off transcription and purified by elution of the crRNA 
transcript from a polyacrylamide gel as described.10 The RNA 
molecules were 5’-labeled with T4 polynucleotide kinase (New 
England Biolabs) and γ-[32P] ATP (Perkin- Elmer).
For the gel-shift assays, 0.5 pmol labeled RNA was mixed 
with 1 µM, 10 µM, 30 µM, 100 µM protein in a 10 µL reaction 
containing 20 mM Hepes at pH 7.5, 100 mM KOAc, 4 mM 
Mg(OAc)
2
, 0.1% (vol/vol) NP-40, and 2 mM DTT. Fifteen 
ng/µL (500 fmol/µl = 500x molar excess) yeast tRNA mix 
(Amicon) were used as non-specific and 15 ng/µl unlabeled 
crRNA transcripts were used as specific competitor molecules. 
The mixtures were incubated for 20 min at 55 °C before adding 
2 µL 50% (vol/vol) glycerol containing 0.25% (wt/vol) xylene 
cyanole. Samples were run on a 8% (wt/vol) polyacrylamide 
gel at 4 °C and visualized by phospho-imaging (GE 
Healthcare).
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Supplementary Figure1 
Analysis of the protein used in biochemical assays 
(A) Coomassie-stained SDS-PAGE and size exclusion chromatography elution profile of 
purified MkCsm3. 
(B) Static light scattering (SLS) chromatogram and values underline the monomeric 
behaviour in solution. 
 
Supplementary Figure 2 
Structure and sequence-based similarities of Csm3 with key Cas proteins 
(A) Structure-based homology modeling of Mk Csm3 (gold) with known structures of 
CRISPR proteins (blue) structurally manually aligned based on the DALI server output and 
their common feature, the ferredoxin fold. The protein is shown in the same orientation to that 
used in Figure 1. The ferredoxin-like fold is the region of highest conservation. The homology 
of the N-terminal ferredoxin fold domains of Bh Cas5d (PDB ID: 3KG4, rmsd: 3.9) and 
Pf Cas6 (PDB ID: 3UFC, rmsd: 4.1Å) is restricted to the core fold of Mk Csm3. Sso Cas7 
(PDB ID: 3PS0, rmsd: 4.2Å) shares the highest structural homology with Mk Csm3 beyond 
the core domain. Both proteins have a similar arrangement of insertions within the ferredoxin-
like fold domain as well as the overall architecture of the C-terminal domain. 
(B) Structure-based sequence alignment of Mk Csm3 (gold) and Sso Cas7 (blue). The 
alignment includes sequences from representative species of both families. Lighter letters 
denote residues identical in more than one third of the species considered; darker letters 
identify residues identical in more than two thirds of the species. The colors are based on the 
comprehensive alignment in Supplementary Figure 4A. Secondary structure elements are 
shown above the sequences with cylinders for α-helices and arrows for β-strands. Sequence 
conservation between Mk Csm3 and Sso Cas7 is mostly restricted to structural residues that 
define the core domain and is low within adjacent regions. 
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Supplementary Figure 3 
Dissecting RNA-binding properties of Csm3 
Electrophoretic mobility shift assays (EMSA) were carried out with the respective [32P]-5′ end 
labeled RNAs and increasing concentrations of Mk Csm3. (A) Mk Csm3 does not specifically 
recognize the stem-loop (lanes 1-4) or psi-tag (lanes 13-16) of the conserved repeat sequence, 
yet shows sequence unspecific binding to U15 (lanes 5-8) and A15 (lanes 9-12).  
 
Supplementary Figure 4 
Mapping of Csm3 RNA-binding residues 
(A) Comprehensive sequence alignment of Mk Csm3 within the Csm-family. The alignment 
includes sequences from representative species. Lighter letters denote residues identical in 
more than one third of the species considered; darker letters identify residues identical in 
more than two thirds of the species. 
(B) A close-up view of conserved residues (Pro50, Ser52, Ser53, Arg57 and D176) of the core 
domain, which were selected as representative mutations within the core (patch2). 
(C) Electrophoretic mobility shift assays (EMSA) were carried out with the respective [32P]- 
5′ end labeled RNAs and increasing concentrations of Mk Csm3. Mutations located within the 
core (patch2) bind U15 ssRNA with comparable affinity to WT protein. 
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RNA-binding interface of the type I-D Cas7 family
Hrle, A., Maier, L.-K., Sharma, K., Ebert, J., Basquin, C., Urlaub, H., Marchfelder, A.
& Conti, E. Structural analyses of the CRISPR protein Csc2 reveal the RNA-binding
interface of the type I-D Cas7 family. RNA Biol. (2014)
Themanuscript ‘Structural analyses of the CRISPR protein Csc2 reveal the RNA-binding
interface of the type I-D Cas7 family’ presents a novel high-resolution protein structure
at 1.8 Å of the Cas7 protein ofThermophilum pendens, the first representative of type I-D.
The detailed structural homology comparison of TpCsc2 with well-studied Cas proteins
confirmed bioinformatic predictions and categorized it into theCas7 family. Based on all
available Cas7 structures, the study highlights denominators and differences within the
Cas7 superfamily. Furthermore a combination ofmutation analysis, protein–RNAcross-
linking, mass spectrometry and fluorescence anisotropy and identified the conserved
RNA binding surface and contributing amino acid residues.
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2 Results
Structural analyses of the CRISPR protein Csc2
reveal the RNA-binding interface of the
type I-D Cas7 family
Ajla Hrle1, Lisa-Katharina Maier2, Kundan Sharma3, Judith Ebert1, Claire Basquin1, Henning Urlaub3,4, Anita Marchfelder2,*,
and Elena Conti1,*
1Structural Cell Biology Department; Max Planck Institute of Biochemistry; Martinsried, Germany; 2Biology II; University of Ulm; Ulm, Germany; 3Bioanalytical Mass Spectrometry
Group; Max Planck Institute for Biophysical Chemistry; G€ottingen, Germany; 4Bioanalytics; Institute of Clinical Chemistry; University Medical Center G€ottingen; G€ottingen, Germany
Keywords: RRM domain, CRISPR, prokaryotic immune system, Cas7, RNA binding
Abbreviations: CRISPR, Clustered regulatory short interspaced palindromic repeats; Cas, CRISPR-associated;
dCASCADE, interference complex subtype I-D; eCASCADE, interference complex subtype I-E; crRNA, CRISPR RNA;
RAMP, Repeat associated mysterious protein; RRM, RNA recognition motif; RNAi, RNA interference; H1 and H2 and H1-2,
b-hairpins of insertion domain 1 (or lid domain); Tp, Thermofilum pendens; Ss, Sulfolobus solfataricus; Mk, Methanopyrus
kandleri; Rmsd, Root mean square deviation; SAD, Single-wavelength anomalous dispersion.
Upon pathogen invasion, bacteria and archaea activate an RNA-interference-like mechanism termed CRISPR
(clustered regularly interspaced short palindromic repeats). A large family of Cas (CRISPR-associated) proteins mediates
the different stages of this sophisticated immune response. Bioinformatic studies have classiﬁed the Cas proteins into
families, according to their sequences and respective functions. These range from the insertion of the foreign genetic
elements into the host genome to the activation of the interference machinery as well as target degradation upon
attack. Cas7 family proteins are central to the type I and type III interference machineries as they constitute the
backbone of the large interference complexes. Here we report the crystal structure of Thermoﬁlum pendens Csc2, a Cas7
family protein of type I-D. We found that Csc2 forms a core RRM-like domain, ﬂanked by three peripheral insertion
domains: a lid domain, a Zinc-binding domain and a helical domain. Comparison with other Cas7 family proteins
reveals a set of similar structural features both in the core and in the peripheral domains, despite the absence of
signiﬁcant sequence similarity. T. pendens Csc2 binds single-stranded RNA in vitro in a sequence-independent manner.
Using a crosslinking - mass-spectrometry approach, we mapped the RNA-binding surface to a positively charged
surface patch on T. pendens Csc2. Thus our analysis of the key structural and functional features of T. pendens Csc2
highlights recurring themes and evolutionary relationships in type I and type III Cas proteins.
Introduction
CRISPR (clustered regularly interspaced short palindromic
repeats) confer an adaptive prokaryotic defense mechanism that
recognizes and inactivates foreign genetic elements,1 a mecha-
nism that is functionally reminiscent of the eukaryotic RNA
interference (RNAi) pathway.2,3 In contrast to RNAi, CRISPR
establishes a genetic memory of previously encountered patho-
gens that is accessed upon re-infection. Foreign nucleic acid
sequences (spacers) derived from viruses or conjugative plasmids
are integrated into the host genome.4,5 The unique spacers are
located within a CRISPR locus and interspersed by a series of
identical host repeat sequences.6 The CRISPR locus is tran-
scribed into a precursor RNA that is subsequently processed to
yield the mature functional crRNAs.7 Adjacent to the CRISPR
locus are genes encoding the protein machinery behind this
response.8 Upon infection, Cas (CRISPR-associated) proteins
mediate spacer acquisition,4,5 crRNA biogenesis,9 target interfer-
ence and degradation.10
The CRISPR-Cas systems have been classified into three
major types (I, II and III), that can be further divided into at least
10 subtypes.11 The classification of Cas proteins is hampered by
the fact that even proteins with the same function have very little
sequence similarity.12,13 Therefore structural data are indispensi-
ble for accurate classification. The diversity within the CRISPR
protein machinery is believed to have evolved out of the demand
to respond to the specific nature of the pathogen as well as the
environment of the host cell (such as thermophilic, mesophilic,
halophilic, etc.). The majority of the Cas proteins contain
RAMP (repeat-associated mysterious protein) domains.14 These
domains are based on a ferredoxin-like fold,15 similar to that of
an RRM (RNA-recognition motif), a ubiquitous RNA-binding
*Correspondence to: Elena Conti; Email: conti@biochem.mpg.de; Anita Marchfelder; Email: anita.marchfelder@uni-ulm.de
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Publication 2: Structural analyses of the CRISPR protein Csc2
domain.16 However, the RRM-like domains in Cas proteins dif-
fer from those of canonical RRM domains.16,17 First, they gener-
ally do not share the conserved consensus sequences that are
involved in RNA binding in canonical RRM domains.16-19 Sec-
ond, they are structurally much more variable,20 as they feature
longer insertions18,19,21 and extensions at the N- and C-
termini.22,23 This variation is reflected in their different func-
tions, which range from having a structural role18 to harboring
catalytic activity.21,24-26
Insight into how Cas proteins assemble the functional inter-
ference complexes has been provided by electron-microscopy
studies of type I-A18/I-E27/I-F28 and III-A29/B30,31 interference
complexes and high resolution X-ray crystallography structures
of single proteins.20 Characteristic of type I and type III systems
are members of the Cas7 family of proteins, which constitute the
core subunit of the interference complexes. Multiple copies of
Cas7 assemble in a helical fashion around the processed
crRNA18,27,28,32 and mediate interactions with further factors,
which ultimately define complex length, activity and target recog-
nition. To date, little information is available on the subtype I-D
proteins and the associated dCASCADE interference complex.
Here, we have studied Thermofilum pendens Csc2, a subtype I-D
protein of the Cas7 family. Subtype I-D is commonly present in
Archaea33 and Cyanobacteria.34 It harbors characteristic features
of both subtypes I and III: a type I HD nuclease domain is fused
to Cas10, the signature protein of type III. The general domain
organization of CASCADE proteins is predicted to resemble
type III proteins,33 emphasizing the prominent role of this sub-
type as an evolutionary link between types I and III. We report
the insights we obtained from the crystal structure and biochemi-
cal analysis of Thermofilum pendens (Tp) Csc2. The comparison
of type I-D TpCsc2 with type I-A Sulfolobus solfataricus (Ss)
Csa218 and type III-A Methanopyrus kandleri (Mk) Csm319
allows building a comprehensive picture of the Cas7 protein fam-
ily and its conserved RNA-binding properties.
Structure Determination of Csc2
We expressed full-length T. pendens (Tp) Csc2 (374 residues)
in E. coli and purified it to homogeneity. Tp Csc2 yielded crystals
in an orthorhombic space group (P222), containing one mole-
cule per asymmetric unit and diffracting beyond 1.8 A

resolu-
tion. X-ray fluorescence scans on the crystals showed a peak at
the Zinc excitation, suggesting the presence of a bound zinc ion
in the crystallized protein. We obtained phases by crystallizing
the selenomethionine derivatized protein and solved the structure
by single-wavelength anomalous dispersion method (SAD). The
structure was refined at 1.8 A

resolution to an Rfree/Rwork of
21/18%. The final atomic model has good stereochemistry
(Table 1) and includes most of the polypeptide. Disordered
regions include a loop between residues Gln134 and Gly147, the
four N-terminal residues and 21 C-terminal residues.
Csc2 has a Central RRM-Like Core Domain with
Three Elaborate Insertion Domains
The overall architecture of Tp Csc2 can be described as com-
posed of four domains (Fig. 1A). At the core of the molecule is a
domain with b–a–b–b–a–b topology reminiscent of a RRM
fold (Fig. 1B). The four b-strands form a twisted b-sheet, with
two a–helices (a1, a2) resting against a concave groove. Strands
b1 and b3 of the core domain lack residues of the so-called
RNP2 and RNP1 motifs, which are required for RNA binding
in canonical RRM domains. In addition, the canonical RNA-
interacting interface of the RRM fold is obstructed from the sol-
vent by an a helix (aE). Overall, a large part of the core domain
is inaccessible to solvent. The most exposed structural element is
helix a1. Helix a1 contains conserved residues and contacts a
conserved glycine-rich loop between helix a2 and strand b4. The
presence of a rather flexible glycine-rich loop at this structural
position is a characteristic feature in the non-canonical RRM
folds of the Cas superfamily, although its exact function remains
elusive.
The core domain is flanked by three peripheral domains that
are composed of elaborate insertions originating from the sec-
ondary structure elements of the core. The first insertion domain
(insertion domain 1 or lid domain) is formed by three b-hairpins
(H1, H2 and H1–2) that create a lid on top of the core (Fig. 1A
and 1B). Hairpin H1 is formed between the b1–a1 elements of
the RRM-like domain and contacts both strand b2 of the core
and helix aE. Hairpin H2 is formed between the b2–b3 ele-
ments of the RRM-like domain. H2 features a sharp bend at the
tip (where Gly205 is located) and a hinge at the bottom (where
the residues Pro196 and Gly211 are located). The bottom of H2
packs against hairpin H1–2. Hairpin H1–2 constitutes the base
of the lid domain and is formed by both the b1–a1 and b2–b3
segments of the RRM-like domain. This hairpin effectively
Table 1. Data Collection and Structure Reﬁnement Statstics of Tp Csc2
Data collection
Native Tp Csc2 SeMet Tp Csc2
Space group P 2 21 21 P 2 21 21
Unit cell (A

)a a D 60.47
b D 80.95
c D 112.60
a D 60.81
b D 81.24
c D 114.02
Resolution range (A

)a 46.22–1.82 (1.88–1.82) 48.68–2.37 (2.46–2.37)
Unique reﬂectionsa 50416 (7188) 23518 (2402)
I/s (I)a 17.8 (1.6) 31.9 (6.4)
Multiplicitya 6.5 (6.0) 13.1 (12.6)
Rmerge (%)
a 6.7 (97.7) 7.3 (43.4)
CC(1/2) (%)a 99.9 (50.5) 99.9 (95.4)
Reﬁnement
Average B-factor 32.70 34.28
Rwork (%) 18.15 (31.75) 20.85 (24.14)
Rfree (%) 21.21 (34.64) 23.72 (25.13)
Rmsd bonds (A

) 0.017 0.004
Rmsd angles () 1.36 0.789
Ramachandran favored (%) 97.0 96.7
Ramachandran outliers (%) 0.0 0.0
aValues in parentheses correspond to the highest resolution shell; SeMet:
Selenomethionine derivatized protein.
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2 Results
extends the b-strands b1 and b3 of the core, after a sharp bend
created by the conserved residues Pro222 and Gly223 (Fig. 2).
The insertion domain 2 (or metal-binding domain) is defined
by an 80 amino-acid long segment between a1–b2 and the very
C-terminal helix aH (Fig. 1B). aH is an elongated helix, embed-
ded within a predominantly hydrophobic cavity lined by the heli-
ces aC and aD. This domain coordinates a Zinc ion via the
residues Cys131, Cys153, His155, Cys156 and in addition
Asp150 (Fig. 1A). Metal binding appears to have a structural
role, maintaining the close packing within the domain. The
insertion domain 3 is a helical domain formed by three helices
(aE, aF and aG) that are between the last b-strand of the core
domain and the C-terminal helix aH. Insertion domain 3 con-
tacts secondary structure elements of the core domain and,
together with the small N-terminal helices aA and aB, it wraps
around the convex surface of the b-sheets and helix a2 (Fig. 1A).
Csc2: a Cas7 Family Protein
Bioinformatic predictions categorized Tp Csc2 within the
Cas7 protein family and suggested it as the Cas7 homolog in sub-
type I-D interference complexes.11 We compared the structure of
Tp Csc2 with those of Sulfolobus solfataricus (Ss) Csa2 (3PS0)18
and Methanopyrus kandleri (Mk) Csm3 (4NOL)19 (Fig. 3A and
3B). Ss Csa2 and Mk Csm3 are Cas7 homologs in the subtypes I-
A and III-A and share a sequence identity of 9% and 20%,
respectively, with Tp Csc2. The RRM-like fold of Tp Csc2 (76
amino acids) superposes with the respective domains with a root
mean square deviation (rmsd) of 1.5 A

for Mk Csm3 and 3.0 A

for Ss Csa2. The main difference in the core domains is that
Tp Csc2 lacks the fifth b-strand that is characteristic of the
b-sheet of Mk Csm3 and Ss Csa2 (Fig. 3A).
Tp Csc2, Ss Csa2 and Mk Csm3 have insertions at equivalent
positions within the core domain. Structure-based comparisons
suggest that the peripheral insertion domains also share similarities.
The lid domain (insertion 1) is in all cases the most flexible part of
the molecule (Fig. 3B). A common structural feature of the lid
domain is the b-hairpin corresponding to Tp Csc2 H1 (structural
element 1 in Figure 3B), which protrudes toward the front of the
RRM-like core. Insertion domain 2 is in all cases a predominantly
a-helical domain. In both Tp Csc2 and Mk Csm3, this domain
contains a structural Zinc ion (Fig. 3A and 3B). In the case of Ss
Csa2, insertion domain 2 does not require a metal ion to be folded.
A common structural feature of insertion domain 2 in the three
structures is helix aD, which is buried in the heart of the proteins
(structural element 2 in Figure 3B). Another conserved feature is a
helix that connects this insertion domain to the core domain
Figure 1. Crystal Structure of Thermoﬁlum pendens Csc2. (A) Structure of Tp Csc2 can be divided into four distinct domains: a core domain (green), a lid
domain (insertion 1, blue), a metal-binding domain (insertion 2, red) and a helical domain (insertion 3, yellow). Secondary structure elements of the core
adopt a ferredoxin-like fold with b-a-b-b-a-b arrangement. Multiple insertions within the core deﬁne the accessory domains. Dashed lines indicate the
disordered loops. The inset shows a detailed view of the zinc ion (gray sphere) with coordinating residues. (B) Topology diagram of TpCsc2. a-Helices are
represented as circles and b-strands arrows. The secondary structure elements have been labeled numerically maintaining the nomenclature of RRM
domains. The hairpins of insertion domain 1 are labeled as described in the text (H1, H2 and H1–2). The a-helices of in the insertion domains are labeled
with letters (aA to aH).
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Publication 2: Structural analyses of the CRISPR protein Csc2
(structural element 3 in Figure 3B). In the case of Tp Csc2, this
structural element corresponds to the C-terminal helix aH. In the
case of Mk Csm3 and Ss Csa2, this structural element is derived
from a topologically different region. Similarly, helices at the base
of the core domain are present in all three proteins but are derived
from different elements (structural element 4 in Figure 3B).
Generally, the structural conservation among the Cas7 proteins is
not reflected in high sequence similarities. The exception is a sol-
vent-exposed platform formed by the segment preceding b2 at the
interface between the core domain and insertion domain 2 (struc-
tural element 5 in Figure 3C), which is not only conserved at the
structural but also at the sequence level.
Figure 2. Structure-based sequence alignment of Tp Csc2. The alignment includes four sequences from representative species of the Csc2 family, based
on a comprehensive alignment. Secondary structure elements are indicted by the cartoon above the sequences, color-coded and labeled according to
Figure 1A. Colors represent the percentage of sequence identity (dark > 60%, light 60–30%). U15 cross-linked residues are highlighted with yellow dots.
Blue dots above the K179 and R183 mark the mutated amino acids, brackets indicate the boundaries of the sequence spanning (P197-L214), which was
replaced by (GS)3 (Dloop mutant).
www.landesbioscience.com 1075RNA Biology
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2 Results
In order to confirm our classification and pervious bioinfor-
matic analysis, we compared Tp Csc2 to well-studied Cas protein
families (Cas6 and Cas5), based on the structural analysis by
Reeks et al. Although Cas5 and Cas6 proteins also contain an
RRM-like domain as a core structural element and a glycine-rich
flexible region between a2 and b4, the peripheral domains
diverge. First, the b hairpin between b2-b3 is part of the lid
domain in Tp Csc2 and other Cas7 family members, while in
Cas5d it can be seen as an extension of the RRM b strands, in
Cas6 it is present in both RRM domains. Second, the insertion
Figure 3. Structural comparison of Cas7 proteins. (A) Topology diagrams of Tp Csc2, Ss Cas7 and Mk Csm3 highlight the high structural conservation
within the core RRM-like fold (boxed in gray) and show the connectivity of the insertion domains. The topological arrangement of the insertions 1–3 is
similar in all proteins. Variations within secondary structure elements of the three proteins reﬂect subtype speciﬁcities. (B) Crystal structures of Cas7
orthologs, Tp Csc2, Ss Csa2,Mk Csm3, depicted according to the orientation in Figure 1A after optimal superposition of their RRM-like domains. The mol-
ecules are overall colored in gray. Signiﬁcant structural similarities are colored according to the color-code of the respective proteins, Tp Csc2 (salmon), Ss
Csa2 (orange), Mk Csm3 (blue). Numbers (1–5) refer to the signiﬁcant structural elements discussed in the text. Dashed lines indicate the structurally
unresolved loops. (C) Boxes highlight the structurally and sequence-conserved basic residues along b2 and the preceding insertion.
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Figure 4. For ﬁgure legend, see page 1078.
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domain 2 that is present between a1 and b2 in Tp Csc2 and
other Cas7 proteins is absent in the Cas6 and Cas5 family. Third
are the structurally variable C-terminal domains, which consist
of a second RRM domain in the cases of most Cas6 proteins and
an extended b-hairpin in Cas5d representatives. Despite the uni-
fying RRM-like core, the structural variation of the peripheral
domains might reflect the different RNA binding requirements.
Mapping the RNA-Binding Interface
Proteins of the Cas7-family assemble around processed crRNA
and constitute the backbone of the interference complex.27,29,31
Several Cas7 monomers are involved in binding to the variable
pathogen derived spacer region, exposing it to the complementary
target DNA.27 We sought to determine the RNA-binding
Figure 5. A structurally and functionally conserved surface groove in the Cas7 protein family. Upper panels: cartoon representation of the structures of
the Cas7-like proteins Tp Csc2 (salmon), Ss Csa2 (orange),Mk Csm3 (blue) (in the same orientations as in Figure 3B). Lower panels: corresponding surface
representations showing the electrostatic potential (red for electronegative and blue for electropositive). For all proteins positively charged patches are
present at the interface between the core and insertion domain 2 (identiﬁed with a circle). Conserved lysines and arginines contribute to these patches
(Fig. 2) and in Tp Csc2 (arrows point to pink residues) are involved in RNA binding (Fig. 4). Residues reported to have an effect on RNA binding in
Ss Csa2 and Mk Csm3 (arrows point to pink residues) are located within positively charged surfaces of the respective lid domains.
Figure 4 (See previous page). Mapping the RNA-binding surface of Thermoﬁlum pendens Csc2. (A) Electrophoretic mobility shift assays (EMSA) with
wild-type Tp Csc2. Left panel: EMSA were performed with 32P -50-end labeled poly(U)15 or poly(U)15 RNAs and increasing concentrations of Tp Csc2 (0, 5,
25, 50mM). The positions of the free RNA probe (arrow head) and of the RNA-bound complexes (asterisks) are shown on the right. Right panel: EMSA
assay with Tp Csc2 and 32P -50-end labeled crRNA. (B) MS/MS mass spectra of Tp Csc2 peptides, carrying an additional mass corresponding to one (panel
two and three) or two (panel one) uracil nucleotides associated with the respective amino-acid. Peptide sequence and the fragment ions are indicated
on top. The direcly crosslinked residues are colored yellow. The peptide fragmentation occurs with the cleavage of amide bonds resulting in b-ions and
y-ions when the charge is retained by the N-terminal and C-terminal fragments, respectively. #, #,1 #2 and #3 indicate the b- and y-ions that were
observed with a mass shift corresponding to U’, U-H3PO4, U-H2O and U, respectively. IM: Immonium ions. U’: U marker ion adduct of 112.0273 Da. (C)
Mapping RNA-binding properties on the Tp Csc2 crystal structure. Upper panel: a cartoon representation of Tp Csc2 is shown in gray (in the same orienta-
tion as in Figure 1A) with the crosslinked residues colored in yellow (stick representation) and regions targeted for mutagenesis colored in blue (K178E/
R183E and Dloop, indicated with scissors, stick representation). Lower panel: surface representation of Tp Csc2 (in the same orientation as in panel C)
depicting the electrostatic potential (red for electronegative and blue for electropositive). (D) Quantitative measurements of RNA-binding afﬁnities.
Upper panel: 13% SDS-PAGE with the wild-type (WT) an mutant proteins used in the ﬂuorescence anisotropy (FA) assay and a table with the Kd values
obtained. The Dloop mutant was engineered by replacing the segment between Pro197 and Leu214 with a (GS)3 sequence. Lower panel: FA measure-
ments of WT and mutant Tp Csc2 with a 50-6-carboxy-ﬂuorescein-labeled poly(U)15 -RNA.
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Publication 2: Structural analyses of the CRISPR protein Csc2
interface in Tp Csc2. In electrophoretic mobility shift assays
(EMSAs), Tp Csc2 bound a polyU RNA of 15 nt length (poly
(U)15 and poly(A)15, (surrogates of the variable spacer sequence)
in a comparable fashion as previously shown for Mk Csm319
(Fig. 4A, left panel). At increasing concentrations, Tp Csc2 binds
likely in multiple copies on the 15-mer RNA oligonucleotides, as
shown by the supershift in the gel (Fig. 4A, left panel, concentra-
tion 25 mM and 50 mM). A similar behavior was observed upon
binding to the Tp crRNA (Fig. 4A, right panel).
Next, we sought to identify RNA binding interface of the pro-
tein using a crosslinking - mass spectrometry approach. We incu-
bated Tp Csc2 with poly(U)15 RNA, and cross-linked the
complex by subjecting it to UV irradiation at 254 nm. We used
LC-MS/MS mass spectrometry to detect and sequence peptides
cross-linked to an RNA nucleotide as previously described.35 UV
crosslinks favorably occur with sulfur-containing or aromatic side
chains that are in close proximity to the nucleic acid, although
not necessarily in direct contact. The mass spectrometric analysis
identified three modified peptides (Fig. 4B). The reactive resi-
dues that were directly conjugated to a uridine (Cys131, Met83
and Trp346, Figure 4C, upper panel) encircle a central posi-
tively-charged patch on the surface of the protein, suggesting that
this region mediates RNA binding (Fig. 4C, lower panel). More-
over, this patch is adjacent to the conserved segment preceding
b2 that is enriched in lysine and arginine residues (structural ele-
ment 5 in Figure 3C).
We targeted surface exposed regions of Tp Csc2 for mutagene-
sis and used quantitative RNA-binding experiments to compare
the mutants to the wild-type protein (Fig. 4D). In fluorescence
anisotropy experiments, Tp Csc2 bound a poly(U)15 RNA with
an affinity in the low micro-molar range (Fig. 4D, black curve in
lower panel). Reverse-charge mutations of two positively charged
residues in structural element 5 (K179E/R183E) resulted in a 6-
fold reduction of RNA-binding affinity as compared with the
wild-type protein (Fig. 4D, light blue curve in the lower panel),
consistently with the information form the structural and mass-
spectrometry analyses. Importantly, a positively charged surface
groove is present at the equivalent structural position (between
the core RRM-like domain and insertion domain 2) in the struc-
tures of the Cas7 family proteins Ss Csa2 and Mk Csm3 (Fig. 5).
This groove corresponds to the predicted site for crRNA binding
on the Cas7 family protein CasC deduced from the interpreta-
tion of the cryo-EM structure of the eCASCADE27 complex
(Fig. S1).
In the case of Ss Csa218 and Mk Csm3,19 the lid domain is
involved in nucleic-acid binding (Fig. 5). For Tp Csc2 we did
not identify direct RNA-binding residues from the lid by mass-
spectrometry. Replacing the 18 residues that shape the tip of the
lid domain (between Pro197 and Leu214) with a generic (Gly-
Ser)3 linker (Fig. 4C, upper panel) resulted in a modest reduc-
tion of poly(U)15 RNA-binding affinity as compared with the
wild-type protein (Fig. 4D, dark blue curve in the lower panel).
We conclude that the influence of the lid domain in crRNA rec-
ognition or crRNA directed target DNA recognition depends on
the specific Cas7 protein family, while the positively-charged
surface groove between the core and the insertion 2 domain
appears to be a conserved functional site.
Conclusions
A common structural feature of many Cas proteins is the
central RRM-like fold and the presence of peripheral insertion
domains. The structural diversity within these peripheral
domains is thought to be responsible for the multitude of Cas
protein functions.20 Computational12,17 and biochemical18,19
studies have contributed to classifying the Cas7 proteins. Nev-
ertheless weak sequence homology makes structural data indis-
pensable to enable a complete understanding of their structure-
to-function relationship. In this study, we solved the structure
of Tp Csc2 and confirmed the classification of the Csc2 protein
as a Cas7 protein of the subtype I-D. The structural similarity
among Tp Csc2 and known Cas7 proteins, such as Mk Csm3
and Ss Csa2, encompasses the central RRM-like core domain as
well as the arrangement of the insertion domains. Tp Csc2 and
Mk Csm3 share higher sequence and structural similarities.
This is in line with previous reports suggesting that Csc2 pro-
teins resemble their type III Cas7 counterparts.15 Despite lack-
ing significant sequence similarity, the structural features as
well as the charge distribution are strongly conserved within
type I orthologs. Subtype specificities are reflected by the varia-
tions within the topology, structural composition and flexibility
of the peripheral domains, such as the absence or presence of
metal coordination and different secondary structure elements
within the lid domain.
The basic physiological role of Cas7-like proteins of type I
interference complexes18 as well as its homologs, Csm3 in
type III-A and Cmr4 in type III-B systems,29,36 is to bind
the variable crRNA spacer sequence and with it constitute a
platform for stable binding of target DNA. In this study, we
have defined the RNA binding interface of Tp Csc2. We
show that Tp Csc2 binds variable sequences of ssRNA. The
affinity toward the RNA is within the low micro-molar range,
weak yet significant, and in line with the protein’s physiologi-
cal function. We further investigated the RNA-binding prop-
erties of Tp Csc2 using crosslinking mass spectrometry and
structure-based mutation analyses. Here, we identified the
RNA-protein interface and pinpointed functionally relevant
residues. We show that Tp Csc2 possesses a critical, positively
charged groove formed by conserved residues in the interface
between the core and the second insertion domain. This fea-
ture is largely conserved among characterized protein family
members. Our findings are in accordance to the predicted
crRNA-binding interface of CasC, the E. coli Cas7 ortho-
log.27 Therefore we speculate that upon dCASCADE assem-
bly, multiple copies of Tp Csc2 may adopt a similar
arrangement within the complex as CasC in the eCASCADE,
defining a channel and exposing the central positively charged
groove toward the solvent (Fig. S1).
Taken together our study highlights the evolutionary relation-
ship within the Cas7 protein family and helps to better
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understand the RNA-interacting features that are conserved
among the Cas7 proteins. Further structural studies will identify
the contribution of the insertion domains on protein interactions
during dCASCADE assembly.
Accession Numbers
The coordinates and the structure factors of Thermofilum pen-
dens Csc2 have been deposited in the protein Data Bank with the
accession code 4TXD.
Experimental Procedures
Protein expression and purification
The gene for the Csc2 from T. pendens was ordered as a syn-
thetic construct (GeneArt, Life technologies). His- and His-
SUMO tagged Tp Csc2 proteins were expressed using E. coli
BL21-Gold (DE3) Star pRARE cells (Stratagene) grown in TB
medium and induced overnight at 18C. The cells were lysed in
buffer A (50 mM TRIS-HCl pH 7.5, 1 M NaCl, 10 mM imid-
azole, 10% glycerol) supplemented with protease inhibitors
(Roche). The lysate was heated to a temperature of 55C for
10 min and subsequently centrifuged at 25000 g. The protein
was purified from the resulting supernatant at room-temperature
by Ni2C- affinity chromatography as an initial step and further
purified over a HiTrap Heparin column (GE Healthcare) to
remove minor contaminants. The His-tag was removed by treat-
ment with SUMO protease. Size-exclusion chromatography
(SEC) on a Superdex 75 column (GE Healthcare) was performed
as a final step of purification using buffer B (20 mM HEPES pH
7.5, 150 mM NaCl and 5 mM DTT and 10% glycerol). Seleno-
methionine derivatized protein was purified as described above
from E. coli grown in M9 media complemented with the essential
amino acids and selenomethionine.37
Crystallization and structure determination
Native crystals of Tp Csc2 were grown at 20 C by sitting-
drop vapor diffusion from drops formed by equal volumes of
protein (at 9.5 mg/ml) and of crystallization solution containing
0.05 M Mes pH 5.6, 0.2 M KCl, 0.01 M MgCl2, 5% Peg 8000
and 17% glycerol. Crystals were cryoprotected with a final con-
centration of 20% glycerol prior to data collection. Selenome-
thionine derivatized crystals were obtained in similar conditions
and cryo-protected as described above.
Native and SAD data were collected at the PXII and PXIII
beamlines of the Swiss Light Source (SLS) (Villigen, Switzerland),
respectively. Data were processed with XDS38 and scaled using
Aimless.39 Selenium sites were located and experimental phases
were calculated using the AutoSol pipeline in Phenix.40 Model
building and refinement were performed with COOT41 and Phe-
nix and the final model was validated using Molprobity.42
Biochemical assays
The RNAmolecules poly(U)15, poly(A)15 and the crRNA (spacer
1 of locus 2, sequence: ACUAAGAGCC UCCUUUGCCC
ACGGCAUCGG UAGGUCAGGU CCACGUUCAA AAU-
CAGCAAG)43 were synthesized by Purimex. The poly(U)15, and
poly(A)15 RNA were 5
0 labeled with T4 polynucleotide kinase (New
England Biolabs) and g-32P ATP (Perkin-Elmer), the cRNA was 30
labeled with a-32P-pCp (Hartmann Analytic) and T4 RNA ligase
(Fermentas, Thermofisher Scientific). For the gel-shift assays using
poly(U)15 and poly(A)15, 0.5 pmol labeled RNA was mixed with
5 mM, 25 mM, and 50 mMTpCsc2 protein in 10 mL reaction vol-
ume containing 20 mM Hepes at pH 7.5, 100 mM KOAc, 4 mM
Mg(OAc)2, 0.1% (vol/vol) NP-40 and 2 mM DTT. For crRNA
gel-shift assays, 0.14 pmol labeled RNA was mixed with 1 mM,
20 mMand 200mMTpCsc2 protein.
The mixtures were incubated for 20 min at 55C before add-
ing 2 mL 50% (vol/vol) glycerol containing 0.25% (w/vol)
xylene cyanole. Samples were separated on a 8% (w/vol) poly-
acrylamide gel at 4C and visualized by phospho-imaging (GE
Healthcare).
Fluorescence anisotropy
Fluorescence anisotropy measurements were performed with a
50-6-carboxy-fluorescein-labeled poly(U)15 RNA at 20C in
50 ml reactions on a Genios Pro (Tecan). The RNA was dis-
solved to a concentration of 10 nM and incubated with Tp Csc2
for 20 min at 55C before adding upon measurement. The exci-
tation and emission wavelengths were 485 nm and 535 nm,
respectively. Each titration was measured three times using ten
reads with an integration time of 40 ms. The data were analyzed
by nonlinear regression fitting using the BIOEQS software.44
Crosslinking–mass spectrometry analysis
Tp Csc2 – poly(U)15 contacts sites were investigated with
mass spectrometry after UV-induced protein–RNA crosslinking
as described.35,45 The purified crosslinks were analyzed using
Top10HCD method on an Orbitrap Velos instrument and the
data were analyzed using OpenMS and OMSSA as a search
engine (see Supplementary Experimental Procedures).
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Thermoproteus tenax
Plagens, A., Tripp, V., Daume, M., Sharma, K., Klingl, A.,Hrle, A., Conti, E., Urlaub, H.,
Randau, L. In vitro assembly and activity of an archaeal CRISPR-Cas type I-A Cascade
interference complex. Nucleic Acids Res. (2014)
The study characterizes the archaeal type I-A interference complex ofThermopreoteus
tenax (Tt). The complex was reconstituted from the individual subunits and used to
identify interactions amongst the subunits as well as sequence motifs required for effi-
cient DNA degradation. Mass spectrometry shows that the Cas3HD nuclease and Cas3
helicase proteins are an integral part of the assembly. Size exclusion chromatography
(Fig. 8), RNA binding assays (Plagens et al., Figure 2B) and TEM imaging (Fig. 8)
demonstrate that Tt Cas7 (Csa2) binds unspecifically to crRNA and other small RNA
contaminants, resulting in the oligomerization of Cas7. The oligomerization of Cas7
outside of the crRNP was also oberserved for the S. solfataricus homolog Csa2 and the
Cas7-like protein Cmr4 [63, 69]. Interestingly, the proteins MkCsm3 and TpCsc2 did
not exhibit this behavior at any stage.
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Figure 8: Tt Cas7. a. Coomassie stained gel and b. size exclusion profiles of Tt Cas7 with (+) and
without (-) benzonase treatment shows monomeric (light blue) vs. oligomeric states (dark blue). c.
Transmission electronmicrograph of Tt Cas7 unspecifically bound to E. coli RNA (peak in panel b). Scale
bar: 50 nm. See Plagens et al., Fig. S6.
49
2 Results
In vitro assembly and activity of an archaeal
CRISPR-Cas type I-A Cascade interference complex
Andre´ Plagens1, Vanessa Tripp1, Michael Daume1, Kundan Sharma2, Andreas Klingl3,
Ajla Hrle4, Elena Conti4, Henning Urlaub2 and Lennart Randau1,*
1Prokaryotic Small RNA Biology Group, Max Planck Institute for Terrestrial Microbiology, D-35043 Marburg,
Germany, 2Bioanalytical Mass Spectrometry Group, Max Planck Institute for Biophysical Chemistry, D-37077
Go¨ttingen, Germany, 3Cell Biology and LOEWE Research Centre for Synthetic Microbiology, Philipps-Universita¨t
Marburg, D-35043 Marburg, Germany and 4Department of Structural Cell Biology, Max Planck Institute of
Biochemistry, D-82152 Martinsried, Germany
Received December 17, 2013; Revised and Accepted January 17, 2014
ABSTRACT
Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPR)-CRISPR-associated (Cas)
systems of type I use a Cas ribonucleoprotein
complex for antiviral defense (Cascade) to mediate
the targeting and degradation of foreign DNA. To
address molecular features of the archaeal type
I-A Cascade interference mechanism, we estab-
lished the in vitro assembly of the Thermoproteus
tenax Cascade from six recombinant Cas proteins,
synthetic CRISPR RNAs (crRNAs) and target DNA
fragments. RNA-Seq analyses revealed the process-
ing pattern of crRNAs from seven T. tenax CRISPR
arrays. Synthetic crRNA transcripts were matured
by hammerhead ribozyme cleavage. The assembly
of type I-A Cascade indicates that Cas30 and Cas300
are an integral part of the complex, and the interfer-
ence activity was shown to be dependent on the
crRNA and the matching target DNA. The
reconstituted Cascade was used to identify
sequence motifs that are required for efficient DNA
degradation and to investigate the role of the
subunits Cas7 and Cas300 in the interplay with
other Cascade subunits.
INTRODUCTION
The coevolution of viruses with their prokaryotic hosts led
to the development of speciﬁc and highly divergent
antiviral prokaryotic immune systems. One complex
group of adaptive immune systems that is widespread in
bacterial and archaeal genomes is termed Clustered
Regularly Interspaced Short Palindromic Repeats
(CRISPR)-CRISPR-associated (Cas). Cells that harbor
these systems can be immunized against the attack of
viruses by the integration of a virus-derived genome
fragment into the host genome (1). The genetic memory
of previous infections is mediated by CRISPR loci, which
consist of a series of short repeat sequences (typically 24–
37 bp) that are separated by spacer sequences (2–4). Cas
proteins are often encoded in proximity to the CRISPR
loci and are key players during all phases of immunization
and protection of the cell (5,6). In the ﬁrst phase, the
adaptation, the injected viral DNA is recognized and a
fragment is inserted into the host CRISPR array (7–9).
This activity is often dependent on a short conserved
sequence (2–5 bp) deﬁned as the protospacer adjacent
motif (PAM) that ﬂanks the original spacer sequence
(termed protospacer) in the viral genome (10,11). The
genetic imprint is activated by the transcription of the
CRISPR into a long precursor-crRNA (pre-crRNA),
which is typically processed by the endoribonuclease
Cas6 into short crRNAs that are characterized by an 8-
nt 50-hydroxyl repeat tag, a complete spacer sequence and
a 20–30 cyclic phosphate repeat end (12–18). During a
repeated viral attack, the mature crRNAs can be
incorporated into a large Cas ribonucleoprotein interfer-
ence complex to target the viral DNA for degradation
(19–21).
These basic principles of CRISPR-Cas immunity are
conserved, but careful computational and biochemical
analyses of the differences among the executing interfer-
ence machines, the composition of conserved Cas marker
proteins and the nature of the targeted nucleic acids led to
the identiﬁcation of three distinct major types and several
subtypes of CRISPR-Cas systems (5,22). The type
I CRISPR-Cas systems can be further divided into six
different subtypes (subtypes I-A to I-F), and the respective
interference complex is termed Cascade (19). In type III
systems, interference is executed by the Csm (subtype III-A,
targeting DNA) or Cmr complex (subtype III-B, targeting
RNA) (23–25). In contrast, bacterial type II systems are
*To whom correspondence should be addressed. Tel: +49 6421 178 600; Fax: +49 6421 178 599; Email: lennart.randau@mpi-marburg.mpg.de
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characterized by the single large multifunctional protein
Cas9, which is involved in both the maturation of
crRNAs and the interference of DNA (26–28).
First details of the Cascade structure and the molecular
mechanism were obtained for type I-E systems of
Escherichia coli. The I-E Cascade shows a seahorse-shaped
architecture with a size of 405 kDa and is composed of the
conserved subunits Cas6e, Cas7, Cas5e and the subtype-
speciﬁc nucleic acid-binding proteins Cse1 and Cse2
(19,29,30). The helical backbone of I-E Cascade is
formed of six Cas7 copies that are tightly bound to a
mature crRNA (31,32). The I-E Cascade facilitates the
base pairing of the bound crRNA with the complementary
DNA by screening for the short PAM sequence, resulting
in strand invasion of the RNA and additional displace-
ment of the non-complementary strand to form the
R-loop structure, which recruits Cas3 to degrade the
targeted viral DNA (18,33–36). The effector protein
Cas3 contains a DExH-like helicase domain (Cas30) and
a HD phosphohydrolase domain (Cas300), which are
responsible for the unwinding of double-stranded DNA
(dsDNA) and cleavage of single-stranded DNA
(ssDNA) in dependence of adenosine triphosphate
(ATP) and divalent metal ions, respectively (37–39).
The type I CRISPR-Cas subtypes differ in Cas protein
content, which implies divergent Cascade assembly
strategies and functional differences. Comparative
studies of these different Cascade complexes will help to
gain insight into the evolution and propagation of
CRISPR-Cas systems, the integration of one or multiple
immunity systems into the cellular protein network and
the adaptation mechanisms to diverse prokaryotic envir-
onments (5,40). Analysis of the CRISPR-Cas system of
the crenarchaeon Thermoproteus tenax identiﬁed a type
I-A Cascade module (csa5, cas7, cas5a, cas30, cas300,
cas8a2), essential genes for the adaptation of foreign
DNA (cas1/cas2, cas4), a type III-A gene cluster, a
second subset of a Cascade module and seven CRISPR
loci spread throughout the genome (41,42). In Sulfolobus
solfataricus, the type I-A Cascade sub-complex of Cas7
and Cas5a was identiﬁed and shown to bind crRNA
and complementary ssDNA. The recombinant Cas7
proteins assembled into multimeric right-handed helical
structures (43).
Here, we show the assembly of a complete type I-A
Cascade from individual in vitro-produced Cas proteins,
ribozyme-processed synthetic crRNAs and short
protospacer DNA fragments. The strategy for the
protein body assembly of the mature Cascade follows
the co-refolding of insoluble recombinant I-A Cas
proteins from bacterial inclusion bodies to recover the
six protein complex. Synthetic crRNAs were created
by in vitro transcription of crRNA constructs fused to
cis-acting hammerhead ribozymes. The assembly of the
Cascade ribonucleoprotein complex yielded active mol-
ecules that showed crRNA-speciﬁc DNA targeting and
degradation. This in vitro assembly strategy allowed us
to obtain insights into the Cascade assembly and DNA
cleavage mechanism and to identify the PAM require-
ments for target degradation.
MATERIALS AND METHODS
Strains and growth conditions
Cells of T. tenax Kra1 (DSM 2078) grown
heterotrophically in Thermoproteus medium (44) were a
gift from R. Hensel (Essen). E. coli strains TOP10
(Invitrogen) and Rosetta2(DE3)pLysS (Stratagene) were
cultured in LB medium at 37C shaking at 200 rpm. For
protein production, 1mM isopropyl-b-D-1-thiogalacto-
pyranoside (IPTG) was added to a growing culture
(OD600: 0.6) and incubated for 4 h.
Isolation of small RNAs, production of crRNAs and DNA
substrates
For the preparation of T. tenax small RNAs (<200 nt),
0.1 g pelleted cells were lysed by homogenization and sub-
sequently isolated according to the mirVanaTM miRNA
Isolation Kit (Ambion). To generate synthetic crRNAs,
forward and reverse complementary DNA oligonucleo-
tides (cr5.2h or cr5.13h, respectively) were synthesized
that contained a selected spacer sequence (spacer 5.2 or
spacer 5.13) and were fused with the sequence of a
minimal cis-acting hammerhead ribozyme at the 50-end
(Supplementary Table SI). The oligonucleotides were
phosphorylated, hybridized and cloned under control
of the T7 RNA polymerase promoter sequence
(cr5.2h: BamHI/HindIII, cr5.13h: HindIII/EcoRI) into
pUC19. The crRNA was prepared by run-off transcrip-
tion in a reaction containing 40mM HEPES/KOH, pH
8.0, 22mM MgCl2, 5mM dithiothreitol, 1mM spermi-
dine, 4mM of ATP, CTP, GTP and UTP, 20U RNase
inhibitor, 1 mg T7 RNA polymerase and template DNA
[PCR products with sequence-speciﬁc primers (cr5.2PCRf/
r or cr5.13PCRf/r, respectively)] at 37C for 4 h. For the
self-cleaving reaction of the hammerhead ribozyme, the
transcription reaction was directly diluted with 4
volumes of 30mM MgCl2 in DEPC-H2O and incubated
for 1 h at 60C. The cleaved crRNA was puriﬁed by
phenol/chloroform extraction (pH 5.2), EtOH
precipitated with the addition of glycogen (1:100, v/v),
mixed with 2 formamide loading buffer (95%
formamide, 5mM EDTA, pH 8.0, 2.5mg bromophenol
blue, 2.5mg xylene cyanol), heated for 5min at 95C,
separated by a denaturing-PAGE (8M urea, 1 TBE,
10% polyacrylamide) next to an RNA marker (low
range ssRNA ladder, NEB) and visualized by toluidine
blue staining. The gel bands were cut out and eluted over-
night on ice in 500ml elution buffer (20mM Tris–HCl, pH
7.5, 250mM sodium acetate, 1mM EDTA, pH 8.0, 0.25%
SDS) and EtOH precipitated. All DNA oligonucleotides
used for cloning and as cleavage substrates were cus-
tom-synthesized (Euroﬁns MWG Operon,
Supplementary Table SI).
RNA sequencing
The isolated small RNA was treated with T4
Polynucleotide Kinase (PNK) to ensure proper termini
for adapter ligation (45). First, for the dephosphorylation
of 20–30-cyclic phosphate termini, 10 mg of RNA was
incubated at 37C for 6 h with 20U T4 PNK (NEB) in
5126 Nucleic Acids Research, 2014, Vol. 42, No. 8
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1 T4 PNK buffer. Subsequently, 1mM ATP was added,
and the reaction mixture was incubated for 1 h at 37C to
generate monophosphorylated 50-termini (46). RNA
libraries were prepared with an Illumina TruSeq RNA
Sample Prep Kit (Ambion), and sequencing on an
Illumina HiSeq2000 sequencer was performed at the
Max-Planck Genome Centre, Cologne, Germany. Reads
were mapped to the T. tenax reference genome
(FN869859) with CLC Genomics Workbench 6.0.
Puriﬁcation of Cascade proteins
The gene constructs of csa5, cas7, cas5a, cas30, cas300 and
cas8a2 in pET24a(+) (Novagen) were used as previously
described (41). Cas300 mutants were created using the
QuikChange site-directed mutagenesis protocol
(Stratagene) according to the manufacturer’s instructions.
Established mutations were conﬁrmed by sequencing
(MWG Euroﬁns). Soluble Csa5 could be puriﬁed, as
cells were homogenized in buffer 1 (100mM HEPES/
KOH, pH 7, 10% glycerol, 10mM ß-mercaptoethanol
(ß-Me), 10mM CaCl2, 300mM NaCl), lysed, cleared by
centrifugation (45 000 g, 1 h, 4C) and heat precipitated
(30min, 90C). The cleared supernatant (14 000 g,
30min, 4C) was dialyzed overnight in salt-free lysis
buffer 1 and puriﬁed via a Hi Screen Blue FF afﬁnity
column using a FPLC A¨kta-Puriﬁcation system
(GE Healthcare) eluted with a linear salt gradient (0–
2M NaCl) at 420mM NaCl. Fractions containing Csa5
were pooled, dialyzed overnight in salt-free buffer 1 and
puriﬁed via an anion-exchange chromatography with a
MonoQ 5/50 GL column (GE Healthcare) eluted with a
linear salt gradient (0–1M NaCl) at 100mM NaCl. For
pull-down assays of Cascade in vivo, Csa5 with a
C-terminal 6 His-tag was used as a bait protein.
Therefore, csa5 was cloned into pET20b(+), protein
expressed and cells lysed in buffer 1 without CaCl2. The
Csa5-His protein was puriﬁed from E. coli cell lysate by
Ni-NTA afﬁnity chromatography (HisTrap HP, GE
Healthcare) and eluted with a linear imidazole gradient
(0–500mM) at 150mM imidazole. Cas7 was puriﬁed by
cell lysis in buffer 1, heat precipitation at 80C and cation
exchange chromatography with Heparin Sepharose
(GE Healthcare) as described earlier (41). Additionally,
the Cas7 full-length protein was expressed as a recombin-
ant His-SUMO-tagged fusion protein using
BL21-Gold(DE3)Star pRARE (Stratagene) overnight at
18C. The cells were lysed by sonication in buffer
2 (100mM potassium phosphate, pH 7.5, 500mM NaCl,
10% glycerol, 1mM ß-Me) supplemented with 20mM
imidazole, benzonase (NEB) and protease inhibitors
(Roche), and Cas7-SUMO was further puriﬁed using
Ni-NTA afﬁnity chromatography. The salt concentration
was lowered to 100mM NaCl in 50mM Tris, pH 7.5, and
the His-SUMO-tag was cleaved off by adding SUMO
protease overnight during dialysis. The protein was
further puriﬁed over a HiTrap Heparin Sepharose HP
column (GE Healthcare) to remove non-speciﬁcally
bound nucleic acids. Size-exclusion chromatography on
a Superdex 75 column (GE Healthcare) was preformed
as a ﬁnal step of puriﬁcation in buffer 3 (100mM NaCl,
50mM Tris, pH 7.5, 10% glycerol, 5mM dithiothreitol).
The insoluble proteins Cas5a, Cas30, Cas300 and Cas8a2
were puriﬁed from inclusion bodies and solubilized in
4M guanidine hydrochloride (GdmCl). The purity of
all proteins was determined by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS–PAGE)
and Coomassie blue staining alongside the protein
marker (ColorPlusTM prestained protein ladder,
broad range, NEB). The protein concentration was
determined by the Bradford protein quantiﬁcation
method (BioRad).
Reconstitution assays
The reconstitution of the Cascade complex was previously
described (41). Brieﬂy, equal amounts (300mg) of each
solubilized protein Cas5a, Cas30, Cas300 and Cas8a2 were
mixed with the puriﬁed proteins Csa5 and Cas7 in recon-
stitution buffer (3.5M GdmCl, 100mM HEPES/KOH,
pH 7, 5% glycerol, 10mM ß-Me, 10mM MgCl2,
300mM NaCl) and the denaturing agent was removed
via stepwise dialysis into GdmCl-free buffer at room tem-
perature. Aggregated proteins were precipitated
(14 000 g, 30min, 4C), soluble proteins concentrated
with centrifugal ﬁlter units (MWCO: 10 kDa) and
analyzed by SDS–PAGE. The reconstitution of all 63
subunit combinations was tested via rapid dilution into
1ml GdmCl-free reconstitution buffer of equal amounts
(25mg) of each subunit. To minimize aggregation, the
protein solution was added drop-wise (5 mg total protein)
to the reconstitution buffer. Aggregated proteins were
precipitated (14 000 g, 30min, 4C), soluble proteins
were trichloroacetic acid (TCA)-precipitated and the
identical amounts of supernatant and pellet analyzed by
SDS–PAGE.
Pull-down assays and mass spectrometry analyses of
in vivo Cascade proteins
To determine the protein–protein interaction in vivo,
pull-down assays were performed with C-terminal
His-tagged Csa5 used as a bait protein bound to a cobalt-
chelate matrix and T. tenax cell extract as a prey. For the
production of cell-free T. tenax extract, 1 g cells were resus-
pended in lysis buffer 3 (100mM HEPES/KOH, pH 7.5,
300mM ß-Me) and lysed as described elsewhere (47). To
stabilize the interaction of proteins, a chemical cross-
linking with formaldehyde was performed. One hundred
micrograms puriﬁed Csa5, 1mg cell extract and 1% for-
maldehyde (37% formaldehyde/10% MeOH) were mixed,
incubated for 15min on ice and the reaction stopped by the
addition of 200mM glycine for 5min on ice. Subsequently,
the pull-down assay was performed according to the
ProFound Pull-Down PolyHis Protein:Protein
Interaction Kit (Pierce). The cross-linked protein:cell
extract was incubated for 30min at 4C on the cobalt
resin, washed ﬁve times with 40mM imidazole in buffer 1
without CaCl2 and eluted at 290mM imidazole. Proteins
were TCA-precipitated, separated by SDS–PAGE and
visualized with silver staining (Pierce Silver Stain Kit).
For the mass spectrometry analysis, the protein:cell
extract was pelleted by EtOH precipitation and digested
Nucleic Acids Research, 2014, Vol. 42, No. 8 5127
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in solution in the presence of urea as described previously
(48). The resultant peptides were desalted using STAGE
tips (49). Further, the desalted peptides were analyzed by
liquid chromatography tandem mass spectrometry on an
LTQ Orbitrap Velos instrument (Thermo Fischer
Scientiﬁc) under standard conditions. The protein identiﬁ-
cation was performed with MaxQuant (version 1.2.2.5)
using the Andromeda search engine (50,51).
Protein–protein and protein–RNA interaction assays
The protein–protein interaction and the native molecular
mass of Cascade or the Cas7 subunit was determined by
size-exclusion chromatography with a Superdex 200 10/300
preparatory-grade column (GE Healthcare, 24ml). Protein
containing fractions were TCA-precipitated [1:4 of 100%
(v/v)] and analyzed by SDS–PAGE. To verify the binding
of Cascade to crRNA, 50mg of synthetic crRNA was added
to 500mg of reconstituted Cascade complex incubated at
65C for 30min to facilitate RNA binding and separated
by gel ﬁltration. Fractions were split and protein extracted
via TCA precipitation and analyzed during separation
on SDS–PAGE, whereas RNA was isolated by Proteinase
K treatment (10ml, 6U Proteinase K, 30min at 37C),
phenol/chloroform extraction, EtOH precipitation and de-
tection via denaturing-PAGE (10% polyacrylamide) and
toluidine blue staining.
Electrophorectic mobility shift assay
The Cascade complex or the Cas7 subunit were tested for
the ability of binding synthetic crRNA in electrophorectic
mobility shift assays (EMSAs). As the binding of Cascade
was metal-independent, the complex was reconstituted in
the presence of 10mM CaCl2 instead of MgCl2 to reduce
RNA cleavage. A total of 5 pmol of the synthetic crRNA
substrate was 50-labeled with [g-32P]-ATP (5000 ci/mmol,
Hartmann Analytic) and T4 PNK (Ambion) for 2 h at
37C; the reaction stopped by the addition of formamide
loading buffer and the separation by denaturing-PAGE
(10% polyacrylamide). After autoradiographic exposure,
the RNA band were cut out, gel eluted and EtOH
precipitated. Up to 5 mM of reconstituted Cascade was
incubated with 2–4 nM of 50-labeled crRNA in binding
buffer (100mM HEPES/KOH, pH 7, 100mM NaCl,
10mM ß-Me, 50 ng yeast RNA) for 30min at 70C. The
reaction was immediately stopped on ice, mixed with 1
loading buffer (Qiagen) and Cascade:crRNA complexes
separated from free crRNA by non-denaturing
TBE-PAGE (6% polyacrylamide, 1 TBE). The ability
of monomeric Cas7 to bind to synthetic crRNA was
tested by incubating protein with 2–4 nM of 50-labeled
crRNA in binding buffer without yeast RNA for 30min
at 80C, ran on 2% TAE-agarose gels and visualized by
phosphorimaging. Binding of the two Cas7 versions
(Cas7, Cas7-SUMO) to contaminating nucleic acids
during the puriﬁcation process was veriﬁed by loading
100mg protein on 1% TAE-agarose gels stained with eth-
idium bromide alongside the DNA marker (2-log DNA
ladder, NEB). The speciﬁcation of the contaminated
nucleic acid was conducted by adding 2U DNase
I (RNase-free, NEB), 1 ng RNase A (biochemistry grade,
Ambion) or 25U benzonase (NEB) in the appropriate
reaction buffer to the protein solution and incubated for
30min at 37C before loading on agarose gels.
Transmission electron microscopy (TEM)
To further analyze samples of Cas7 puriﬁcations, 5 ml of
a concentrated protein solution was applied to car-
bon-coated 400 mesh copper grids. After blotting on a
ﬁlter paper, the samples were washed twice on a drop of
double distilled water and blotted each time. Finally, the
proteins were negatively stained with 2% (w/v) uranyl
acetate for 20 s, blotted again on ﬁlter paper and left for
air drying (52,53). Electron microscopy and further
analysis was carried out on a JEOL JEM-2100 transmis-
sion electron microscope (JEOL, Tokyo, Japan) operated
at 120 kV. The microscope was equipped with a 2k 2k
CCD camera F214 in combination with the EM-Menu
4 software (TVIPS, Gauting, Germany).
Nuclease assays
The reconstituted Cascade was tested for the nucleolytical
activity of the Cas300 subunit. A total of 5 pmol of the
ssDNA oligonucleotide (int 5.2_CCT for) was 50-labeled
with [g-32P]-ATP (5000 ci/mmol, Hartmann Analytic) and
puriﬁed as described earlier in the text. In all, 100 nM
refolded Cascade was incubated with 2 nM of 50-labelled
ssDNA in nuclease buffer (100mM HEPES/KOH, pH
7.0, 100mM NaCl, 5mM MgCl2, 5mM MnCl2, 10mM
ß-Me, 20 ng yeast total RNA) at 70C for 10min, the
reaction stopped via EtOH precipitation and resuspended
in 10mM Tris–HCl, pH 8.5, and formamide loading
buffer. Each sample was boiled, measured via scintillation
counting (Beckman LS6000) and samples with identical
counts per minute after normalization were loaded on
a 15% denaturing polyacrylamide gel alongside the low
molecular weight marker (10–100 nt, Affymetrix) running
in 1 TBE (8 watts, 2 hours). Cleavage products were
visualized by phosphorimaging.
To test for the cleavage of dsDNA, short substrates
were designed that mimic an invasive viral DNA.
Therefore, the spacer sequence of crRNA 5.2 or 5.13
was used, the different PAM added upstream and
ﬂanked with random sequences up- and downstream
(T7 promoter and T7 terminator, respectively) and each
DNA oligonucleotide was synthesized either in forward or
reverse complementary direction (for/rev: int 5.2_CCT, int
5.2_CCA, int 5.2_TCA, int 5.2_TCG, int 5.2_AAA, int
5.2_Rep or int 5.13_CCT, respectively). A total of
5 pmol of each forward and reverse oligonucleotide was
50-labeled with [g-32P]-ATP (5000 ci/mmol, Hartmann
Analytic), puriﬁed as mentioned earlier and hybridized
with 1.5-fold molar excess of the respective cold comple-
mentary strand by heating at 95C for 5min and slowly
cooling down to room temperature in hybridization buffer
(10mM Tris–HCl, pH 8, 1mM EDTA, pH 8, 100mM
NaCl). For interference tests, 500 nM refolded Cascade
and 500 nM crRNA (crRNA 5.2 or 5.13) were incubated
in interference buffer 1 (100mM HEPES/KOH, pH 7.0,
100mM NaCl, 10mM ß-Me, 20 ng yeast total RNA) at
70C for 20min to allow loading of crRNA into Cascade
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2 Results
and then the reaction started by adding 2 nM of 50-labeled
hybridized dsDNA and interference buffer 2 (5mM
MgCl2, 5mM MnCl2, 2mM ATP) at 70
C for 10min.
The reaction was stopped via EtOH precipitation and
loaded on 20% denaturing TBE-polyacrylamide gels or
on 10% sequencing gels (Model S2 sequencing gel electro-
phoresis apparatus, Life Technologies) alongside the low
molecular weight marker or (10–100 nt) or seven speciﬁc
labeled fragments (8–66 nt).
RESULTS
RNA-Seq analyses reveal the processing pattern of
T. tenax crRNAs
One requirement for CRISPR immunity is the processing
of crRNA precursors to yield mature crRNAs. To obtain
a comprehensive view of the processing pattern of
crRNAs in T. tenax, total small RNA was isolated and
sequenced via Illumina HiSeq2000 RNA-Seq method-
ology. T4 PNK treatment of T. tenax small RNAs was
required to facilitate adaptor ligation during RNA-Seq
library construction, which conﬁrms the presence of
50-OH termini (45). Previously, seven CRISPR loci with
a total of 142 spacer sequences were identiﬁed, and
crRNA transcripts were veriﬁed for ﬁve clusters
(TTX_1, 4, 5–7) via northern blot detection, whereas
two clusters (TTX_2–3) showed no distinct processing
pattern (41). In total, 13 357 720 individual sequence
reads were mapped to the T. tenax reference genome
(FN869859). Constitutive crRNA production and a
gradual decline of mature crRNAs from the leader
proximal to the leader distant region within each active
cluster were identiﬁed (Figure 1). The read coverage indi-
cates the relative abundance and the processed termini of
crRNAs from the different CRISPR arrays. Individual
crRNAs for the ﬁrst spacers were represented by up to
1 334 585 reads (spacer 1.1, 10% of total reads), which
demonstrates a massive accumulation of crRNAs in vivo.
All identiﬁed crRNAs contained a clearly deﬁned 50-ter-
minal 8 nt tag (TTX_1: 50-UUUGAAGG-30 or TTX_4–7:
50-AUUGAAAG-30). The 30-termini are gradually
shortened and mostly contain a minimal 2-nt tag
(50-GA-30). Additionally, two spacers (spacer 4.34 and
spacer 5.32) that were not listed in the CRISPR
database could be identiﬁed, increasing the total number
of 144 spacers in T. tenax. In contrast, the CRISPR loci
(TTX_2–3) were inactive and showed no mature crRNAs
with deﬁned termini.
Cas30 and Cas300 are an integral part of the type I-A
Cascade complex
Typical for archaeal subtype I-A CRISPR systems is the
organization of Cascade genes in an operon structure and
their transcription as a polycistronic unit, which includes
individual genes for the helicase (Cas30) and nuclease
(Cas300) domains of Cas3 (41). This organization suggests
a different complex formation than Cascade:Cas3
complexes of the bacterial subtype I-E, in which Cas3 is
recruited to an assembled Cascade bound to target DNA.
To substantiate the protein–protein interactions of the
Cascade complex in vivo, we performed pull-down assays
of T. tenax cell extracts with the C-terminal His-tagged
Csa5 as bait protein (Supplementary Figure S1A). The
interacting proteins were subjected to an in solution
trypsin digest followed by mass spectrometry analyses. In
these experiments, we could identify Cas7, Cas5a, Cas30,
Cas300 and Cas8a2 as interaction partners of Csa5, all six
proteins whose genes are organized in an operon
(Supplementary Table SII). This suggests an alternative
mechanism of Cascade formation, in which the two Cas3
domains are not recruited but are an integral part of the
Cascade complex in advance of the immune response.
Noteworthy, none of the two copies of Cas6 in the
genome of T. tenax were found in the data. Additionally,
we could also detect a second Cas7 homolog (TTX_0235,
40% similarity), produced from a distant cas gene cluster
without an encoded csa5 gene, as a potential interaction
partner of Csa5.
The in vitro assembled Cascade efﬁciently binds a
synthetic mature crRNA
To obtain mature crRNAs with an 8 nt tag (50-AUUGAA
AG-30) and a 50-hydroxyl-terminus, we designed a
ribozyme maturation strategy that overcomes the need
for recombinant Cas6 to be available. A DNA construct
was designed that contained a minimal cis-acting hammer-
head ribozyme fused to the sequence of a mature crRNA
under the control of a T7 RNA polymerase promoter
(Supplementary Figure S2A). The synthetic crRNA was
obtained by in vitro transcription and self-cleavage of the
RNA transcript at 60C. This methodology was tested for
two different crRNA constructs [crRNA 5.2 (50 nt) and
5.13 (54 nt)], resulting in a cleavage efﬁciency of 60%
(Supplementary Figure S2B) (54,55). These synthetic
mature crRNAs were tested for their capability in
complex binding to establish a fully in vitro assembly
strategy of functional Cascade modules. In this procedure,
the co-refolding of the insoluble subunits Cas5a, Cas30,
Cas300 and Cas8a2, in combination with the puriﬁed
proteins Csa5 and Cas7, yielded soluble Cascade
(Supplementary Figure S1A–C). First attempts showed
an increased refolding efﬁciency in the combination of
all six Cascade subunits (41). Therefore, we investigated
the co-refolding of all possible 63 compositions of Cascade
subunits to scan for a minimal stable core of Cas proteins.
Surprisingly, only the co-refolding of all six proteins
resulted in high amounts of soluble protein recovery of
50%, whereas in contrast all other 62 combinations
resulted in negligible amounts (up to 10%) of soluble
protein (Supplementary Figure S3). An up-scaled
protocol for the assembly of the six-protein Cascade
revealed soluble proteins with concentrations of up to
4mg/ml. The assembled Cascade was then incubated for
30min at 65C to remove impurities or misfolded
heat-instable subunits before size-exclusion chromatog-
raphy for screening of Cascade complex formation. The
analysis of the elution proﬁle (12–17ml elution volume)
showed that all six co-refolded proteins eluted in one
fraction, followed by smaller sub-complexes and
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monomeric protein subunits (Figure 2A and
Supplementary Figure S4). The functionality of Cascade
was ﬁrst assayed by analysis of binding to the synthetic
crRNA. The assembled complex was incubated with
crRNA, applied to size-exclusion chromatography and
identical fractions were checked for protein and RNA
content. The ﬁrst fractions of the Cascade proﬁle
co-eluted with the added crRNA. Visible on the
denaturing gel are bands at the expected size of 50 nt
(Figure 2A, crRNA). Two controls showed that the
assembled Cascade was not cross-contaminated with
small RNA from the E. coli expression host (Figure 2A,
RNA) and unbound crRNA was not eluting in the re-
spective fractions (Figure 2A, Cascade). Thus, mature
crRNAs are supporting the Cascade formation, and the
established ribozyme methodology can be used to prepare
synthetic crRNA molecules to be loaded onto Cascade.
In type I-E systems, the subunit Cas7 constitutes the
helical backbone of Cascade that is formed on binding
of the crRNA (31). To verify the RNA-binding activity
of Cas7 in I-A systems, we analyzed T. tenax Cas7 in more
detail. The puriﬁcation strategy for untagged soluble Cas7
resulted in multimeric proteins that eluted at the void
volume from the used gel ﬁltration column indicating
protein complex sizes >600 kDa (Supplementary
Figure S5A). The treatment of Cas7 with DNase I,
RNase A or benzonase identiﬁed a cross-contamination
of Cas7 with E. coli RNAs (<500 nt), which suggests
that Cas7 multimerization is obtained by RNA binding
independent of its sequence (Supplementary Figure S5B).
Transmission electron microscopy (TEM) of this sample
revealed long helical ﬁlaments of up to 50-nm length,
similar to previously reported structural studies of S.
solfataricus (43). Additionally, we could also observe the
occurrence of interlaced ﬁlaments of two Cas7 helices
illustrating the potential for complete coverage of RNA
molecules with Cas7 subunits (Supplementary Figure S6).
To prevent polymeric Cas7 artifacts, an alternative
puriﬁcation strategy of a Cas7-SUMO fusion protein was
established that resulted in monomeric and RNA-free Cas7
(Supplementary Figure S5A and C). This protein prepar-
ation was subsequently used for the in vitro assembly of
Cascade (Figure 2A). A comparison of the crRNA
binding behavior in EMSAs showed the recurrence of
high-shifting multimeric Cas7 structures for the sole Cas7
protein (Figure 2B) and lower shifts and an increased
afﬁnity toward crRNA for Cas7 in a Cascade assembly.
The addition of total yeast RNA or unlabeled crRNA
resulted in similar Cas7 band shifts and underlines an
unspeciﬁc afﬁnity toward RNA for the individual Cas7
subunit (Supplementary Figure S7). In contrast, speciﬁc
binding of Cascade to the synthetic crRNA 5.13 was seen
in EMSAs, with protein concentrations ranging from
0.125–2 mM (Figure 2C). A second synthetic crRNA
(crRNA 5.2) is bound by Cascade with a similar afﬁnity
(Supplementary Figure S8).
Figure 1. Processing of crRNAs in T. tenax. The abundance of crRNAs was veriﬁed by mapping the Illumina HiSeq2000 sequencing reads to the
T. tenax Kra1 reference genome. Sequence coverage (reads) for the seven T. tenax CRISPR clusters (crRNAs are indicated by numbers on the x-axis)
is visualized. The processing sites could be identiﬁed within the repeat elements, generating crRNAs with a 50-terminal 8-nt tag [50-(A/U)UUGAA(A/
G)G-30, underlined] and variable trimming of the 30-ends with most of the crRNAs terminating with a 1–2-nt tag (50-G/GA-30). The trimming sites
for each CRISPR locus are indicated by triangles.
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The exonucleolytically ssDNA cleavage activity of Cas300
is inhibited by the addition of crRNAs
Previous analysis of the nuclease domain of a Cas3
enzyme indicated endo- and exonucleolytic ssDNA
cleavage and revealed an HD motif within its active site,
which is involved in the coordination of transition metal
ions (38). Therefore, nuclease assays with a 93 nt linear
ssDNA substrate were performed to biochemically char-
acterize the T. tenax Cas300 subunit within a coordinated
Cascade structure. Nuclease assays with an assembled
Cascade lacking crRNA showed increasing cleavage
activity at Cascade concentrations of 0.05–0.5mM. At
the highest Cascade concentration, up to 75% ssDNA
was degraded during 10 min incubation at 70C. A time
course cleavage assay with 0.1 mM Cascade demonstrated
degradation of the substrate within 10min (Figure 3A).
The cleavage reaction showed a strict dependence on
divalent metal ions, as increased cleavage of Cascade
was only observed in the presence of Mn2+ ions,
followed by Mg2+ ions, while Ca2+ ions inhibited the
reaction. The highest cleavage rate was observed with
the combination of Mg2+ and Mn2+ ions
(Supplementary Figure S9). Next, we tested the inﬂuence
of crRNA addition on the unspeciﬁc ssDNA nuclease
activity. The used crRNA (crRNA 5.2) and the ssDNA
fragment (int 5.2_CCT for) are not complementary to
each other to prevent the formation of non-cleavable
RNA:DNA hybrids. Cascade was ﬁrst loaded with
crRNA, followed by the addition of the ssDNA substrate
to the reaction to mimic the in vivo situation of Cascade
assembly. The comparison of Cascade ssDNA cleavage
rate at 0.1mM without crRNA and with 0.5mM crRNA
for the identical time points showed an inhibition of the
nuclease activity (Figure 3A). The strongest inhibitory
effect could be observed at 0.05mM added crRNA after
10 min incubation, which resulted in an over twofold
decrease in activity (65% versus 28.5% remaining
ssDNA). The lowered cleavage rate can also be seen for
higher concentrations of crRNA (0.5 mM: 55%, 2.5 mM:
45% uncleaved substrate), but is less signiﬁcant, presum-
ably due to hybrid formation of excess crRNAs
(Figure 3B). To verify that Cas300 is the sole ssDNA
nuclease domain within the archaeal Cascade, we
aligned the T. tenax Cas300 with the previously
characterized Methanocaldococcus jannaschii Cas300
(MJ0384) sequence and introduced mutations of three of
the four highly conserved residues of the HD domain
motif (H19A, H55A and D56A) that are expected to in-
activate exonuclease cleavage (37). The produced Cas300
mutants were isolated and puriﬁed according to the
wild-type Cas300 puriﬁcation protocol and assembled
within Cascade via the co-refolding procedure
(Supplementary Figure S10). Each Cas300 mutant showed
a deﬁciency in ssDNA nuclease activity, most dramatically
observed for D56A (12% cleaved ssDNA), followed by
H19A (18% cleaved substrate) (Figure 3C).
Cascade-mediated interference is dependent on crRNA and
the protospacer DNA
Next, the assembled I-A Cascade was tested for cleavage
of dsDNA in dependence of the spacer encoded crRNA to
show in vitro type I-A Cascade-mediated interference.
First, short dsDNA fragments were designed that mimic
viral protospacer DNA. The spacer sequence 5.2 (40 bp)
was ﬂanked by random sequences on both sides
(25 bp each). Directly upstream of the spacer the PAM
sequence CCT was integrated. The PAM sequence CCN
was identiﬁed in S. solfataricus on the basis of viral
Figure 2. Cascade assembly and RNA binding. (A) The Cascade subunits (Csa5, Cas7, Cas5a, Cas30, Cas30 0 and Cas8a2) were assembled via a co-
refolding procedure of insoluble recombinant proteins, incubated with synthetic crRNA 5.2 (crRNA) or no RNA (RNA), and protein interaction
was veriﬁed via size-exclusion chromatography. In all, 15% SDS–PAGE of individual fractions (fractions 10–18) shows distinct protein bands of
assembled Cas protein subunits. The Cascade-containing fractions were additionally analyzed for bound RNA content by 10% Urea-PAGE. A
protein-free sample served as a running control (Cascade). (B) A comparison of the EMSAs for crRNA binding by the individual Cas7 subunit
(lanes 1–7: 0, 0.2, 0.5, 1, 2, 4, 5mM) or Cas7 assembled into Cascade (lanes 8–10: 0.5, 2, 5 mM) on 1% agarose gels demonstrates the formation of
high shifts for Cas7 alone and lower, more diffuse shifts for Cascade. (C) EMSAs veriﬁed the binding of the 50-[g-32P]-ATP labeled crRNA 5.13 by
Cascade (with Cas7 puriﬁed via a SUMO-fused construct) in increasing concentrations (lanes 1–6: 0, 0.125, 0.25, 0.5, 1, 2 mM) and in the presence of
yeast RNA via 6% native PAGE.
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BLAST hits of spacer targets (10). The non-target
(int 5.2_CCT for, crRNA non-complementarity) or the
target DNA strand (int 5.2_CCT rev, crRNA complemen-
tarity) was 50-labeled and hybridized with 1.5-fold excess
of the complementary cold strand to obtain two labeled
dsDNA fragments. The synthetic mature crRNA con-
struct 5.2 was supplied by hammerhead self-cleavage and
ﬁrst loaded into Cascade before the addition of the
dsDNA substrates, the metal ions Mg2+ and Mn2+, as
well as ATP. The separation of cleavage products via
20% denaturing-PAGE identiﬁed a Cascade-dependent
degradation pattern of the dsDNA substrates with differ-
ences in fragment length for the non-target and target
strand (Figure 4A). As a control, the Cas300 nuclease
mutant D56A was assembled into Cascade, which
showed no cleavage activity of the protospacer DNA.
Cascade loaded with a synthetic crRNA 5.13 that is not
complementary to the DNA target showed also no
dsDNA cleavage activity demonstrating crRNA-
mediated target guidance. In return, the reaction was per-
formed using the spacer sequence 5.13 with identical
ﬂanks in the dsDNA substrate as used before
(Figure 4B). Accordingly, only the matching crRNA
5.13 was capable to guide the Cascade-mediated
cleavage of the dsDNA substrate, whereas neither the
incorporated crRNA 5.2 nor the Cascade mutant Cas300
D56A showed nuclease activity. The cleavage pattern of
the non-target and target strand was similar for dsDNA
5.13 in comparison with dsDNA 5.2. Therefore, the
cleavage products of the interference reaction with the
labeled non-target and target strand of each dsDNA
substrate 5.2 or 5.13 were separated on 10% sequencing
gels to specify the fragment lengths (Supplementary
Figure S11). Each reaction was loaded next to a marker
with ssDNA fragments of 10–100 nt length and a mixture
of seven ssDNA fragments of 8–66 nt length to pinpoint
the dominant cleavage products. Cleavage sites were
observed in the middle of the non-target strand within
the protospacer (at position 43–47 nt), and smaller 50-
terminal fragments were generated with a minimal
length of 10 nt (Figure 4C). The target strand is cleaved
over its entire length, with smallest fragments of 9 nt. The
comparison of both DNA substrates showed no signiﬁ-
cant differences in the fragmentation pattern, indicating
a sequence unspeciﬁc cleavage of Cascade in dependence
of the position within the R-loop structure (Figure 4D).
The Cascade reconstitution platform allows the
identiﬁcation of PAM-dependent target DNA cleavage
The co-refolded Cascade in combination with in vitro
processed crRNA provides an active interference
complex cleaving dsDNA in a RNA sequence-dependent
manner. This set up allows the modulation of individual
components and to test their inﬂuence on Cascade-
mediated interference. First, the Cas300 mutants H19A,
Figure 3. Type I-A Cascade cleaves ssDNA unspeciﬁcally and is inhibited by crRNA. (A) Cascade (0, 0.05, 0.125, 0.25, 0.5 mM) was incubated with
a 50-[g-32P]-ATP labeled ssDNA fragment (int_5.2 CCT for) in the presence of Mg2+ and Mn2+ ions and the nucleolytic cleavage reaction was
resolved on 15% denaturing gels. After 1–10-min incubation at a ﬁxed Cascade concentration of 0.1 mM, >70% of the substrate is cleaved. In the
presence of 0.5 mM unlabeled crRNA, the reaction is inhibited. (B) This observation was tested in the presence of 0, 0.05, 0.5 and 2.5 mM crRNA, and
the amount of remaining substrate estimated via line proﬁle plots (Image J) was plotted for three different reaction times (1, 2, 10min) and reactions
performed in triplicate. (C) Cas30 0 subunit with HD domain mutations (H19A, H55A, D56A) was assembled into Cascade and then tested in ssDNA
cleavage assays.
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H55A and D56A were assembled into Cascade and tested
for their ability to cleave dsDNA substrates (Figure 5A).
All three mutants were impaired in dsDNA cleavage. The
H19A and D56A mutants showed no activity for the non-
target or target strand, while H55A is strongly reduced in
dsDNA cleavage. Next, the effect of different PAM se-
quences on the in vitro interference reaction was assayed.
It should be noted that Cascade recognizes PAM se-
quences as so-called target interference motifs that might
slightly differ from the PAM sequence recognized during
adaptation (56). Owing to missing viral targets of T. tenax
spacers, the exact PAMs are not known. Detailed analysis
of S. solfataricus CRISPR systems revealed CCN
sequences located 50 to the DNA strand corresponding
to the crRNA (non-target strand) as functional PAMs
(10,57), and computational studies identiﬁed the TCN
motif as a potential PAM (56,58). Therefore, the
designed dsDNA protospacer substrate 5.2 was modiﬁed
upstream in the spacer-adjacent three base pair motif,
while the spacer and the ﬂanking sequences remained
identical. The tested dsDNA substrates contained the
PAM sequences CCT, CCA, TCA, TCG, AAA and a
motif identical to the 50-tag of the crRNA (mimicking
self-targeting at the CRISPR locus) (Figure 5B). The
interference reaction showed similar Cascade cleavage
patterns of dsDNA for the PAM CCT and CCA,
Figure 4. Interference activity of in vitro assembled type I-A Cascade. (A) The assembled Cascade complex is loaded with crRNA 5.2 for 20min at
70C, and the interference reaction is started with the addition of ATP, Mg2+, Mn2+ and the dsDNA substrate (in_5.2 CCT), which is either
50-[g-32P]-ATP labeled on the non-target (forward) or the crRNA target strand (reverse). Cleavage reactions were stopped at three different time
points (1, 5, 10min at 70C). The reaction products of the cleaved dsDNA were separated on 20% denaturing gels. The non-matching crRNA 5.13
and the Cas30 0 D56A mutant are used as controls. (B) In parallel, the crRNA 5.13 is loaded into Cascade, and cleavage of the matching dsDNA
substrate (in_5.13 CCT) is visualized. (C and D) The cleavage products are analyzed on 10% Urea-PAGE for each strand (in_5.2 CCT for/rev and
in_5.13 CCT for/rev) with two different markers (Supplementary Figure S9). The cleavage sites are marked within the proposed R-loop structure that
is formed during the interference reaction [(C) dsDNA 5.2, (D) dsDNA 5.13].
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conﬁrming that CCN motif is a PAM that allows DNA
target cleavage. A reduced activity was observed for the
TCA PAM, while substrates with the TCG, AAA or the
50-tag motif were not cleaved by Cascade.
DISCUSSION
Type I CRISPR-encoded interference is mediated by a
crRNA-guided Cascade complexed with Cas3 to degrade
the foreign target DNA. Here, we described the produc-
tion and assembly of an archaeal type I-A Cascade with
co-refolded recombinant Cas proteins and synthetic
crRNA transcripts, which resulted in an active complex
capable of crRNA-guided degradation of dsDNA in
dependence of PAM sequences.
The analysis of T. tenax RNA-Seq read mapping
revealed the mature crRNA termini and conﬁrmed
previous northern blot analyses, which indicated that
T. tenax harbors ﬁve highly active CRISPR loci and two
inactive CRISPR loci (41). These inactive and active
clusters contain conserved motifs for transcription initi-
ation and differ mainly in their respective repeat sequences
(seven base exchanges and one base length difference).
Therefore, it is plausible that this repeat is not processed
by the two encoded Cas6 proteins. Accordingly, in type
III-A systems, crRNAs or their precursors cannot be
detected in Cas6 deletion mutants suggesting degradation
of the primary transcript (59). Alternatively, the
transcription of the two inactive loci could be regulated
by an unknown mechanism. To engineer functional syn-
thetic crRNAs, the in vivo processing of mature crRNAs
by Cas6 had to be mimicked, as soluble recombinant Cas6
was not available. The technique of fusing a cis-acting
hammerhead ribozymes to RNA transcripts to obtain
deﬁned termini (54,55) was adapted for the production
of crRNAs, which resulted in 8 nt tags with 50-hydroxyl
ends (Supplementary Figure S2A and B). This method-
ology allows the in vitro production of crRNAs that
start without the guanosine base that is required for
proper T7 RNA polymerase transcription initiation. The
RNA-Seq data additionally revealed gradually degraded
30-termini for all crRNAs. The used synthetic crRNAs
contained a 2 nt tag (50-GA-30), which was observed for
the majority of crRNA reads. The trimming of the
crRNAs’ 30-end is typically observed in many different
bacteria and archaea, but the exact mechanism is not
known (60,61). It is likely that Cas6-processed crRNAs
are protected by Cascade proteins binding to the
conserved 50-end, whereas the free 30-ends are
unspeciﬁcally trimmed by cellular RNases due to a
missing secondary structure or that crRNAs are unstable
at elevated temperatures (62,63). For organisms with
multiple encoded CRISPR-Cas effector complexes,
distinct crRNA species with varying 30-ends might be
sorted between complexes in dependence of their length
(64). These potential parameters for crRNA loading into
Figure 5. Analysis of Cas30 0 mutants and PAM recognition for in vitro assembled type I-A Cascade. (A) The Cas30 0-constructed mutants
(H19A, H55A, D56A) were assembled into Cascade and tested for dsDNA cleavage. (B) The dsDNA substrate 5.2 was mutated to include the
indicated 3-bp long PAM sequences (CCT to CCA, TCA, TCG, AAA or a PAM identical to the crRNA 8-nt tag). Cascade-mediated interference
reactions were performed with either 50-[g-32P]-ATP labeled non-target (forward) or the crRNA target strand (reverse) as a substrate, while Cascade
was loaded with the spacer matching crRNA 5.2. The loaded non-matching crRNA 5.13 served as a negative control.
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recombinant Cascade could be tested by engineering
multiple modiﬁed synthetic RNAs. Other possible appli-
cations for the use of synthetic crRNA transcripts are dye-
labeled RNA constructs for smFRET measurements or
crRNA-Cascade cross-linking with photoreactive nucleo-
tide analogs that facilitates detailed information about the
RNA structure and motion during complex formation and
a precise mapping of the cross-link between crRNA and
Cas protein subunit (65–67).
Previous research focused on the detailed analysis of the
E. coli type I-E Cascade function and structure (19,31).
One main feature of the type I-E interference mechanism
is a separation into the Cascade module that is binding
the crRNAs recognizing the matching DNA target and the
Cas3 protein, which is recruited by Cascade to the
crRNA:dsDNA R-loop structure. The E. coli Cascade is
built up by the subtype speciﬁc subunits Cse1 and Cse2
that are proposed to interact with the DNA target, the
conserved crRNA binding subunits Cas7 and Cas5e and
the pre-crRNA cleaving endoribonuclease Cas6e
(18,29,30). From a mechanistic point of view, this arrange-
ment guarantees a streamlined processing of the pre-
crRNA transcripts, immediate crRNA protection and
the scanning for the complementary DNA target,
localized within one protein complex. Additionally, the
transcription of pre-crRNAs and cascade genes are
strictly repressed by the global regulator H-NS and
activated with the help of the transcription factor LeuO,
ensuring a fast response to a viral attack (68–70).
In this study, we analyzed an archaeal type I-A CRISPR-
Cas system, which showed remarkable differences in the
assembly of Cascade and the crRNA production. A
typical feature found in archaeal genomes is the splitting
of the two Cas3 domains into separate genes (Cas30:
helicase domain, Cas300: nuclease domain) and a gene organ-
ization into one cascade genes operon that can be regulated
by changes of the environmental parameters (41). Similar to
type I-E Cascade, the crRNA binding subunits cas7 and
cas5a and two subtype-speciﬁc subunits csa5 and cas8a2
are encoded within the operon. However, two cas6 genes
are encoded separately at distant locations in the genome.
Pull-down assays supported that the genomic cas gene or-
ganization mirrors the Cas protein assembly, as both Cas3
subunits, Cas7, Cas5a and Cas8a2 were interacting with
Csa5. The Cas6 protein could not be identiﬁed
(Supplementary Table SII). In agreement, the co-refolding
of all possible protein combinations showed the necessity of
Cas3 for the formation of a stable Cascade complex,
indicating that the two Cas3 subunits are not recruited but
are rather an integral part of the Cascade I-A complex. In
contrast to type I-E systems, pre-crRNA transcription and
crRNA production appears to be constitutive, as evidenced
by the high abundance of crRNAs detectable in RNA-Seq
data. Therefore, regulation of Cascade immunity appears to
rely on the activation of Cas protein production. The tran-
scription of the Cascade genes might be activated by the
encoded regulator protein Csx1 (Csa3), which is followed
by assembly of Cascade:Cas3 and immediately loaded with
crRNA to cleave the protospacer DNA target (71). A
possible reason for the differences in Cascade assembly
might be the thermophilic lifestyle of T. tenax, which
would make a later recruitment of Cas3 to Cascade
assembled in an R-loop structure under elevated tempera-
tures challenging. Interestingly, type I-A systems are exclu-
sively found in thermophilic organisms, supporting the
evolutionary conservation of this alternative Cascade for-
mation strategy (6).
The established assembly of the T. tenax Cascade
allowed us to investigate the type I-A interference
reaction and the role of individual subunits in more
detail. In Cascade nuclease assays, Cas300 was identiﬁed
as the primary deoxyribonuclease subunit, cleaving linear
ssDNA substrates exonucleolytically in the dependence of
the divalent Mg2+ and Mn2+metal ions. Mutations in the
conserved HD domain motif (H19A, H55A and D56A)
inhibited the cleavage activity. The large group of HD
domain proteins comprises enzymes that are primarily
involved in nucleic acid metabolism and signal transduc-
tion and react on a broad range of substrates, including
ssDNA, RNA and R-loop structures (37,72). The degrad-
ation of ssDNA substrates by the Cas300 subunit was pre-
viously characterized for different Cascade subtypes from
M. jannaschii, S. thermophilus or Thermus thermophilus,
and a crystal structure revealed the active site with two
bound metal cations (37–39). The observed unspeciﬁc
cleavage of ssDNA by Cas300 in vitro would pose a
problem within the cell. The addition of non-matching syn-
thetic crRNA to the nuclease assays indicated an inhibition
of this background cleavage activity. This suggests that
Cascade might ﬁrst bind crRNA, which inhibits the unspe-
ciﬁc ssDNA cleavage until the correct dsDNA target is spe-
ciﬁcally located. Another example for the interplay
between Cascade subunits was observed for the binding
of crRNAs. The puriﬁcation procedure, EMSA assays
and TEM imaging conﬁrmed that T. tenax Cas7 binds
unspeciﬁcally to both crRNAs and other small RNA con-
taminants. This interaction resulted in the formation of
long helical Cas7 multimer structures. The observation of
helical Cas7 ﬁlaments was also made for a Cascade
sub-complex of the subunits Cas7 and Cas5a of S.
solfataricus (43). The cryo-electron microscopy structure
of the I-E Cascade revealed a seahorse-like shape, in
which six copies of the Cas7 subunit are forming the
backbone, combined to a Cascade stoichiometry of 1
Cse1, Cas5e, Cas6e, 2 Cse2 and 6 Cas7 (18,31). The
binding behavior of T. tenax Cas7 embedded in I-A
Cascade changed signiﬁcantly. The shifting of crRNA
appeared lower during EMSA assays, the gel ﬁltration
showed no formation of extended Cas7 multimers and no
helical structures were observed in TEM pictures. These
observations indicate a coordinated assembly of I-A
Cascade and a capping mechanism by other Cascade
subunits that block Cas7 from forming extended
multimeric ﬁlaments. The exact stoichiometry for I-A
Cascade could not be determined as the amount of
functional refolding is not known. Future work on the
Cascade structure via TEM, crystallization or native mass
spectrometry is required to address these questions.
In interference assays the assembled I-A Cascade
exhibited crRNA-mediated cleavage of dsDNA molecules.
In the targeting event, Cascade facilitates base pairing of
the crRNA with the complementary target strand and
Nucleic Acids Research, 2014, Vol. 42, No. 8 5135
 at M
PI Biochem
istry on A
ugust 7, 2014
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
60
Publication 3: Functional characterization of the type I-A Cas7 protein in T. tenax
additional displacement of the non-target strand to
produce the R-loop structure (33,35). An open question
is the nature of the crRNA seed sequence speciﬁcally for
the type I-A CRISPR-Cas system, deﬁned as the minimal
sequence complementarity of crRNA and target DNA for
binding (32,73). The existence of an adjacent PAM was
shown to be essential for directing DNA cleavage (57).
Functional PAM sequences for the T. tenax I-A Cascade
were CCA or CCT, whereas other ﬂanking sequences
yielded a reduced (TCA) or impaired activity (TCG).
The origin of the T. tenax spacers is not known.
Therefore, the established interference assay allowed us
to identify this basic requirement for Cascade-mediated
cleavage and can be used to complement plasmid-based
in vivo assays that determined the PAM sequences in vivo
for I-A and I-B systems (11,56,74,75). The main function
of the PAM is the discrimination between host CRISPR
loci DNA and protospacer/target sequences. Cascade ﬁrst
screens for the speciﬁc PAM followed by a helical desta-
bilization and strand invasion of the crRNA, which leads
to the R-loop formation (61,76). An outstanding question
is the mechanism for the identiﬁcation of the correct
PAM, which triggers the crRNA-loaded Cascade for tar-
geting. Two candidates Csa5 and Cas8a2 that are
described as the small and large subunit in Cascade
might interact with the DNA target and/or recognize the
PAM (5,77). The Cascade-mediated interference assays
reﬂect the stepwise degradation of the dsDNA, as Cas300
ﬁrst cleaves in the middle of the looped out non-target
strand (at position 43–47 nt) followed by a gradual
cleavage in 30–50 direction. In a second step, the target
strand is then cleaved over the entire length also in 30–50
direction, which was reported previously for other
members of the Cas3 family (37–39). The identiﬁed
minimal cleavage products are similar to ones found in
the type I-E system with 8–10-nt fragment length, which
suggests a conserved cleavage mechanism (35).
In conclusion, the established in vitro assembly and
interference activity protocols of a type I-A Cascade with
synthetic crRNA molecules highlight similarities and dif-
ferences between this archaeal interference complex and
the type I-E Cascade. These studies are expected to aid in
the assembly of other Cascade complexes to help us to
understand commonalties and differences in the evolution
of the diverse type I Cascade machineries.
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Supplementary Data are available at NAR Online.
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SUPPLEMENTARY DATA 
 
SUPPLEMENTARY FIGURES 
 
Fig. S1: Protein purification of all six Cascade subunits. (A) The soluble protein Csa5 was purified via a 
two-column strategy. Depicted are the pellet (P) and supernatant (S) fractions after cell lysis and 
ultracentrifugation, followed by the heat precipitated (HP, 90°C) Csa5 sample, further purified samples via 
Blue Sepharose affinity chromatography (BS) and MonoQ anion-exchange chromatography (MQ) on a 
15% SDS gel next to the protein marker (M). (B) The insoluble subunits Cas5a, Cas3', Cas3'' and Cas8a2 
were individually purified via inclusion body isolation and solubilization in 6 M GdmCl. The 15% SDS gel 
shows the subunits before usage in Cascade assembly. (C) The soluble subunit Cas7 was fused with a 
SUMO tag to omit cross-contamination with E. coli RNA and oligomerization. Depicted are the individual 
protein fractions alongside the protein marker (M) separated on a 15% SDS-PAGE. Cas7-SUMO was 
purified via Ni-NTA chromatography (NI), followed by a SUMO protease (S-P) treatment during dialysis. 
After concentration of native Cas7 (centrifugal filter units, MWCO: 30 kDa) the cleaved off SUMO tag was 
visible in the flow-through (FT). Cas7 was further purified with Heparin cation-exchange chromatography 
(HE) and gel filtration (GE) resulting in monomeric Cas7. 
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Fig. S2: Production of synthetic crRNAs. (A) Mature crRNAs 5.2 and 5.13 were produced via fusion of the 
crRNA sequence to the sequence of a minimal cis-acting hammerhead (hh) ribozyme, resulting in a self-
cleavage (arrow marking the cleavage site) directly upstream of the 8 nt 5'-tag. (B) The self-cleavage of 
the transcript (precursor) into crRNA and hh was induced by a direct incubation at 60°C (conc.), dilution of 
the sample in 4 vol of 30 mM MgCl2 in DEPC-H2O (Mg2+) or dilution in 4 vol of in vitro transcription buffer 
(buffer) followed by heat incubation, yielding the synthetic mature crRNAs 5.2 (50 nt) and 5.13 (54 nt). 
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2 Results
 
Fig. S3: Co-refolding combinations of Cascade subunits. All possible 63 combinations of Cascade 
subunits were reconstituted by the rapid dilution method and for each protein, the obtained bands on the 
SDS gel compared between soluble protein (supernatant) and aggregated protein (pellet). Plotted is the 
average of co-refolded supernatant (%) of 60 combinations that contained insoluble proteins (c: Cas5a, d: 
Cas3', e: Cas3'', f: Cas8a2), while the soluble proteins (a: Csa5, b: Cas7) are not taken into account. Only 
the combination that contained all six Cascade subunits (6p) showed a recovery of soluble protein above 
50%, in contrast to combinations with missing subunits (1p-5p) that resulted in soluble protein of less than 
10%. 
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Fig. S4: Size-exclusion chromatograms of assembled Cascade. The Cascade subunits (Csa5, Cas7, 
Cas5a, Cas3', Cas3'' and Cas8a2) were assembled via the co-refolding procedure and incubated with 
synthetic crRNA 5.2 (crRNA) or no RNA (-RNA) and protein was followed via absorption at 280 nm. A 
protein-free sample of the crRNA served as a control of the elution profile (crRNA control). The 
chromatograms demonstrate that protein is eluting in the fractions 10-18 ml (Fig. 2A). 
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Fig. S5: Comparison of Cas7 and Cas7-SUMO purification procedures. (A) The two Cas7 versions (native 
purification or SUMO-tagged) exhibit different elution profiles on size-exclusion columns. The native 
purification of Cas7 results in completely assembled large multimeric complexes (black line, elution 
volume: 8.2 ml), while the Cas7-SUMO version elutes after cleavage of the SUMO-tag as a monomer (red 
line, elution volume: 15.5 ml). (B) 100 µg of Cas7 loaded on a 1% agarose gel and stained with EtBr next 
the DNA marker shows cross-contamination of E. coli RNA (C), which are cleaved by RNase A or 
Benzonase, but not by DNaseI. (C) The purification of Cas7-SUMO is free of any cross-contamination, 
which is shown by loading identical amounts of protein on a 1% agarose gel. 
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Fig. S6: Helical artifact formation of Cas7 with E. coli RNA. A typical TEM analysis of a Cas7 purification 
resulted in cross-contamination with E. coli RNA and the formation of helical (black arrows) and double-
helical filaments (white arrows) of up to 50 nm length. Scale bar: 50 nm. 
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2 Results
 
Fig. S7: Specificity of Cas7 binding to crRNA. At a fixed Cas7 concentration of 4 µM the specificity of 
crRNA binding (crRNA 5.2) was tested by competing amounts of yeast RNA (lane 2-6: 0, 10, 50, 250, 500 
ng) or increasing amounts of unlabeled crRNA 5.2 (lane 7-10: 1:1, 1:10, 1:100, 1:1000). Only the highest 
concentration of unlabeled crRNA abolished the Cas7 shift indicating an unspecific binding of Cas7 to 
crRNA. Lane 1 serves as a crRNA loading control. 
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Fig. S8: Cascade binding to the synthetic crRNA 5.2. The assembled Cascade was tested in EMSAs for 
specific binding to the constructed crRNA 5.2. Increasing concentrations (0, 0.125, 0.25, 0.5, 1, 2, 4, 5 
µM) of Cascade in the presence of yeast RNA showed a shifting of the 5'-labeled (with [γ-32P]-ATP) 
crRNA 5.2 on 6% non-denaturing gels comparable to the synthetic crRNA 5.13. 
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2 Results
 
Fig. S9: The cleavage of ssDNA by Cascade is metal-dependent. Cascade was incubated with the 5'-[γ-
32P]-ATP labeled short ssDNA substrate (int 5.2_CCT for) and different metal combinations for 10 min at 
70°C and the cleavage products were separated on a 15% denaturing gel next to the low molecular 
weight marker. The assay was repeated three times and in each reaction the remaining substrate 
estimated via line profile plots (Image J), which indicated that Cascade in the combination with Mg2+ and 
Mn2+ ions has the highest activity (~70% cleaved) on ssDNA. 
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Fig. S10: Co-reconstitution of Cascade with wild-type Cas3'' and Cas3'' mutants. All Cascade complexes 
were assembled via the same co-refolding procedure of insoluble proteins including either Cas3'' WT, 
Cas3'' H19A, Cas3'' H55A or Cas3'' D56A. A 15 µl sample of the supernatant after Cascade co-refolding 
into native buffer, centrifugation and concentration was loaded on the 15% SDS gel alongside the protein 
marker (M), demonstrating the same reconstitution efficiency for all Cas3'' proteins within Cascade. 
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2 Results
 
Fig. S11: Size determination of the cleavage products appearing in the Cascade interference reaction. 
The 5'-[γ-32P]-ATP labeled non-target and target strand of each dsDNA substrate 5.2 or 5.13 were 
separated on 10% denaturing sequencing gels alongside the 5'-labeled low molecular weight marker (10-
100 nt) or a mixture of seven ssDNA fragments (8-66 nt) to specify the fragment length of cleavage hot 
spots. Lanes marked with C are the loading controls of the dsDNA. 
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SUPPLEMENTARY TABLES 
Table SI: Oligonucleotides and RNA sequences for cloning and substrate generation 
name sequence 
cr5.2h (125bp) BamHI – T7 promoter – hammerhead – crDNA, 5.2 – HindIII  
cr5.2h for (119nt) GATCCTAATACGACTCACTATAGGGCAATCTGATGAGTCCGTGAGGACGAAACGGTACC
CGGTACCGTCATTGAAAGCGTTGATGCGGCCGCGACTGGCTGACTCAGCTATTACGTTG
A 
cr5.2h rev(119nt) AGCTTCAACGTAATAGCTGAGTCAGCCAGTCGCGGCCGCATCAACGCTTTCAATGACGG
TACCGGGTACCGTTTCGTCCTCACGGACTCATCAGATTGCCCTATAGTGAGTCGTATTA
G 
cr5.13h (126bp) HindIII – T7 promoter – hammerhead – crDNA, 5.13 – EcoRI 
cr5.13h for (120nt) AGCTTAATACGACTCACTATAGGCAATCTGATGAGTCCGTGAGGACGAAACGGTACCCG
GTACCGTCATTGAAAGATCGCTTGTCCAACCGGGCTCCTCTATATGTCGTCATTAGCTT
AG 
cr5.13h rev (120nt) AATTCTAAGCTAATGACGACATATAGAGGAGCCCGGTTGGACAAGCGATCTTTCAATGA
CGGTACCGGGTACCGTTTCGTCCTCACGGACTCATCAGATTGCCTATAGTGAGTCGTAT
TA 
cr5.2PCRf (19nt) GGGGATCCTAATACGACTC 
cr5.2PCRr (20nt) TCAACGTAATAGCTGAGTCA 
cr5.13PCRf (19nt) GCCAAGCTTAATACGACTC 
cr5.13PCRr (20nt) TCTAAGCTAATGACGACATA 
crRNA 5.2 (50nt) AUUGAAAGCGUUGAUGCGGCCGCGACUGGCUGACUCAGCUAUUACGUUGA 
crRNA 5.13 (54nt) AUUGAAAGAUCGCUUGUCCAACCGGGCUCCUCUAUAUGUCGUCAUUAGCUUAGA 
int 5.2 (93bp) SalI – 5'-proto – PAM (NNN) – spacer 5.2 – 3'-proto – HindIII 
int 5.2_CCT for (93nt) GTCGACTAATACGACTCACTATAGACCTCGTTGATGCGGCCGCGACTGGCTGACTCAGC
TATTACGTTCCGCTGAGCAATAACTAGCAAGCTT 
int 5.2_CCT rev (93nt) AAGCTTGCTAGTTATTGCTCAGCGGAACGTAATAGCTGAGTCAGCCAGTCGCGGCCGCA
TCAACGAGGTCTATAGTGAGTCGTATTAGTCGAC 
int 5.2_CCA for (93nt) GTCGACTAATACGACTCACTCGCAGCCACGTTGATGCGGCCGCGACTGGCTGACTCAGC
TATTACGTTCCGCTGAGCAATAACTAGCAAGCTT 
int 5.2_CCA rev (93nt) AAGCTTGCTAGTTATTGCTCAGCGGAACGTAATAGCTGAGTCAGCCAGTCGCGGCCGCA
TCAACGTGGCTGCGAGTGAGTCGTATTAGTCGAC 
int 5.2_TCA for (93nt) GTCGACTAATACGACTCACTCGCAGTCACGTTGATGCGGCCGCGACTGGCTGACTCAGC
TATTACGTTCCGCTGAGCAATAACTAGCAAGCTT 
int 5.2_TCA rev (93nt) AAGCTTGCTAGTTATTGCTCAGCGGAACGTAATAGCTGAGTCAGCCAGTCGCGGCCGCA
TCAACGTGACTGCGAGTGAGTCGTATTAGTCGAC 
int 5.2_TCG for (93nt) GTCGACTAATACGACTCACTCGCAGTCGCGTTGATGCGGCCGCGACTGGCTGACTCAGC
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TATTACGTTCCGCTGAGCAATAACTAGCAAGCTT 
int 5.2_TCG rev (93nt) AAGCTTGCTAGTTATTGCTCAGCGGAACGTAATAGCTGAGTCAGCCAGTCGCGGCCGCA
TCAACGCGACTGCGAGTGAGTCGTATTAGTCGAC 
int 5.2_AAA for (93nt) GTCGACTAATACGACTCACTCGCAGAAACGTTGATGCGGCCGCGACTGGCTGACTCAGC
TATTACGTTCCGCTGAGCAATAACTAGCAAGCTT 
int 5.2_AAA rev (93nt) AAGCTTGCTAGTTATTGCTCAGCGGAACGTAATAGCTGAGTCAGCCAGTCGCGGCCGCA
TCAACGTTTCTGCGAGTGAGTCGTATTAGTCGAC 
int 5.2_Rep for (98nt) GTCGACTAATACGACTCACTATAGAATTGAAAGCGTTGATGCGGCCGCGACTGGCTGAC
TCAGCTATTACGTTCCGCTGAGCAATAACTAGCAAGCTT 
int 5.2_Rep rev (98nt) AAGCTTGCTAGTTATTGCTCAGCGGAACGTAATAGCTGAGTCAGCCAGTCGCGGCCGCA
TCAACGCTTTCAATTCTATAGTGAGTCGTATTAGTCGAC 
int 5.13 (97bp) SalI – 5'-proto – PAM (CCT) – spacer 5.13 – 3'-proto – HindIII 
int 5.13_CCT for (97nt) GTCGACTAATACGACTCACTATAGGCCTATCGCTTGTCCAACCGGGCTCCTCTATATGT
CGTCATTAGCTTACCGCTGAGCAATAACTAGCAAGCTT 
int 5.13_CCT rev (97nt) AAGCTTGCTAGTTATTGCTCAGCGGTAAGCTAATGACGACATATAGAGGAGCCCGGTTG
GACAAGCGATAGGCCTATAGTGAGTCGTATTAGTCGAC 
Csa5-His for (20nt) TCCTAATACGACTCACTATA 
Csa5-His rev (23nt) GGAGCCACCCAAGCTTCCCCTTA 
Cas3''-H19A for (34nt) CCAGACCTACGAAGACGCCATCACGCAGGCTCTG 
Cas3''-H19A rev (34nt) CAGAGCCTGCGTGATGGCGTCTTCGTAGGTCTGG 
Cas3''-H55A for (32nt) CTAGCCGTGGAGTTCGCCGACCTAGGCAAGCT 
Cas3''-H55A rev (32nt) AGCTTGCCTAGGTCGGCGAACTCCACGGCTAG 
Cas3''-D56A for (29nt) CGTGGAGTTCCACGCCCTAGGCAAGCTCG 
Cas3''-D56A rev (29nt) CGAGCTTGCCTAGGGCGTGGAACTCCACG 
MI_8 (8nt) CATCAACG 
MI_9 (9nt) GCATCAACG 
MI_12 (12nt) GCCGCATCAACG 
MI_22 (22nt) GCCAGTCGCGGCCGCATCAACG 
MI_42 (42nt) GCATCTAATACGACTCACTATAGGGAGCGAATGAAACGAGCG 
MI_54 (54nt) GCAGCACTCGAGCAATTGTTACACGAAACCTTTACCCACACGTTCCACGGTGCC 
MI_66 (66nt) AGCTTTAATACGACTCACTATAGATTAATCCCATAATACTTTTCTAGGTCTGGGCGGAA
TGGATCC 
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Table SII: MS analysis of in vivo pull-down Cascade experiments. Proteins co-purifying with Csa5 were 
identified by in solution trypsin digestion and followed by MS. 
ORF protein 1) intensity 1) coverage [%] 2) intensity 2) coverage [%] 
TTX_1250 Csa5 8.46E+10 96.2 6.22E+10 96.2 
TTX_1251 Cas7 - - 836940 7.9 
TTX_1252 Cas5a - - - 3.5 
TTX_1253 Cas3' 30243000 14 134950 1.2 
TTX_1254 Cas3'' - - 71119 4.9 
TTX_1255 Cas8a2 12116000 14.4 - - 
TTX_0235 Cas7 27699000 17 138670 3.2 
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2 Results
2.4 Follow-up on Publication 3: RNA-binding features of Tt Cas7
I followed up on the the collaborative study and investigated the RNA binding prop-
erties of TtCsa2, the type I-A Cas7 homolog. As TtCas7 binds an unspecific poly-U20
sequence in comparable fashion and in the same affinity range as Tp Csc2 (Fig. 9), I
chose to map the RNA surface using a similar approach. Mass spectrometric analysis
identified six crosslinked peptides and 5 specific RNA-amino acid crosslinks on TtCas7
(Fig. 9).
50
100
R
el
at
iv
e 
In
te
ns
ity
y5 #2
857.4144
y4 #2
760.3618
y5 #3
937.3834
y4 #3
840.3248
y5 #1
743.3836
y4 #1
646.3314
y3 #1
549.2787
754.3916
y6 #
y5 #
y4 #
y3 #
175.1189
a2
274.1874
489.2451
683.3517
586.2986
171.1127
143.1179
y2
y1
b2
1000100 200 300 400 500 600 700 800 900
m/z
y1y2y6# y5# y4# y3#
+ [U]
a2
b2
VAPPYVR
#    =  Observed as an adduct with [Fragment of U = -C3O = 52]
#1    =  Observed as an adduct with [U’]
#2    =  Observed as an adduct with [U-H3PO4]
#3    =  Observed as an adduct with [U-H2O]
y4#
1
y3#
1
y5#
3
y4#
2
y5#
2
y5#
1
y4#
3
50
100
R
el
at
iv
e 
In
te
ns
ity
y5 #2
857.4144
y4 #2
760.3618
y5 #3
937.3834
y4 #3
840.3248
y5 #1
743.3836
y4 #1
646.3314
y3 #1
549.2787
754.3916
y6 #
y5 #
y4 #
y3 #
175.1189
a2
274.1874
489.2451
683.3517
586.2986
171.1127
143.1179
y2
y1
b2
1000100 200 300 400 500 600 700 800 900
m/z
y1y2y6# y5# y4# y3#
+ [U]
a2
b2
VAPPYVR
#    =  Observed as an adduct with [Fragment of U = -C3O = 52]
#1    =  Observed as an adduct with [U’]
#2    =  Observed as an adduct with [U-H3PO4]
#3    =  Observed as an adduct with [U-H2O]
y4#
1
y3#
1
y5#
3
y4#
2
y5#
2
y5#
1
y4#
3
50
100
R
el
at
iv
e 
In
te
ns
ity
IM F
218.1509
525.3160
933.4631
888.9012
1559.7032
y11 #
y10 #
1428.5674
1104.5317
a4
448.2202
476.2155
317.2205
348.1570
388.2579
277.1197
a2
770.4029
656.3616
a5
561.3032
589.3003
120.0814
249.1243
y10
y8
b8
y7
y6
b5
y5
b4
y4
b3
y3
b2y2
1000100 200 300 400 500 600 700 800 900 1100 1200 1300 1400 1500 1600 1700 1800
m/z
y1
147.1133
#    =  Observed as an adduct with [U]
y10# y7 y6 y5 y4 y3
+ [U]
a2
b4b3b2
FEAQLSVTGAGNMGNYNMHAVAK
y11# y8 y2 y1
b8b5
a5a4a3
50
100
R
el
at
iv
e 
In
te
ns
ity
IM F
218.1509
525.3160
933.4631
888.9012
1559.7032
y11 #
y10 #
1428.5674
1104.5317
a4
448.2202
476.2155
317.2205
348.1570
388.2579
277.1197
a2
770.4029
656.3616
a5
561.3032
589.3003
120.0814
249.1243
y10
y8
b8
y7
y6
b5
y5
b4
y4
b3
y3
b2y2
1000100 200 300 400 500 600 700 800 900 1100 1200 1300 1400 1500 1600 1700 1800
m/z
y1
147.1133
#    =  Observed as an adduct with [U]
y10# y7 y6 y5 y4 y3
+ [U]
a2
b4b3b2
FEAQLSVTGAGNMGNYNMHAVAK
y11# y8 y2 y1
bb5
a5a4a3
50
100
R
el
at
iv
e 
In
te
ns
ity
PV-H2O
179.0452
334.1768
405.1987
276.1555
518.2823
y5
617.3520
1031.5846 1118.6143
884.5090
813.4713
PVLEEK
714.4041
696.3937
PVLEE
568.2979
PVLE
439.2554
PVL
310.2129
PV
197.1284
IM F
147.1129
a2
159.1129
187.1077
120.0809
U-H3PO4
227.0664
y10y9
y8
y7
y6
y4
y3
b3
y2
b2
y1
1000100 200 300 400 500 600 700 800 900 1100 1200
m/z
y10 y8 y7 y6 y5 y4 y3
+ [U]
a2
b3b2
VSFAVPVLEEK
y2 y1y9
50
100
R
el
at
iv
e 
In
te
ns
ity
PV-H2O
179.0452
334.1768
405.1987
276.1555
518.2823
y5
617.3520
1031.5846 1118.6143
884.5090
813.4713
PVLEEK
714.4041
696.3937
PVLEE
568.2979
PVLE
439.2554
PVL
310.2129
PV
197.1284
IM F
147.1129
a2
159.1129
187.1077
120.0809
U-H3PO4
227.0664
y10y9
y8
y7
y6
y4
y3
b3
y2
b2
y1
1000100 200 300 400 500 600 700 800 900 1100 1200
m/z
y10 y8 y7 y6 y5 y4 y3
+ [U]
a2
b3b2
VSFAVPVLEEK
y2 y1y9
  0   5  25  50  50 Tt Cas7 (µM)
free probe
super shift
complex
U15 A15 RNA
*
*
a b
Figure 9. RNA-binding properties of Tt Cas7.
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Figure 9: RNA-binding properties of Tt Cas7.
a. Electrophoretic mobility shift assays (EMSAs) with wild-type Tp Csa2. Left panel: EMSAs were carried
out with 32P-5′-end labeled poly-U15 or poly-A15 RNAs and increasing concentrations of Tp Csc2 (0,
5, 25, 50 µM). The positions of the free RNA probe (arrowhead) and of the RNA-bound complexes
(asterisks) are shown on the right.
b.MS/MSmass spectra of Tp Csc2 peptides, carrying an additional mass corresponding to one (panel 2
and 3) or two (panel 1) uracil nucleotides associated with the respective amino acid. Peptide sequence
and the observed fragment ions are indicated as follows: # adduct with [Fragment of U: -C3O]. #1
adduct with [U′]. #2 adduct with [U-H3PO4]. #3 adduct with [U-H2O].
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2 Results
The sequence conservation amongst homologous Cas proteins is weak, therefore I chose
to compare the localization of the crosslinked residues on a structural level and inves-
tigate if the same features which I observed for other Cas7 proteins (Hrle et al., 2014,
Fig. 4) are present. As high-resolution structural data of Tt Csa2 were not available,
I generated a structural model using the Phyre2 sever (Fig. 10). The mapped residues
localize to two regions: the predicted lid domain and the central cleft defined by the
interface of the RRM-like core and the α1-β2 insertion domain. Moreover the identified
peptide lies adjacent to the conserved positively charged cleft (Fig. 10, bottom). This
region harbors conserved arginine and lysine residues, which are found in other Cas7
family homologs (inset in Fig. 10). These results are in agreement with our previously
presented findings (Hrle et al., 2014, Fig. 5) and supported by high-resolution data of the
well-studied type I-E interference complex from the Wiedenheft laboratory [68].
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G28
P155
Y7
V148 M172
cross-linked 
peptide
(V125-E136)
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R126
Figure 10:
Top: the predicted three dimensional model of Tt Cas7 (grey) generated using the Phyre 2 server.
Direct U20-crosslinked amino acid residues are represented as sticks (yellow) and an arrow points to
the location of the identified peptide (highlighted in yellow). The conserved cleft (zoom in) harbors
positively charged residues. A reoccurring feature in the structurally studied Cas7 proteins. Bottom:
Surface potential distribution. Positive charge is shown in blue, negative in red. An arrow points to the
prominent positively charged groove.
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The CRISRP field is expanding rapidly and structural studies are published at a fast pace.
New insights from structural data of single proteins and interference complexes of all
three types have become available in the past fewmonths: The crystal structure of a type I
interference complex [68], several structures of Cas9 [60, 61, 83], EM structures of type
III-A [65] and an EM-aided pseudo-atomicmodel of the type III-B interference complex
[69]. The following two sections discuss the two major achievements of the study. First,
how our single Cas7 protein structures contribute to defining features that distinguish
this protein family from others. Second, how the newly published structural data of
entire complexes embed the knowledge into a functional context of the CRISPR/Cas
adaptive immune response and places the results presented in this thesis in the wider
perspective.
3.1 The Cas7 superfamily – a structural perspective
Cas protein families have been established on the basis of secondary structure predic-
tions and sequence analyses [30]. These have been shown to correlate with the func-
tional properties of the proteins. However, the high level of sequence divergence poses
an obstacle. On the one hand, the degree of sequence diversity is a means of establish-
ing lineages. On the other hand, it impairs the predictions of structural features and
mechanistic details. This is why high-resolution structural data are paramount for our
understanding of Cas proteins. The first published structure of a Cas7 representative was
that of SsCsa2, a type I-A homolog of TtCas7 (one of the subjects of this thesis) [63].
The SsCsa2 structure laid the initial foundation for future structure-based classification
and comparisons. The crystal structures ofMkCsm3 and TpCsc2, the model of TtCas7
and recently published new structures of Cas7 family proteins of I-E and III-B now fully
allow a comprehensive comparison of Cas protein families and the Cas7 sub-types alike
[68, 69, 84, 85].
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3.1.1 Common denominators and sub-type specificities of Cas7 proteins
The three proteins that were the center of investigation in this study –
MkCsm3, TpCsc2 and TtCas7 – had been predicted to belong to the Cas7 protein fam-
ily, yet no functional or structural data were available [70]. We compared our individual
crystal structures ofMkCsm3, TpCsc2 to representatives of three other major Cas pro-
tein families, namely Cas7, Cas5 and Cas6. All three protein families are representatives
of the RAMP superfamily [29, 30]. Central to their architecture is at least one RRM-like
domain and, despite limited sequence conservation, most of the proteins have a con-
served glycine-rich region between α2 and β2 of the RRM domain [70]. The functional
relevance of this reoccurring sequence motif remains elusive. However, one can specu-
late on a role in mediating RNA interaction by granting structural flexibility to a crucial
and otherwise rather rigid structural element.
The features that characterize the different Cas protein families (5/6/7) within the RAMP
superfamily are the absence or presence of additional peripheral domains surrounding
the RRM-like core [29, 30]. These domains are defined by insertions between the se-
condary structure elements of the core; the distinct arrangements of secondary structure
elements are specific to each protein family (Fig. 11). In case of the Cas7 family proteins,
these peripheral domains give the proteins their crescent shape and unique RNAbinding
capabilities. Four major features distinguish Cas7 proteins from Cas6 and Cas5 repres-
entatives. Each feature is described below based on the comparison of our and all known
structures.
RRM-like domain
All Cas7 protein structures, includingMkCsm3, TpCsc2 and TtCsa2, harbor one cent-
ral RRM-like domain, with a β1-α2-β2-β3-α2-β4 topology. Four β-strands fold into a
twisted antiparallel β-sheet, lined by two α-helices. As in all Cas7 proteins described to
date, the strands β1–β3 lack the consensus sequence motifs RNP2 and RNP1 reported
to be necessary and sufficient for binding RNAmolecules in RNPs (ribonucleoproteins)
[27, 30]. Thus Cas7 proteins mediate these interactions in a different manner. Struc-
tural super-positioning of the RRM-like domains with Cas7, Cas6 and Cas5 representa-
tives highlights the identical arrangement of the secondary structure elements across the
proteins families. The presence of either one or two RRM-like domains was long seen
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as a discriminating feature between Cas protein families, as all Cas6 proteins contain
two sequential RRM-like domains, linked by β4 of the first one [70]. However, recent
structures of the Cas7-like protein Cmr1 have extended the feature of a second RRM-
like domain to the Cas7 family [69, 86]. Conversely, Cas5 proteins with two RRM-like
domains have been predicted bioinformatically, but confirmation on structural level is
pending [70].
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Figure 11: Domain organisation of RAMPs
Schematic representation of the domain organization of the RAMP superfamily. The core domain
with a β1-α2-β2-β3-α2-β4 topology is highlighted by a gray square. Peripheral domains are constituted
by insertions between the secondary structure elements of the core. A β-hairpin in domain 1 and a
glycine-rich region between α2-β4 are common toCas5 Cas7 andCas6 protein families. Apart from that,
Cas family proteins vary in the absence, presence of and different topological arrangements within the
peripheral domains.
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Domain 1
The domain 1, which we termed the lid (Jackson et al. refer to it as the thumb) is defined
by secondary structure elements of two insertions between β1 and α1, as well as β2 and β3
(Fig. 11). The most prominent characteristic is its flexibility. It can change from partially
unstructured to hairpin and helical structures, depending on the functional require-
ments (mediating protein–protein or protein–RNA interaction). One hairpin between
β1 and α1 is present in Cas7, Cas6 and Cas5 protein families [29]. A second hairpin is
formed by an elaborate insertion between β2 and β3 and appears to be a Cas7 family
denominator. In all but TpCsc2 and EcCasC it was structurally not resolved (Figure 12,
top panel). The crystal structure of the entire Cascade complex demonstrated that the
hairpin observed in single-protein structures of TpCsc2 is not a packing artifact, but
functionally relevant: In TpCsc2 and EcCasC copies 1–5 the β2–β3 insertion included
a hairpin, involved in intramolecular and RNA interaction (Fig. 12, CasC-2) [68]. In
the first copy of EcCasC however, the very same region folds into a short helix, which is
essential for Cas6 interaction (Figure 12, CasC-1) [68]. The possibility to take up two dif-
ferent conformations underlines the flexibility and importance of this sub-type specific
element in complex formation. Moreover, a hairpin formed by both the β1–α1 and β2–β3
segments constitutes the base of the lid domain. This hairpin extends the β-strands β1
and β3 of the RRM-like core – a feature that is also present in Cas5 and Cas6 families.
However, there it is not part of an insertion, but formed by elongated beta sheets of the
core itself [29].
Domain 2
The insertion domain 2 is located between α1 and β2. In all known cases, this domain
contains helical elements and two anti-parallel β-strands (with the exception of the all-
helicalMkCsm3) the topological order of which varies strongly. Together with the core
domain this insertion defines a central cleft that harbors solvent-exposed, positively
charged residues and a second glycine-rich cluster (Hrle et al., 2014, Fig. 5). In TpCsc2
and MkCsm3, a zinc ion is structurally coordinated. Interestingly, in line with the di-
vergent sequential arrangement of secondary structure elements, themetal coordination
varies between subtypes, as residues required for coordination (histidines and cysteines)
are not always present in this region. Superpositioning of the available Cas7 protein
structures via the RRM showed that all have a different curvature. This can be attributed
to the orientation of the insertion 2 domain relative to the core. Structural data from the
86
3.1 The Cas7 superfamily – a structural perspective
I-E
Ec CasC-2
I-E
Ec CasC-6
I-E
Ec CasC-2
I-E
Ec CasC-1
hairpin helix
180°
I-D
Tp Csc2
a
b
Figure 12: Structural flexibility of Cas7 proteins.
a. Crystal structures of I-D TpCsc2 (purple) and I-E Ec CasC copy2 (green)with resolvedhairpin structure
in domain 1. Superposition (middle box) highlights structural similarities beyond the RRM-like core.
b. Individual crystal structures of the three observed conformations of Ec CasC within the type I-E
interference complex. The first copy (Ec CasC-1) features a small α-helix at the tip of insertion β2-β3 of
domain 1. This structural element is rearranged to a β-hairpin in the copies 2 to 5 (displayed on the
example of copy 2). Domain 2 of the sixth copy of Ec CasC is rotated by 180○ compared to all other
copies.
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entire type I/E interference complex showed that domain 2 of the last copy of EcCasC
is rotated by 180○ compared to the other copies (Fig. 12, CasC-6), triggered by its in-
teraction with Cas5, the large subunit protein, and the 5′-end of the crRNA [68]. This
indicates that there is an inherent structural flexibility of the junction between the core
and insertion domain 2.
Domain 3 (C-terminal extension)
The third domain follows after β4, packs against theRRMand (with exception ofTpCsc2),
contributes a fifth β-strand to the β-sheet of the core domain. In TpCsc2, three helices
constitute the domain and the fourth C-terminal helix, re-joins with insertion domain
2. In Cmr4 this domain is defined by elements of the β2-β3 insertion [69].
Surface charge and conservation
Sequence diversity is the basis of all subtype-specific variation in topology and structural
compositionwithin the peripheral domains. Despite low sequence homologywithin and
between subtypes, both positive surface charge and solvent-exposed conserved residues
are located within the central groove and the lid domain. Both surfaces mediate RNA
binding in all known structures [68, 84, 85].
3.1.2 Cas7-like proteins of type III-B
Additional valuable information on the Cas7 proteins has became available with the
structures of proteins belonging to the RNA-targeting Cmr complex of Pyrococcus furi-
osus (Pf) [69]. The proteins Cmr4, Cmr6 and Cmr1 have been classified as Cas7-like
proteins by Makarova et al. [30]. Previous EM studies of the same complex had shown
that four copies of Cmr4, as well as one copy each of Cmr6 and Cmr1 assemble into a
backbone-like superhelical arrangement (Fig. 13) [66, 67]. Biochemical analysis showed
a distinct cleavage pattern that could just be explained by a catalytic activity that is part
of Cmr4 itself [67, 69].
The comparison of the structures presented in this thesis with the above-mentioned in-
dividual structures of Cmr proteins from Pyrococcus furiosus beautifully shows how the
peripheral domains of Cas7 have adapted to the requirements of the system.
88
3.1 The Cas7 superfamily – a structural perspective
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              proteins
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E227/M215 Y229/R217D26/D35H15/R21 E227/M215 Y229/R217D26/D35H15/R21
Figure 13: Cas7-like proteins of the Cmr4 complex of Pyrococcus furiosus.
a. Cas7-like proteins of the Cmr complex, assemble into a superhelical arrangement. Four copies of
Cmr4 are followed by one copy of Cmr6 and one copy of Cmr1. Cmr4 is a unique Cas7-like protein
with differently pronounced insertion domains and an active site within the domain 1 (lid). Cmr6 has
similarities to both Cmr1 and Cmr4. Cmr1 harbors a second RRM after β4 . Similarly to Cas6 it is also
positioned at the 3′-end of the crRNA and caps the complex.
b. Sequence alignment of Cmr4 and representatives of the Csm3 family. Both proteins have been
shown to excite catalytic activity towards RNA targets. The residues that constitute the active site are
conserved and highlighted (red: Pf Cmr4; blue:Mk Csm3).
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Cmr4
Cmr4 is a Cas7-like protein with an RRM-like core featuring similar peripheral domain
arrangements [69]. Fourmain featuresmakeCmr4 unique (Fig. 13 a, Cmr4 in red). First,
insertion 2 is reduced to a single helix between β1 and α1, which is a stark contrast to
other described Cas7 proteins where this insertion is more pronounced and defines the
nucleotide binding cleft. The modification of this structural element probably reflects
the different nature of the substrate RNA that is bound. Second is the lid domain, which
topologically formed by the same insertions. Here the insertion between β2 and β3 is
very long (150 residues). It contributes a β-hairpin to the lid and also folds into a second
elaborate domain of its own. Here helical elements pack against the front surface of the
RRM β-sheet and a β-barrel flanks one edge of the RRM β-sheet, extending it after β2.
Compared to the other Cas7 proteins, this takes up the same position as the C-terminal
extension domain. Third there is an additional insertion in β3-β4, forming a fifth blade
that additionally extends the β-sheet. Fourth and finally, the most striking feature of the
Cmr4 protein is that it is the first Cas7-like protein found to exhibit a catalytic activity in
an in vitro reconstituted complex, generating a characteristic cleavage pattern of its RNA
target [69]. The activity is located within the lid domain and residues from different
unstructured elements come together to form an active site that is topologically distinct
from nuclease sites in other family members. The same catalytic residues are conserved
in the type III-A homologue Csm3 (Fig. 13 b), one of which corresponds to the arginine
we found to be essential for RNAbinding, drawing a functional connection frombinding
to catalysis (Hrle et al., 2013, Fig. 4D). In our hands, the single MkCsm3 did not show
catalytic activity towards the bound RNA substrate. In context of the complete complex
however, this may change. Recently, V. Siksnys reported to have measured an affinity
towards an RNA target, expanding the function of the complex from targeting DNA to
RNA (V. Siksnys, personal communication). This could provide an explanation for why
it structurally resembles the type I DNA targeting complexes but possesses the catalytic
site for RNA degradation.
Cmr6 and Cmr1
From 5′ to 3′ crRNA direction, Cmr6 and Cmr1 extend the superhelical arrangement
of sequential Cmr4 RRM domains [69]. Cmr1 is a unique Cas7 family protein, as it
has two RRM domains; just as in Cas6, the second RRM is located after β4 (Fig. 13 a,
Cmr1 in yellow). Two RRMdomains of Cmr1 form a single structural unit by interacting
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closely with each other via their insertion domains elements. This interaction creates a
composite surface groove that is lined by conserved basic and hydrophobic residues.
Mutation analysis and structural data suggest that Cmr1 employs this conserved cleft for
nucleotide binding and of the 3′-end of the crRNA [69]. Despite lack of biochemical data
and the fact that they belong to different families, one can speculate that Cmr1may share
functional analogies to Cas6 in crRNA processing. This is supported by its location and
nucleotide binding of the 3′-end of the crRNA and the presence of two RRM domains.
The second proteinCmr6 has an overall architecture that resembles theN-terminal RRM
of Cmr1, with exception of the lid domain, which superposes well with Cmr4 (Fig. 13 a,
Cmr6 in orange). The fully resolved Cmr4 β2–β3 hairpin connection hints towards what
the currently unresolved equivalent insertion of Cmr4 would look like.
3.2 Form follows function: Cas7 proteins in the interference complex
Initially, our knowledge on Cas7 assembly and crRNA interaction was based on the in-
terpretation of electron microscopy structures of type I and III interference complexes.
These studies have confirmed that Csm3 is present in multiple copies in the type III-
A Csm complex [65]. For TtCas7, we have shown its tendency to oligomerize around
crRNA by EM, similar to the behavior of its Sulfolobus sulfataricus ortholog [63]. In all
cases, multiple copies of Cas7 proteins were wrapped around the crRNA.They constitute
the helical backbone of the interference complex and contribute to its elongated shape.
Initial cryo-EM structures of crRNA and the target-bound type I-E interference com-
plex gave a first higher resolution picture [51]. Now, the recently solved structure of the
corresponding interference complex (containing a total of 11 proteins and a 61 nucleotide
crRNA) allows a detailed view and understanding of the versatile protein interaction and
RNA binding sites [68]. It shows that the endonuclease Cas6e, which is bound to the 3′
stem loop of themature crRNA recruits the first copy of Cas7 via a hydrophobic cleft, the
binding site for the short helix within the insertion β2–β3 of the lid domain of Cas7. In
total, the six copies of Cas7 (EcCasC) tightly intertwine with the crRNA and oligomer-
ize, forming a helical backbone (Fig. 14 a, left panel). The structure shows that Cas7 has
two distinct RNA contact sites, both of which are sequence-unspecific. Each Cas7 binds
5 nucleotides via a central cleft. A hairpin within the insertion β2–β3 of the next Cas7
copy folds over the top of the RNA and contacts an accessible positively charged binding
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site within the cleft. This dents every sixth base and pins the RNA into the channel in
a pseudo A configuration (Fig. 14 a, inset). The last Cas7-RNA interaction is locked by
a similar hairpin structure of the terminal Cas5 protein. This positions and divides the
RNA into six segments.
3.2.1 RNA binding properties of Type I-A/D and III-A Cas7 homologs
Our data on the Cas7–RNA interaction obtained from the functional analysis of three
Cas7 homologs,MkCsm3, TpCsc2 and TtCas7, agree with the findings of type I-E Cas7
in context of its Cascade complex discussed above. First we showed that all proteins bind
their natural substrate, the specific crRNA. In the case ofTtCsa2, we visualized the oligo-
merization along an RNA template by electronmicroscopy (Plagens et al., 2014, Fig. S6).
Oligomerization of TtCsa2 also occurred with nucleic acid contaminants. The binding
of Cas7 to an unspecific sequence did not come entirely unexpected, as it was assumed
to contact mostly the variable spacer region. We demonstrated the RNA sequence-
unspecific binding nature of Cas7 proteins by showing thatMkCsm3 prefers an unspe-
cific, unstructured A20 and U20 substrate over a specific, structured repeat sequence.
Later, we found A20 and U20 single-stranded RNA to bind to all three Cas7 proteins
we studied, however with different affinities: Type I-A and I-D homologs bound with a
higher affinity (µM) compared to the type III-A Csm3. This behavior can be due to the
fact that additional subunits or Cas7-like proteins are needed to stabilize the interaction
in the type III-A complex. In case of the type III-B homolog Cmr4, binding of RNA only
occurs in context of complex assembly (C. Benda, personal communication). A similar
yet less pronounced effect could account for the lower affinity of Csm3.
3.2.2 RNA binding surface of Type I-A/D and III-A Cas7 homologs
For all following experiments, we chose U20 as a single-stranded unstructured RNA se-
quence as it is a suitable substrate for protein-RNA cross-linking. By a combination of
UV crosslinking and mutation analysis, we pinpointed two RNA interacting surfaces
formed by residues within the central cleft and residues on the lid domain (Figure 14 b,
inset). These findings turned out to be in line with the contact sites identified in the type
I-E complex (Fig. 14 a, inset).
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Figure 14: Cas7 backbone of interferences complexes.
a. Individual copies of the Cas7 protein Ec CasC are labeled 1 to 6 from 3′–5′ crRNA (black). Inset:
Copies 5 (surface representation) and 6 (cartoon representation) and the first 22 nucleotides 3–5′ of
the crRNA are shown. The RNA binds to Ec CasC via a central cleft and is pinned to this site by the
insertion between β2 and β3 , of the next copy. This insertion contains a hairpin as a structural element.
b. The superposition of TpCsc2 to Ec CasC 1–6 gives an initial picture of the type I-D backbone and
underlines the conserved superhelical assembly of Cas7 proteins throughout the subtypes. The copies
of TpCsc2 are labeled 1 to 6 from 3′–5′ crRNA (black). Inset: Copies 5 (surface representation) and
6 (cartoon representation) and the first 22 nucleotides 3–5′ of the crRNA are shown in the same
orientation as above for Ec CasC. Amino acids thatwe showed to interact with RNA (crosslinked: yellow;
mutated: cyan) are in accordance with the RNA-binding interface of the type I-E complex [68].
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For type III-A, we performed a mutational analysis, which demonstrated the involve-
ment of a conserved arginine (R21) in the lid domain in RNA binding. Interestingly,
mutations of conserved exposed residues along the α1 helix of the core or a loop-out
mutation of the insertion β2–β3 in the lid domain did not significantly perturb the bind-
ing (Hrle et al., 2013, Figs. 4D, S4C). This can be due to the synergistic effect of the
various binding sites: A combination of mutations within the two different binding sites
might be necessary to show an effect. Aided by UV crosslinking we identified a signific-
ant number of contacts within the central positively charged cleft ofTtCsa2 and TpCsc2
and identified a conserved consensus motif containing arginine and lysine residues. In
the case of the E. coli Cas7, these residues are replaced by methionines that significantly
contribute to the direct interaction with the phosphate backbone and the bases [68]. We
observed that a minimal length of RNA is required for Cas7 interaction. This finding
is in line with the model that Cas7 proteins work together to stabilize binding in a co-
operative manner. Around 15 nucleotides are needed in order for one copy of Cas7 to
stabilize the interaction of the subsequent one.
Next to the Cas6 family, the Cas7 family now belongs to the best understood amongst
the Cas proteins from a structural and functional perspective. The proteins provide a
comprehensive platform for protein-protein and protein-nucleic acid interactions. They
interact with every single other subunit of the interference complex from the 3′ to 5′
of the crRNA [68, 87]. Moreover, the Cas7 homolog Cmr4 of the RNA-targeting Cmr
complexes has evolved a catalytic site for RNA cleavage. Future structural studies of
target-bound interference complexes will shed light on the structural rearrangements
that occur within Cas7 proteins upon target recognition. Initial EM data suggest that the
insertion domain between α1 and β2 of the last two Cas7 copies (closest to the 5′ crRNA
end) undergoes a rotation and enables a distal lysine rich helix to contact the backbone
of the target DNA [51, 68]. Interestingly one crosslink we obtained within TpCsc2 was
located in this region.
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The increasing availability of sequencing data of prokaryotic and phage genomes com-
bined with comprehensive bioinformatics efforts has shed light on the expansive protein
machinery that administrates the CRISPR immune response. Based the organization of
the cas genes within the locus as well as secondary structure predictions of the respect-
ive proteins, these studies have classified the myriads of different Cas proteins [30]. The
increasing number of crystal structures of individual Cas proteins has provided a wealth
of information on the molecular mechanisms, such as for the assembly of Cas7 family
proteins into the interference complex, the Cas6 mediated crRNA processing and Cas3-
dependent target cleavage in type I systems [29]. In addition, a great challenge has been
to obtain crystal structures of the entire interference complexes. However even though
the novel crystal structures allow new insights into the diverse protein machinery and
its underlyingmechanisms, several aspects remain elusive and are subject to ongoing re-
search. One point of interest will be to address the mechanisms of target DNA binding
in a thermodynamically feasible fashion, given that the process is ATP-independent [9].
Jackson et al. suggest that the pre-ordering of crRNA-guide into a pseudo-A helical ar-
rangement by the Cas7 subunits enhances target detection and may reduce the entropic
penalty in order to provide a thermodynamic advantage for target binding. Structural
comparisons with Cas9 and Argonaute proteins reveal that these proteins apply a similar
mechanism: by kinking the RNA helix, the protein mediates pre-ordering of the RNA
guide. In type I interference complexes, the Cas7 insertion that introduces the kink also
covers this base and makes it inaccessible for the target DNA [68]. How full target hy-
bridization is achieved remains elusive. One can speculate that a structural rearrange-
ment, which has been shown by cryo EM of the type I-E, takes place to expose the RNA
guide. In case of Cas9, the crystal structure of the target-bound complex suggests that
the RNA–DNA hybrid forms a contiguous A-form duplex [61]. Another open question
is the nucleic acid specificity of type III Csm and Cmr complexes towards RNA. Classi-
cally Csm3 is known to target DNA, whereas Cmr targets RNA [33, 47]. However, recent
studies reported that Csm3 is capable of targeting RNA in vitro using the same catalytic
site. These findings need to be validated in vivo, as they have important implications for
archaeal biology: Is RNA targeting solely a response to RNA viruses, or is it used as a
means of post-transcriptional regulation in these organisms?
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Beyond the achievements of basic research, CRISPR has uncovered a powerful tool for
laboratory and clinical applications alike: Cas9, a single nucleic acid-guided protein,
which can perform a plethora of genome editing functions. Two discoveries have broad-
ened its potential for genome engineering. First the discovery that one can disable one
or both nuclease activities without interfering with target recognition [57]. Second the
successful fusion of Cas9’s two guide RNAs (tracrRNA and crRNA) to a single small
guide RNA (sgRNA) [57]. These findings allowed the creation of programmable syn-
thetic machinery, which unifies all three types of sequence-defined biological polymers.
Proteins, RNA or DNA can be targeted to any dsDNA sequence by simply fusing them
to either Cas9 or the sgRNA. Applications range from targeted genome editing, targeted
genome regulation, programmable genome reorganization and visualization [81]. Thus
the system holds tremendous potential for studying and engineering living systems.
CRISPR systems have stormed onto the scene. The speed at which they can be adapted
to new targets, their high efficiency and versatility makes them poised to overtake more
established technologies based on TALENs or zinc finger nucleases, both of which de-
pend on engineering custom-made proteins for each DNA target [88, 89]. Within a year
after their introduction, libraries of small guide RNAs have been synthesized that can
be used to target 90% of all genes in humans and model organisms [81]. Highlights of
the application of CRISPR technologies include the generation of triple knockout mice
in ‘single shot’ [90] and the excision of HIV from infected human cells [91]. Specificity
and off-target effects still limit the applicability of CRISPR/Cas technology, in particular
for the treatment of human diseases by gene therapy [92]. However, this also provides
a strong driving force for basic research. For instance, biochemical analysis and crystal
structures of Cas9 provide mechanistic details of target recognition and open up possi-
bilities for engineering Cas9 towards higher target specificity [83, 93].
In summary, the emerging CRISPR/Cas fields provides ample opportunities for basic
scientists trying to understand evolutionary relationships as well as molecular engineers
aiming at benefiting human health.
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